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Abstract 
 
In this thesis we validate the efficacy of a new adenoviral construct in prostate cancer 
cell lines in preparation for a gene and immunotherapy clinical trial in prostate cancer. 
By demonstrating the constructs ability to infect prostate cancer cells and cause them 
to die with the introduction of the prodrug, CB1954 as well as releasing a biologically 
active cytokine, GMCSF we secured GTAC approval to proceed to a phase I/II 
clinical trial in patients with local relapse after treatment with curative intent for 
prostate cancer. A tertiary endpoint in the trial is evidence of immune responses 
relating to treatment. To measure this we have modified an interferon gamma 
ELISpot assay to measure T cell mediated immune responses. We have then used this 
assay on 38 patients with suspected or diagnosed prostate cancer. In this study we 
have found the assay to be acceptable to patients and deliverable within the setting of 
the clinical trial. We found evidence of strong immune responses in patients with low 
and intermediate risk prostate cancer based on D’Amico’s classification with these 
responses declining in more advanced patients. We found that some interventions lead 
to an increase in immune responses and these observations warrant further 
exploration. 
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Abbreviations 
 
EDTA ethylenediamine tetra-acetic acid 
EBV Ebstein-Barr virus 
DMSO dimethyl sulphoxide 
DRE Digital rectal examination 
FITC fluorescein isothiocyanate 
HLA Human leukocyte antigen 
HSV-TK Herpes Simplex Virus: Thymidine kinase 
kb kilo-base 
kDa kilo-Dalton 
i.u. international units 
M molar 
mg milligram 
ml millilitre 
mM millimolar 
moi multiplicity of infection 
  
ii 
MTT  (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide, stock concentration 
5mg / ml) 
g microgram 
M micromolar 
m micrometer 
ng nanogram 
nM nanomolar 
nm nanometer 
PBS phosphate buffered saline 
PBMC Peripheral blood mononucleocyte 
PBSc (complete)   2 litres PBS + 0.264g CaCl2.2H2O and  
 0.2g MgCl2 
pfu plaque forming unit(s) 
PHA Phytohaemagglutin 
PSA Prostate Specific Antigen measured in ng/ml 
rpm revolutions per minute  
SDS Sodium dodecyl sulphate 
SGT Suicide gene therapy 
  
iii 
TAE  242 g of Tris.HCl, 57.1 ml of glacial acetic acid, 
18.2 g of disodium EDTA in 1 litre of dH2O 
T10E1  10 mM Tris, 1 mM EDTA, pH 8 
T10E1N100  10 mM Tris, 1 mM EDTA, 100 mM NaCl, pH8 
TRUS Trans rectal ultrasound of prostate 
TURP Trans urethral resection of prostate 
Tween Polyoxyethylene-sorbitan monooleate
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1 Introduction 
 
1.1 The Prostate 
 
The prostate is a walnut-sized part glandular, part fibromuscular gland found at the 
base of the bladder in men. It envelopes the proximal (membranous) urethra, and is an 
exocrine gland which contributes 10-30% of the total volume of the ejaculate. In the 
adult male, it may weigh up to 20 grammes. As the male ages, the gland commonly 
hypertrophies, driven by testosterone and its more active metabolite, 
dihydrotestosterone. Malignant change is common in the older prostate gland with a 
histological prevalence of 15-30% of men aged 50-60 years, rising to 60-70% of men 
by the age of 80 years [Selley et al. 1997; Pienta 1994; Jones 1993]. 
 
1.1.1 Embryology and cellular development  
 
The prostate gland is an endodermal structure, which develops from the urogenital 
sinus in response to testosterone and its more potent metabolite, 
dihydrotestosterone. Buds from the prostatic part of the urethra grow in to the 
surrounding mesenchyme, and differentiate into the glandular epithelium of the gland, 
and this starts when the foetus is 10 weeks old. These buds branch out to form ducts 
and terminate in acini. Up until puberty, these ducts and acini are lined with multiple 
layers of immature simple and stratified squamous epithelial cells [Wernert, Seitz, and 
Achtstatter 1987]. 
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After birth, the gland undergoes a period of growth through the first year, and then 
enters a quiescent phase until the testosterone surge associated with the onset of 
puberty. At this point, the glands grows in size and the immature epithelial cells 
differentiate into a two-layered epithelium, characterised by a peripheral layer of 
cuboidal basal cells and an inner layer of secretory epithelial cells [Aumüller et al. 
1990]. The mature prostate secretes and stores a fluid that makes up about 30% of the 
seminal fluid volume, and is rich in zinc as well as being slightly alkaline (pH7.29) 
[Cunha et al. 1987]. 
The prostate has three main cell types: 
Basal – these cells are found at the basement membrane and are relatively 
undifferentiated. They express low levels of androgen receptors (AR) and do not 
undertake any secretory activity [Sar et al. 1990]. 
Secretory luminal – the most ubiquitous cell type, these cells make up the glandular 
component of the prostate and constitute the exocrine compartment. They secrete 
prostate acid phosphatase (PAP) and prostate specific antigen (PSA) and express high 
levels of AR and rely on androgens for their survival [Kyprianou and Isaacs 1988]. 
Neuroendocrine – these cells are found throughout the prostate, they express serotonin 
and thyroid-stimulating hormone receptors and do not express AR [Kyprianou and 
Isaacs 1988]. 
Since the 1980s, there has been mounting evidence for the existence of a stem cell 
population in the prostate. Stem cells have the capacity for self renewal and are 
responsible for maintaining the full repertoire of differentiated cell types within their 
native structure. They can undergo asymmetric division, which gives rise to a new 
stem cell as well as a more differentiated transit amplifying daughter cell. These 
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amplifying cells have a limited life, but divide rapidly thus expanding that 
differentiated cell line [Jones and Watt 1993]. 
 
1.1.2 Anatomy 
 
The prostate is located in the true pelvis of the male, enveloping the proximal extra-
mural urethra at the base of the bladder. It is an exocrine gland of the male 
mammalian reproductive system, with 70% of the prostate consisting of 
tubuloalveolar glands arranged in lobules surrounded by a stroma, and an ill-defined 
fibromuscular capsule which constitute the other 30% [LeDuc 1939, Brandes 1964]. 
The stroma is rich in collagen and smooth muscle, and is continuous with the poorly 
defined capsule. Increased tone in these smooth muscle fibres contributes to 
obstruction of urine flow through the prostate and reducing this tone by using alpha-
adrenergic blocking agents can improve the symptoms of obstruction. 
In 1988, McNeal described the anatomy of the prostate as zonal, with each zone being 
defined by the point at which their ducts drain into the urethra, their differing 
pathological lesions and their embryological origin [McNeal et al. 1988]. These zones 
are demonstrated in figure 1.1. 
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1 – central zone,   
2, 5 - urethra,   
3 – transitional zone,   
4 – fibromuscular zone,   
6 – capsule,   
7 – peripheral zone,   
8 – ductus deferens. 
 
 
 
Figure 1.1 – Zonal anatomy of the prostate [McNeal et al. 897-906] 
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The transitional zone contains 5-10% of the glandular tissue in the prostate, and is the 
area in which benign prostatic hypertrophy commonly occurs.   Up to 20% of prostate 
cancers originate in this area. 
The central zone contains 25% of the glandular tissue in the prostate.  It is believed 
that these glands embryologically originate from the Wolffian duct [McNeal et al. 
1988] as they drain around the openings of the ejaculatory ducts. This may explain 
why cancers are rarely found here (<5%) 
The peripheral zone contains 70% of the glandular tissue in the prostate, and these all 
drain into the prostatic urethra. This area is the origin for around 80% of all prostate 
cancers. 
The anterior fibromuscular stroma has no glands, but can account for up to a third of 
the weight of the prostate. It is continuous with the capsule and it is rare to find 
prostate cancer in this area. 
 
1.2 Prostate Cancer 
1.2.1 Epidemiology 
 
Prostate cancer is the commonest cancer in men in the UK and North America. In 
2010, there were 40,975 new cases of prostate cancer diagnosed in the UK. There 
were 10,721 deaths from prostate cancer during the same period 
(http://info.cancerresearchuk.org/cancerstats/types/prostate/). A man has a 16.6% 
(1:6) lifetime risk of being diagnosed with the disease and a 3.4% lifetime risk of 
death from the disease. Data from the North American Cancer Registry demonstrates 
that prostate cancer accounts for 28% of cancers in white men and racial variation was 
seen from 15% in Korean men to 37% in Afro-American men. 
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Prostate cancer is the second leading cause of cancer deaths in white and black US 
men (10% of all cancer deaths among white men and 16% of all cancer deaths among 
black men).  
The incidence of prostate cancer is expected to increase from 12.4% in 2000 to 19.6% 
in 2030 in the over 65 year-old population, and undergo a four-fold increase over the 
first half of this century [Lunenfeld 2002]. The overall incidence has increased 
markedly in recent years due to an increase in PSA testing and prostate biopsying at 
the end of the last millenium. Figure 1.2 shows that this increase in surveillance may 
be yielding an increase in incidence, but there is no associated increase in mortality. 
This is either due to a genuine improvement in treatment or due to the identification 
of patients with subclinical, non lethal prostate cancer. As such, the role of PSA 
screening is contentious and has probably contributed to the rapid rise in the prostate 
cancer incidence in the last twenty years. We know from the European Randomized 
Study of Screening for Prostate Cancer that 1470 individuals need to be screened, and 
48 men treated to prevent one prostate cancer death [Schroder et al. 2009] over 9 
years (figure 1.3). 
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Figure 1.2 – Age standardised (European) incidence and mortality per 100,000 
population, prostate cancer, by sex, Great Britain, 1971 – 2002 
(http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/) 
 
 
 
Figure 1.3 - As of December 31, 2006, with an average follow-up time of 8.8 years, 
there were 214 prostate-cancer deaths in the screening group and 326 in the control 
group. Deaths that were associated with interventions were categorized as being due 
to prostate cancer. The adjusted rate ratio for death from prostate cancer in the 
screening group was 0.80 (95% CI, 0.65 to 0.98; P=0.04). The Nelsen–Aalen method 
was used for the calculation of cumulative hazard [Schroder et al. 2009]. 
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Figure 1.4 shows data from the Northern Ireland Cancer Registry, the Welsh Cancer 
Intelligence and Surveillance Unit, the Information and Statistics Division, NHS 
Scotland and the Office for National Statistics, England to calculate the incidence of 
prostate cancer by age in the UK population in 2006.   
 
 
Figure 1.4 – Incidence of prostate cancer by age in the UK population 
(http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/). 
 
Prostate cancer risk increases with age (fig 1.4), with 70% of all cases in the United 
States being diagnosed in men over 65 years of age. Autopsy studies in men who have 
died from non-prostate related disease suggests prostate cancer is under diagnosed 
(fig 1.5). It has been estimated that a 50-year-old man has a lifetime risk of 42% for 
developing histologic evidence of prostate cancer, a 9.5% risk of developing clinical 
disease, and a 2.9% risk of dying of prostate cancer [Carter, Piantadosi, and Isaacs 
1990]. 
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Figure 1.5. The probability of developing prostate cancer with age based on screening 
the living population and at autopsy in those that have died from heart disease 
[American Cancer Society 2003]. 
 
The natural history of prostate cancer is not entirely understood, however, it is a 
disease that often progresses from an androgen dependent (AD) to an androgen 
independent (AI) state. This progression is a multi-step process mediated in part by 
interactions between the cancer cells and the local stroma. These interactions lead to 
ongoing activation of the androgen receptor in the absence of androgen. Factors such 
as stromal insulin-like growth factor-1, epidermal growth factor, forskolin and 
interleukin-6 have all been shown to stimulate epithelial cancer cells [Culig et al. 
1994; Nazareth and Weigel 1996; Ueda et al. 2002]. 
Prostate tumour growth has been shown to be greater in the presence of prostate 
stromal cells [Hirschowitz and Kaplan 1979], and fibroblast-derived growth factors 
from the stroma play an important role in the development of tumours in the prostatic 
epithelium [Kalluri and Zeisberg 2006]. 
Early prostate cancer is largely an asymptomatic disease. These tumours commonly 
arise in the periphery of the gland and have little impact on the flow of urine through 
the prostatic urethra. Advanced disease can give rise to local symptoms relating to the 
urinary tract and bowel, or can cause symptoms due to metastatic spread which is 
commonly to the skeleton. 
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Early prostate cancer is mostly diagnosed on prostate biopsies undertaken in patients 
in whom there is a suspicion of prostate cancer. This suspicion may be due to subtle 
changes found on palpating the gland during a digital rectal examination, an elevated 
prostate specific antigen blood test, or a strong family history. Early prostate cancer 
can also be incidentally found in patients having a resection of supposedly benign 
hypertrophied prostate tissue that is causing symptoms through obstruction. 
Advanced prostate cancer is often found in symptomatic patients or those with greatly 
elevated PSA’s with a clinically malignant prostate gland. This diagnosis can be 
confirmed with a biopsy, although the biopsy will often not influence the management 
of the patient. 
Once a diagnosis is made, the disease should get a histopathological grading and 
clinical staging. 
 
1.2.2 Histopathological grading 
 
Adenocarcinomas represent 95% of all prostate cancers and 85% of these cancers are 
multi-focal [Byar and Mostofi 1972]. The histological grading of prostate cancer was 
devised by the Veterans Administration Cooperative Urological Research Group and 
was published by Dr Donald F Gleason [Gleason 1966] in the 1960s. Unlike other 
grading systems that are based on the morphological features of individual cells, the 
Gleason grading system is based entirely on the architecture and histological pattern 
of the carcinoma cells in relation to the benign prostatic cell groups in H&E-stained 
sections. Five basic patterns (scored 1–5) are described. (figure 1.6). To reflect the 
multifocality of the disease, a histological sum score (summed from scores of two 
most dominant patterns) is calculated, which can range from 2 (least aggressive) to 10 
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(most aggressive). Gleason grading of the cancer is the most widely used, and 
accepted histopathological method for providing information about the prognosis of 
prostate cancer. Gleason grade in prostate cancer is one of the most significant 
predictors of patient outcome [Bostwick 1994] and can predict the final pathological 
stage for patients with clinically localized prostate cancer [Partin et al. 1993]. 
 
 
Figure 1.6: Gleason’s grading system [Gleason 1966] 
 
Other relevant prognostic variables include PSA, clinical staging and tumour volume. 
Microscopic evidence of perineural and vascular invasion, as well as capsular and 
seminal vesicle involvement, are also important prognostic signs. 
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1.2.3 Staging 
 
Prostate cancers are staged using the TNM system (Urological Tumours) from the 
American Joint Committee on Cancer (AJCC) 6th edition (2002) and International 
Union Against Cancer (UICC) 6th edition. as demonstrated in Table 1.1. The 
incidence data are from the BAUS cancer registry 2008 dataset. 
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STAGE SUB- 
STAGE 
DESCRIPTION 
T1 
 
Incidence 
= 0.4% 
 Clinically unapparent tumour, not detected by DRE nor visible by 
imaging 
a Incidental histological finding; <5% of tissue resected during 
TURP  
b Incidental histological finding; >5% of tissue resected during 
TURP  
c Tumour identified by needle biopsy due to elevated PSA  
T2 
 
Incidence 
= 62.4% 
 Confined within the prostate (detectable by DRE, not visible on 
TRUS) 
a Tumour involves half of the lobe or less 
b Tumour involves more than one half of one lobe but not both lobes 
of the prostate 
c Tumour involves both lobes of the prostate  
T3 
 
Incidence 
= 23.0% 
 Tumour extends through the prostate capsule but has not spread to 
other organs 
a Unilateral extracapsular extension 
b Bilateral extracapsular extension  
c Tumour invades seminal vesicle(s)  
T4 
 
Incidence 
= 14.2% 
 Tumour is fixed or invades adjacent structures other than seminal 
vesicles 
a Tumour invades bladder neck and/or external sphincter and/or 
rectum 
 
b Tumour invades levator muscles and/or is fixed to pelvic wall  
 
 
N0  No lymph node metastasis  
N1  Metastasis in single lymph node <2 cm in greatest dimension  
N2  Metastasis in single lymph node >2cm but <5 cm in greatest 
dimension, or multiple lymph nodes, none >5 cm  
N3  Metastasis in lymph node >5 cm in greatest dimension  
M0  No distant metastasis  
M1 a Non-regional lymph node metastasis  
b Bone metastasis 
i) Axial skeleton only 
ii) Extending to peripheral skeleton 
c Metastasis at other sites 
Table 1.1 - Prostate cancer TNM staging system (Urological Tumours) 
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1.2.4 Tables and Nomograms 
 
Using pre-treatment PSA, biopsy Gleason’s score and TNM (2002) data, a variety of 
tools are available to predict the outcomes of the treatment options available to the 
patient.  D’Amico demonstrated that pre-operative risk stratification for T1 and T2 
disease can be used to predict prostate cancer specific mortality after undergoing 
radical surgery or radiotherapy [D'Amico et al. 2003] (table 1.2).  
 
Table 1.2 - D’Amico’s risk stratification 
 
Partin demonstrated that these data could be used in the form of Partin’s tables to 
predict the final pathological stage of their prostate cancer after radical surgery [Partin 
et al. 1993]. 
 
1.2.5 Treatment of prostate cancer 
1.2.5.1 Organ confined disease (T1a-T2c, N0, M0) 
 
A patient diagnosed with organ confined prostate cancer has a number of treatment 
options. Which of these options should be favoured depends on a number of variables, 
Risk PSA Gleason score Stage 
Low-risk  < 10 ng/mL ≤ 6   T1c or T2a. 
Moderate-risk  10 - 20 ng/mL = 7 T2b. 
High-risk  > 20 ng/mL ≥ 8 T2c 
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such as the patient’s health and life expectancy, and the prognostic characteristics of 
the prostate cancer itself. 
The options include active curative approaches, such as radical surgery or 
radiotherapy. Non-curative approaches consist of manipulation of the pituitary-
gonadal axis either medically (androgen deprivation) or surgically (castration), and 
conservative approaches such as ‘active surveillance’ or ‘watchful waiting’. 
Radical surgery can be performed through a number of routes. A trans-abdominal 
approach can be used, either trans- or retroperitoneal, and this approach can be made 
using an open incision or using laparoscopic (‘keyhole’) techniques. The prostate can 
also be approach via the perineum in an open fashion. The laparoscopic techniques 
bring the benefit of quicker recovery from surgery, without compromise to the 
oncological outcome or potency. The laparoscopic techniques take slightly longer to 
perform and are harder to master [Roumeguere et al. 2003]. In some series, the 
laparoscopic techniques resulted in poorer post-operative continence [Touijer et al. 
2008]. Those patients with high risk, organ confined prostate cancer may benefit from 
neoadjuvant taxane based chemotherapy and androgen deprivation therapy [Mellado 
et al. 2009] although phase III trial data are awaited. There are other developing 
ablative technologies that are still being researched, such as high intensity focused 
ultrasound (HIFU) and cryotherapy. Satisfactory long term outcome data relating to 
oncological efficacy and functional outcomes are still awaited. 
Radical radiotherapy can be delivered externally via external beam radiotherapy 
(which is fractionated to allow delivery of greater levels of radiation whilst 
minimizing damage to surrounding structures) and from within by implanting 
radioactive seeds within the prostate (brachytherapy). The oncological outcomes are 
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similar with evidence to show that patient selection is important in determining the 
outcome for brachytherapy [Potters et al. 2004].  
Whether surgery or radiotherapy is the superior treatment in organ confined prostate 
cancer is yet to be proved [Welz et al. 2008]. There have been studies showing greater 
long term survival with surgery [Merglen et al. 2007], but the patient populations are 
never satisfactorily matched [Barry et al. 2001].  
There is little indication to consider non-curative approaches such as androgen 
deprivation (AD) or surgical castration (SC) in low risk organ confined prostate 
cancer, as these patients should be considering a curative treatment modality or active 
surveillance. AD or SC should be offered to patients with intermediate or high risk 
prostate cancer who are unsuitable for curative treatment modalities.  
Recognition of the slow and indolent natural history of some prostate cancers 
(D’Amico’s low risk cancers) has allowed conservative approaches to prostate cancer 
to evolve. In patients unsuitable for curative therapies, with a life expectancy of less 
than 10 years, the initial management of low risk, organ confined prostate cancer 
would be one of, ‘watchful waiting’. In this instance the patient’s PSA will be 
monitored on a regular 6-12 monthly basis and treatment instigated in response to 
signs or symptoms of disease progression. In patients suitable for curative therapies 
with low risk, organ confined prostate cancer, the initial management would be one of 
‘active surveillance’. In this instance, the patient is kept under close clinical 
observation with regular 3 monthly PSA assessments and rectal examinations, as well 
as regular biopsies of the prostate to identify upgrading of the cancer and a shift into 
an intermediate or high risk group [Parker 2004]. 
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1.2.5.2 Locally advanced disease (T3-4, Nx/N0, M0 or T1-4, N1,M0) 
 
These patients have fewer options than those with organ confined disease. Their 
treatment plan relies on the accuracy of their clinical staging, which involves a 
subjective digital rectal examination which will over-evaluate 20% of T3 tumours. It 
may also involve the use of an MRI scan of the pelvis, although traditional MRI has 
little diagnostic superiority over the TRUS biopsy the patient will have undergone  
[Wefer et al. 2000]. However, developments in MRI techniques such as use of an 
endoanal coil and gadolinium based contrast agents are showing much promise 
[Younes 2007].    
The gold standard treatment for T3 prostate cancer is the combination of radiotherapy 
and extended hormone therapy. Surgery is an option to those patients who appear to 
be N0 on cross sectional imaging and are clinically T3 disease, and this is supported 
by the European Association of Urology (EAU) guidelines that recommend surgery in 
patients with cT3a, PSA less than 20ng/ml and a biopsy gleason score less than or 
equal to 8. Surgery in this group offers 15 year biochemical free survival rates of up 
to 50% and disease specific survival rates of up to 84%. Functionally, the continence 
outcomes are similar for patients undergoing surgery for locally advanced disease 
when compared with organ confined disease but their erectile function is poorer due 
to a more radical resection being required which will sacrifice the pelvic nerves 
[Xylinas et al. 2009]. There would appear to be a role for the use of adjuvant or 
neoadjuvant androgen deprivation therapy [Kumar et al. 2006], although there would 
be treatment associated morbidity to consider. These patients are often offered salvage 
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radiotherapy, particularly if there are significant positive margins or a poor post 
operative PSA nadir. This is the subject of the RADICALS clinical trial (MRC PR10, 
ISRCTN 40814031) which is due to close to recruitment in 2013. 
Around 30% of patients undergoing prostatectomy for suspected organ confined 
disease are upstaged to T3 disease on pathological assessment of the resected 
specimen [Viney et al. 2009]. There is good evidence to support the early use of either 
medical or surgical androgen deprivation [Messing et al. 1999] in these patients. Like 
those patients undergoing elective prostatectomy for T3 disease, those upstaged post 
prostatectomy patients with high risk disease would also warrant consideration for 
adjuvant radiotherapy [Bolla et al. 2005]. 
These patients can be managed medically with non-steroidal anti androgen agents 
[Iversen et al. 1998]. The benefit of these agents is that there are fewer libido and 
skeletal side effects [Iversen et al. 2000], making them an ideal agent for younger, 
sexually active patients. In patients for whom the above options are unsuitable (such 
as the elderly and the frail), surgical or medical castration can be offered (for those 
with high risk disease). Those with low risk disease could be managed with a 
watchful waiting approach. 
 
1.2.5.3 Metastatic disease (M1) 
 
According to the BAUS cancer registry of 2008, 14.2% of prostate cancer patients 
present with metastases.  The current gold standard in treatment in these cases is AD. 
This can be achieved either surgically, through bilateral subcapsular orchidectomy, or 
through pharmacological manipulation of the pituitary-gonadal axis. The 
pharmacological options include depletion of luteinising hormone (LH) and follicle 
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stimulating hormone (FSH) from the anterior lobe of the pituitary gland 
(adenohypophysis) by continuous stimulation of the gonadotrophin releasing hormone 
(GnRH) receptor by GnRH agonists. Initially there is a flare of LH and FSH secretion 
that lasts about ten days and thereafter, with continuing stimulation, the LH and FSH 
secretion stops. This period of flare requires the use of an anti-androgen, usually for 4 
weeks, to antagonise the increased circulating levels of androgen caused by the higher 
levels of circulating LH and FSH. AD in patients with metastatic prostate cancer gives 
a median survival time of 28 to 53 months [Seidenfeld et al. 1999]. Around 80% of 
patients with symptomatic disease get relief from AD [Dearnaley 1994]. There are 
new GnRH antagonists now becoming available. The benefit of using these agents is 
that there is no flare. This means that an anti-androgen is not needed. GnRH 
antagonists also induce testosterone and PSA suppression significantly faster than 
GnRH agonists [Klotz et al. 2008].  
After 18 months, many of those managed with AD will start to show signs of 
biochemical relapse (as evidenced by an increase of the levels of PSA in the serum). 
In this instance, an anti-androgen is then added to the management to achieve 
complete androgen blockade (CAB). CAB offers negligible benefit when used in 
patients with metatstatic prostate cancer from diagnosis [Seidenfeld et al. 2000; 
Iversen et al. 1998], but in the event of biochemical relapse, the addition of an anti-
androgen can have some benefit [Ryan and Small 2003] which is usually short-lived. 
Then the anti-androgen can be withdrawn, and this also gives a transient biochemical 
benefit. 
Chemotherapy is currently a second line therapy in metastatic prostate cancer. 
Prospective randomized phase III clinical trials show a survival benefit of 3 months 
with associated significant improvement in quality of life in men taking docetaxel and 
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prednisolone when compared with mitoxantrone [Petrylak et al. 2004; Tannock et al. 
2004]. Chemotherapy is currently only indicated in patients who are hormone 
refractory and symptomatic. 
In this patient group, it is also important to manage their symptoms for palliation. The 
spread of the disease is mainly to the skeleton causing bone pain and pathological 
fractures, and to local lymph nodes causing ureteric obstruction.  Metastatic disease in 
the skeleton can be treated surgically, in the event of debilitating long bone fracture 
that will not heal with traditional splinting.  In vertebral collapse with associated 
spinal cord compression, patients are best managed with radiotherapy [Huddart et al. 
1997], although surgery is indicated in some instances [Tazi et al. 2003]. Focal 
treatment to symptomatic non-fractured skeletal metastasis can be managed with 
external-beam radiotherapy to provide symptom relief.  
Multiple symptomatic skeletal metastases can be managed with bisphosphonates. This 
group of agents interferes with the activity of osteoclasts, the cells responsible for 
bone reabsorption and demineralisation. When used, bisphosphonates reduce bone 
pain and skeletal related events in patients with hormone refractory prostate cancer 
[Saad et al. 2002], although there is no impact on overall survival. There are agents 
that interact with the receptor activator of nuclear factor kappa-B ligand (RANKL) 
such as denosumab. In clinical trials denosumab has been shown to delay the 
development of skeletal metastases in prostate cancer [Smith MR et al. 2009]. Alpha 
radiation emitters such as alpharadin are showing promise in the treatment of prostate 
cancer patients with bone metastases. 
The roles of both chemotherapy and bisphosphonates as first line therapies in the 
management of prostate cancer are currently being explored in the STAMPEDE trial 
[James et al. 2009]. This trial also looked for the potential benefit of combination with 
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the cyclooxygenase-2 (Cox-2) inhibitor celecoxib, but this arm has closed with poor 
results. This is in keeping with trial data on Cox-2 inhibitors that show that when they 
are used alone in prostate cancer, the results have been disappointing [Antonarakis et 
al. 2009]. 
New generations of hormone management (e.g. abiraterone and enzalutamide) and 
chemotherapy (e.g. carbazitaxel) have entered clinical practise. Abiraterone is now 
approved for metastatic prostate cancer patients who are progressing despite or who 
are unsuitable for docetaxel. The drug is taken in combination with prednisolone. The 
role of the new generation treatments within the current management pathways are 
still being defined through clinical trials with arms appearing in the STAMPEDE trial. 
Pain associated with advanced cancer of any type is best managed with the input of 
specialist palliative teams, but is mostly a combination of paracetamol, non-steroidal 
anti-inflammatory agents and opiates. 
 
1.2.5.4 Recurrent disease after primary curative therapy 
 
Patients undergoing prostatectomy with curative intent for prostate cancer have a 
PSA-free survival of more than 90% for T2, 80% for T3a, and 70% for T3b prostate 
cancer [Lein et al. 2006]. In patients undergoing radiotherapeutic treatment 
modalities, the biochemical treatment failure rate is as high as 40-60% [Stephenson 
and Eastham 2005]. The poorer outcomes with radiotherapy reflect a higher risk 
patient demographic and a variety of dosing levels. Outcome data should improve 
with improvements in dosing regimens and delivery. Treatment failure, as evidenced 
by a rising PSA after the treatment, may reflect either local recurrence or distant 
recurrence. Local recurrence is a failure of the primary treatment and means there is 
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residual disease in the prostatic bed. As such, the patient can still benefit from further 
curative treatment modalities. In these instances, the cure rates can still be as high as 
70% for salvage surgery (but at least a third can expect some treatment related 
morbidity) [Stephenson and Eastham 2005], and 50% for salvage radiotherapy [Do et 
al. 1998]. Distal recurrence is a failure in the original staging of the disease, with 
micro-metastatic spread having already occurred at the time of the primary treatment. 
These patients will not benefit from further local treatments and will need to be given 
systemic treatments - the gold standard of which is still AD. Identifying whether 
recurrence is local or systemic can be difficult. The PSA kinetics after the primary 
treatment can help profile the likely pattern of recurrence (Table 1.3). Biopsies of the 
prostatic bed and modern imaging techniques such as indium-111-labeled CYT-356 
(ProstaScint) [Fang et al. 2000] can also help. 
 
Parameter Local recurrence Distal recurrence 
Interval to PSA relapse   
<1 yr 7% 93% 
1-2 yr 10% 90% 
2-3 yr 61% 39% 
3+ yr 74% 26% 
PSA doubling time 11.7 months 4.3 months 
Table 1.3 Important biochemical parameters predicting local and systemic relapse 
following radical surgery [Heidenreich et al. 2008] 
 
1.2.6 Unmet therapeutic needs in prostate cancer 
 
Almost half of newly diagnosed prostate cancers are organ confined at presentation. 
Of those in whom a primary curative therapy is undertaken, 35%-65% will have 
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evidence of recurrence within 10 years [Garnick and Fair, 1996; Han et al, 2001; 
Jemal et al, 2006; Moul, 2000]. These numbers are worse for more advanced disease 
states, and this means there are some unmet needs in prostate cancer management.  
 
 
1.2.6.1 Early disease 
With improvements in active surveillance protocols the overtreatment of low-risk 
prostate cancer is diminishing. These protocols still rely on the relatively blunt 
instrument of blood tests for PSA and the invasive trans-rectal prostate biopsy with 
the risks that the technique carries. Further work continues in the utility of more 
accurate serological, histological and radiological techniques to better tailor a 
patient’s management to his disease. 
1.2.6.2 Advanced/progressive disease 
Like patients with metastatic prostate cancer, patients who have progressed despite 
local curative therapeutic treatments have a poor prognosis. They were offered 
treatment with curative intent as they had good life expectancies (10 years or more) 
and as such are likely to die from their disease. With recurrent and progressing 
disease, some control can be given with hormone manipulation and other second line 
therapies, but their median life expectancy with these modalities is 28 to 53 months 
[Seidenfeld et al. 1999].  It is in these patients that there is the need for further 
therapeutic options. Within this group, there are patients who are becoming resistant 
to their hormone therapy as evidenced by a rising PSA but are yet to complain of 
symptoms. Patients at this point in their treatment journey have no further licensed 
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treatment options until they become symptomatic from metastatic disease. It is this 
group that we will be recruiting from in our forthcoming AdGMNR clinical trial. 
1.2.6.3 Metastatic disease 
 
With the availability of new treatment modalities (see above), the life expectancy of a 
patient with metastatic prostate cancer has improved, but many of these patients will 
ultimately go on to die from their disease. This patient group are in need of further 
improvements in the efficacy of their systemic treatments and their side-effects. 
Immunotherapies and gene therapies may provide novel solutions for some of these 
unmet needs. 
 
1.3 Immunotherapy for Prostate cancer 
1.3.1 Basic immunology 
The immune system has two components, innate and adaptive. The innate immune 
system consists of cells that function through cytokine secretion, antigen presentation 
and mediating cell lysis. This system includes non-specific cells such as macrophages, 
mast cells, monocytes, natural killer cells and neutrophils.  
The adaptive immune system is made up of B (derived from the bone marrow) and T 
(derived from the thymus) lymphocytes. The adaptive immune system is designed to 
respond to specific antigens that are identified as ‘non-self’. The response has the 
capacity to develop memory of antigens to which it is exposed as well as amplifying 
its response to antigens. This response is driven by the interaction between B and T 
cells and their interaction with antigens.  
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1.3.2 B Cells 
 
B cells are significant constituents of the humoural immune response. Their principal 
function is to generate antibodies against specific antigens and function as antigen 
presenting cells. In humans, they are developed in the bone marrow and then migrate 
as immature B cells to the spleen where they become transitional B cells. As they 
mature, the antibody they express undergoes a number of changes to generate a 
unique variable domain in the antibodies generated by that particular B cell. Before 
exiting the bone marrow, the B cells are screened in the central lymphoid organ in the 
marrow, and those that bind to self antigens are selected and either induced into 
apoptosis (programmed cell death), anergy (a state of dormancy) or receptor editing, 
where the B cell can further alter the conformation of their variable domain to 
generate a less autoreactive B cell. 
Once exposed to a specific antigen, the B cell is activated and undergoes a further 
change in its phenotype with input from T helper cells, maturing into either an 
antibody generating plasma cell or cloned memory B cells. The antibodies from a 
plasma cell can mediate tumoricidal effects through complement-mediated cell lysis 
or natural killer cell-mediated antibody-dependent cellular cytotoxicity.  
 
1.3.3 T Cells 
 
 
T cells are significant constituents of cell-mediated immunity. T cells originate from 
haemopoietic stem cells from the bone marrow which have migrated to the thymus, 
where they expand in numbers to form immature thymocytes (hence T cell). They are 
characterized by their expression of T cell receptors (see below). In the thymus, the 
thymocytes mature into CD4 or CD8 expressing T cells which then enter the 
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circulation. During this maturation process, 98% of the cells are removed through a 
process called selection. Selection is where the maturing T cell is presented with self-
antigens. Initially, this occurs in the thymic cortex where only those cells that 
recognise self-antigen survive (positive selection). Those cells that have the capacity 
to appropriately identify self-antigen then migrate to the thymic medulla where they 
are presented with more self-antigens. In this setting, those T cells that show too great 
an affinity for self-antigen are destroyed (negative selection). 
T cells consist of subpopulations (T helper cells, cytotoxic T cells, Natural Killer T 
cells, regulatory T cells, memory T cells and γδ T cells) that are characterised by their 
behavior and function. They can be profiled by their expression of specific cell-
surface molecules called cluster of differentiation (CD) molecules. These molecules 
are present on all white blood cells, and are often involved in a cell-surface interaction 
that helps define the role of that particular white blood cell.  
Cytotoxic T cells (CTLs) express CD8 on their surface. This is a dimeric glycoprotein 
that serves as a co-receptor for the T cell receptor. These cells bind to antigen 
presented on the major histocompatability complex (MHC) class 1 molecule, found 
on the surface of almost all cells (see below). Antigens from within these cells are 
expressed on their MHC class 1 and these reflect the health of the cell. Expression of 
viral or tumour antigens may drive a CTL immune response. 
Helper T cells express CD4 on their surface. These cells support the activity of other 
constituents of the immune system. They are activated when a specific antigen is 
presented by a MHC class 2 molecule. These are expressed on antigen presenting 
cells (APCs), and represent antigen products from material ingested and processed by 
the APC. The interaction with the antigen presenting APC will define the nature of 
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that differentiation and the cytokines and role that T helper cell will play. This process 
is poorly understood. 
Regulatory T cells (T regs) express CD4, CD25 and FoxP3. They have been 
categorised into naturally occurring T regs and adaptive T regs and these cells play a 
key role in immunological tolerance. Immune tolerance is important in switching off a 
T cell mediated response and to suppress auto-reactive T cells that weren’t selected 
out in the thymus. 
 
1.3.4 Antigen Processing and Presentation  
 
 
The term antigen is derived from the term antibody generation. In practice, an antigen 
is a macromolecule, usually a protein, which is capable of driving an adaptive 
immune response. Antigens will drive an immune response once they have been 
suitably processed and presented. Antigens are created within a cell through the 
fragmentation of the antigen, and part of that antigen (the peptide) being bound to 
MHC molecules and presentation of the peptide-MHC molecules at the cell surface. 
‘Self’ antigens should be tolerated by the immune system. Failure in this leads to 
autoimmune disorders. ‘Non-self’ antigens should stimulate an immune response 
against that antigen. In cancer cells, antigens presented on the class I or class II MHC 
are called tumour antigens. If these antigens are never expressed by non-malignant 
cell type, these are called tumour-specific antigens (TSAs). If these antigens are 
expressed on both the malignant and non-malignant cell type, these are called tumour 
associated antigens (TAAs).  
Once presented at the cell surface the peptide-MHC molecules can bind to a T cell 
receptor (TCR) on a T cell. The human MHC molecules are coded for on the short 
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arm of the 6
th
 chromosome. There are two classes of MHC and the pathway leading to 
the binding of epitopes with MHC molecules differs from class I to class II MHC 
molecules.  
 
1.3.5 MHC Class 1 Proteins 
 
The class I MHC molecules, of which there are three major (A, B, C) and three minor 
(E, F, G) types, are found on all nucleated cells in the body and they present peptides 
from degraded intracellular proteins. These proteins have been broken down in the 
cytosol by the proteasome, a proteolytic 28 subunit macromolecule, and the resulting 
smaller, 8 to 10 amino acid peptides are translocated into the endoplasmic reticulum 
where they can bind to the MHC class 1. The translocation is facilitated by the 
transporter associated with antigen processing (TAP), and the loading of these 
peptides onto the MHC class 1 molecule is mediated by tapasin, calreticulin, calnexin 
and ERP57. MHC Class 1 molecules interact with the TCR found on CD8+ cytotoxic 
T cells. 
MHC Class 1 molecules are heterodimers, consisting of two components of the 
immunoglobulin (Ig) superfamily, an  chain, which is bound to the cell membrane, 
and an associated 2-microglobulin. The  chain has three domains named 1, 2, 
and 3 and a region adjoining 3 that anchors it in the membrane. All these elements 
are encoded in the MHC by highly polymorphic genes. The 2-microglobulin is not 
polymorphic or attached to the plasma membrane and is encoded by a gene in the 
MHC. Peptide binds to MHC class I 1 and 2 domains [Madden et al. 1992].  
The MHC class I proteins have a distinct cleft in the upper surface. This is generated 
by the way the  chain folds. The variable region forms a close-ended cleft with -
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helical sides and a -pleated sheet floor which will only hold an 8-10 amino acid 
peptide. The amino acid sequence in the variable region varies from allele to allele, so 
polymorphism is maximised in the amino acids which contact antigen [Bouvier and 
Wiley 1994].  
The bound peptide lies extended in the long axis of the binding cleft. It is anchored to 
invariant sites at either end of the cleft by its carboxyl and amino termini. These are 
not the only points of interaction between the peptide and the binding cleft. Amino 
acids at two or three other positions along the peptide interact with amino acids in the 
binding cleft. For a given peptide, the anchor sites of the bound peptide can vary 
between MHC alleles. Amino acids not in the anchor positions can vary considerably, 
allowing a wide variety of peptides to be presented by a few MHC class I alleles. 
These interactions within the cleft present the peptide in a way that can be specifically 
recognized by the TCR.  
The MHC class 1 - peptide complex binds to the complementary TCR on the CTL 
through the 1 and 2 domains. The CD8 molecule on the CTL binds to the class 1 
3 domain which has a species specific non-variable sequence. 
 
1.3.6 Class 2 MHC Proteins 
     
The class 2 MHC molecules, of which there are three major (DP, DQ, & DR) and two 
minor DM & DO) types, are only found on cells specializing in the presentation of 
antigens such as B cells, macrophages and dendritic cells. MHC class 2 proteins are 
also heterodimers but they are made up of an  and  chain which are coded for in the 
HLA-DP, HLA-DQ, and HLA-DR regions of MHC on chromosome 6 in humans. 
These two chains each have two domains (1 and 2 and 1 and 2).  Peptides bind 
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to the class 2 1 and 1 domains, which are polymorphic from allele to allele, and 
these are also the domains that bind the TCR of the CD4+ helper T cell [Fremont et 
al. 1001-04].  
They present peptides from extracellular proteins that have been internalized into an 
intracellular compartment (such as a lysosome) where they are digested, and the 
peptides bound to the MHC class 2 molecule before its migration to the plasma 
membrane. The class 2 peptide-binding site also folds to form a cleft but unlike the 
class I molecule, the cleft is open at either end so that longer, 9 to 30 amino acid 
epitopes can be bound. These epitopes are not anchored by their amino and carboxyl 
but interact with binding pockets along the length of the groove, presenting the 
epitope in a recognizable form for the corresponding TCR [Rammensee 1995]. To 
prevent MHC class 2 binding endogenous peptides, the peptide-binding cleft is 
blocked by the invariant chain. The loading of peptide requires that this chain is 
broken down. This occurs through the action of cathepsin S, resulting in a residual 
fragment called Class 2-associated invariant chain peptide (CLIP) [Driessen et al. 
1999]. This continues to block the cleft until HLA-DM binds to the MHC class 2 and 
releases it allowing peptide to bind and the MHC class 2 - peptide molecule to be 
presented at the cell surface [Busch et al. 2005].  Here the MHC class 2 molecule on 
the APC interacts with the TCR of the CD4+ helper T cell.  
 
1.3.7 The Invariant Chain 
 
The invariant chain is a polypeptide which is complexed with the α and β chains in 
the endoplasmic reticulum during the synthesis of the class 2 MHC. Its presence in 
the peptide binding cleft prevents the binding of cellular peptides and endogenous 
peptides, which would normally be bound to the class 1 MHC. The export of class 2 
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MHC molecules from the rough endoplasmic reticulum to the golgi apparatus is 
facilitated by the invariant chain, followed by the subsequent fusion with the late 
endosome which contains endocytosed degraded proteins. Proteases called cathepsins 
break down the invariant chain leaving a small fragment which blocks the peptide 
binding cleft on the MHC molecule. This small fragment is displaced by HLA-DM, 
an MHC class 2 like structure which facilitates the binding of higher affinity peptides 
and this more stable class 2 MHC is then presented at the cell surface membrane. 
 
1.3.8 Dendritic cells 
 
Dendritic cells (DCs) are specialist antigen presenting cells (APC) which induce and 
regulate the adaptive immune response by stimulating T cells and B cells. They are to 
be found in peripheral tissues and the circulation. The progenitor cells originate from 
the bone marrow and are CD34+. They circulate in the blood, and subsequently give 
rise to a number of subsets of phenotypically and functionally distinct DCs which 
reside in peripheral tissues, such as Langerhans cells in epidermis and dermal DCs in 
dermis [Banchereau and Steinman 1998; Lipscomb and Masten 2002; Banchereau et 
al. 2000].  
These may have been derived from several different populations of precursor cells 
such as monocytes [Randolph et al. 1998; Olweus et al. 1997] . The dendritic cell has 
two phases to its life cycle, immature (an antigen capturing mode) and mature (a T 
cell stimulating mode).  
The immature DC is found in most tissues and in the circulation. They roam the body, 
seeking antigen to present to T cells. These cells are suited to antigen capture with 
high levels of expression of antigen capturing Fc and Fcreceptors, but poor at T cell  
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activation with low expression of stimulatory receptors like; CD40, CD54 and CD86. 
Once antigen has been identified by an APC it can be taken up by phagocytosis, 
macropinocytosis or absorptive pinocytosis and within 24 hours, the phenotype of the 
immature DC changes. The expression of receptors for antigen capture decreases and 
the expression of receptors associated with T cell stimulation increases. This change 
in phenotype coincides with migration of the now mature DC to the local lymph 
nodes and the spleen [Lukas et al. 1996].  
The mature DC has the macroscopic appearance that gives rise to the name ‘dendritic 
cell’. They are stellate with multiple fine dendrites and sheet-like processes which 
extend and retract, increasing the likelihood of interacting with a suitable T cell. 
T cells need to have antigen suitably processed and presented to them at the MHC 
class 2 which are heavily expressed by DCs. The MHC class 2 - peptide complex is 
recognised by the T cell receptor (TCR) and this leads to the activation of the T cell. 
This activation is enhanced by the interaction of other costimulatory factors on the 
DC and the T cell, such as CD40, CD80, CD86 and 4-1BB and their ligands. The DC 
also expresses adhesive molecules, such as CD11a, CD15s, CD18, CD29, CD44, 
CD49d, CD50 and CD54 which facilitate the binding of the DC to the T cell 
[Shortman and Caux 1997; Baggers, Ratzinger, and Young 2000]. It is the expression 
of these co-stimulatory and adhesive molecules that facilitate and drive an effective 
immune response. When antigen is presented by ‘non professional’ APCs, without 
these molecules, tolerance is induced [Lutz and Schuler 2002]. 
DCs largely behave in an immunogenic way, although there are some that are 
tolerogenic. It is believed that those DCs that are derived from the marrow become 
immunogenic, where as those derived from lymphoid tissue will become tolerogenic  
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[Lin, Jacek, and Jacek 2006]. Their interactions with the wider immune system are 
complex and there is still much that is not understood about them, particularly in 
cancer immunology. 
 
1.3.9 T cell receptors (TCR)  
                                                                                                                                    
T cells are a constituent of the white cell population known as lymphocytes. They are 
a key component in cell-mediated immunity. On the surface of these cells are found 
the membrane-bound T cell receptors. These recognize antigenic epitopes presented 
on MHC molecules. TCRs are heterodimers composed of two chains,  and  chains. 
These chains have a membrane anchored constant region and an outward facing 
variable region, ready to bind to a suitable MHC-peptide complex. The variable 
region on each chain has three, hypervariable complementarity determining regions 
(CDR). These CDRs define the antigen-binding specificity. The wide diversity that 
occurs in the CDRs occurs because they are encoded in gene segments that undergo 
somatic recombination during T cell development.   
Each TCR has a single binding site for its target peptide. Peptides presented on MHC 
class 1 molecules will be recognized by those T cells with the co-receptor CD8 bound 
to the TCR. These cells are called cytotoxic T cells [Solheim 1999].  
Peptides presented on MHC class 2 molecules will be recognized by those T cells 
with the co-receptor CD4 bound to the TCR such as T helper cells [Pieters 2000] and 
regulatory T cells. These co-receptors increase the binding affinity of the T cell for 
the MHC class 2 - peptide complex and signal the T cell to become activated.   
A TCR will recognize a particular MHC-peptide complex, and this TCR will not bind 
on another MHC allele. This is called MHC restriction. If this specific peptide is 
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altered, its binding in the MHC binding cleft may change. This can affect the binding 
of the TCR to the MHC complex - peptide. 
 
1.3.10 Immunology in malignancy 
 
Immunotherapy is an evolving therapeutic field in oncology which can be used as a 
primary treatment (such as intra-vesical BCG for non-muscle invasive bladder 
cancer), or can be used to enhance the effectiveness of other conventional treatments 
(interferon-alfa2b as an adjuvant to surgery for metastatic melanoma). With an 
increasing understanding of the immune system and its interaction with cancer cells, 
new therapies are evolving that can mobilize an individual’s own immune system to 
attack and destroy tumour cells. Theoretically, this would be highly specific and thus 
avoid the systemic complications experienced from relatively unselective treatments 
such as chemotherapy. 
 
1.3.11 Immune surveillance and Immunoediting 
 
The role of the immune system in protecting the host from cancers by eliminating 
cancer cells when they arise was proposed in 1957 [Burnet, 1957]. This was called 
immune surveillance. With growing mouse and human evidence the theory has been 
further refined and described as Immunoediting. 
Immunoediting is the interaction between the immune system and cancer cells and is 
described as having three phases; elimination, equilibrium and escape [Dunn et al 
2002]. Newly transformed cells can be initially eliminated by the innate immune 
system through cells such as natural killer cells. As the tumour progresses, adaptive 
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immune response can be provoked by tumour antigen-specific T cells to provide the 
balance seen in the equilibrium phase. After time, immune selection produces tumour 
cell variants that have reduced class I and II MHC expression and thus decreased 
tumour antigen presentation. This, combined with tumour-derived soluble factors 
released in the tumour micro-environment, facilitate the escape from immune attack, 
allowing progression and metastasis [Kim et al. 2006]. 
 
1.3.12 Rationale for prostate cancer as an immunotherapeutic target 
 
Ever since William Coley noted the spontaneous regression of some sarcomas in 
response to local inflammation secondary to local bacterial superinfections in 1891, 
there has been considerable interest in the relationship between the immune system 
and cancer.  
Immune activity within the prostate is well recognized [Palapattu et al 2005; 
Elkahwaji et al 2009]. In men aged 20-40 years old, the most common pathology of 
the prostate is prostatitis. This is a poorly understood entity with acute and chronic 
bacterial forms as well as non-bacterial manifestations of the condition. The aetiology 
may not just be infection [Nelson et al, 2004] but may be due to some autoimmune 
process  [Pontari and Ruggieri, 2004]. What is not clear from the literature, is whether 
prostatitis is a risk factor for an individual developing prostate cancer. Some studies 
have shown an increased risk of prostate cancer in men with symptomatic prostatitis 
[Nakata S 1993]. Other studies have shown that the relative odds of prostate cancer 
were elevated in men with history of prostatitis [Roberts et al 2004], but not with 
statistical significance. Inflammation is frequently present in prostate biopsies, radical 
prostatectomy specimens and tissue resected for treatment of benign prostatic 
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hyperplasia [Platz et al 2004]. A possible relationship between inflammation and 
prostate cancer has led researchers to look at whether anti-inflammatory treatments 
used to curb prostatitis, might help treat prostate cancer (Pruthi et al 2004]. 
There is a strong relationship between immunological activity within prostate cancer 
tumour tissue and tumour grade and outcome. There is an inverse relationship 
between rates of cancer recurrence and number of tumour infiltrating T lymphocytes 
in prostate cancer, [Vesalainen et al 1994]. There is a correlation between 
macrophage levels within prostate tumours versus the tumours grade [Shimura et al 
2000]. These observations are consistent with immunoediting and this implies that 
patient cell–mediated immunity is playing a role in suppressing prostate tumour 
progression.  
When one considers treatments that have a direct tumouricidal effect in prostate 
cancer, such as androgen deprivation, one finds evidence of profuse infiltration by 
activated and oligoclonal-specific T cells within the prostate [Mercader et al 2001]. 
As well as enhanced lymphocyte levels and activated antigen specific T-cells in both 
animals [Roden et al 2004] and humans [Drake et al 2005].   
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There is evidence that immune responses against healthy and malignant prostatic 
tissues can be induced. Considerable work has been done on developing a vaccination 
system using a variety of proteins or peptide derivatives that are prostate specific such 
as: 
 Six-transmembrane epithelial antigen of the prostate (STEAP) [Hubert et al 
1999]. 
 Prostate specific membrane antigen (PSMA) [Murphy et al, 1999; Milowsky 
et al, 2004; Bander et al, 2005]. 
 Prostatic acid phosphatase (PAP) [Fong et al, 2001]. 
 Prostate-specific antigen (PSA) [Pavlenko et al, 2004]. 
Vaccinations using these peptides have been demonstrated to induce humoural and 
cellular responses. This approach has lead to the development of the first FDA 
approved cancer vaccine, Sipuleucel-T, and this is in prostate cancer. This treatment 
platform involves the extraction of dendritic cells from the patient. These cells are 
then incubated with a fusion protein known as PA2024 which consists of PAP and 
GMCSF. These dendritic cells are then re-infused into the patient. There are many 
other examples of the efficacy of GMCSF as an adjunct to immunotherapy in prostate 
cancer [James et al 2001; Sanda et al 1994; Simons et al 1999]. There are also other 
groups exploring similar strategies using APCs that have been modified ex vivo to 
express prostate tumour associated antigens and cytokines [Barrou et al 2004; Zhang 
et al 2003; Rini 2004]. 
There are other examples of patient’s cells being extracted, and modified ex vivo as 
well as in situ cells having been modified with gene therapy to generate an immune 
response in prostate cancer. 
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In the mouse, TRAMP cells modified with interleukin-12 and B7-1 induced strong 
protective immune responses in C57BL/6 mice involving CD4+, CD8+ and natural 
killer cells. The efficacy of B7.1 ligand introduced into prostate cells has also been 
demonstrated by other authors [Kwon et al 1997].  
What also makes the prostate an attractive target for immunotherapies, is that in the 
older male the prostate becomes less important, particularly if he has completed his 
family. Indeed, in many older males, the gland can become a nuisance, causing 
urinary symptoms if the gland has enlarged with BPH. As such, any damage caused to 
non-malignant, healthy prostate tissue will be of little significance. This means that 
antigen targeting therapies can be used against tumour associated antigens, as well as 
tumour specific antigens. 
 
1.3.13 Prostate Tumour Associated Antigens (TAAs) 
In this section, I will introduce the TAAs that we will be using in our experimental 
work. 
 
Prostate specific antigen (PSA) - this glandular kallikrein (KLK) was first described 
in 1979. KLKs are a subfamily of serine proteases that are involved in the post-
translational modification of many polypeptides. [Wang et al 1979] 
The gene encoding for PSA is found on chromosome 19. Transcription is regulated by 
androgens and it generates a 261 amino-acid PSA precursor. This is then cleaved to 
form the 237 single chain form that is secreted into the seminal fluid by the ductal 
columnar epithelial cells. The PSA levels in seminal fluid are one million-fold higher 
than in serum. The small quantities found in the blood are in free and complexed 
forms. PSA’s physiological function is to liquefy seminal fluid. Clinically, it is 
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measured in the blood and used as a marker for the diagnosis, staging and monitoring 
of prostate cancer [Ward, Catto, and Hamdy 2001].  
A number of studies suggest that PSA could be a useful antigen for future 
immunotherapeutic treatments for prostate cancer. Human cytotoxic T lymphocytes 
(CTLs) respond to peptides derived from PSA [Xue et al 1997] and mice immunized 
with plasmid DNA encoding PSA get potent CTL responses to specific tumour cells 
[Kim et al 1998]. When mRNA from a prostate tumor line was transfected into 
autologous DCs, antibody responses directed against PSA antigens were seen [Heiser 
et al 2001]. 
 
Prostate specific membrane antigen (PSMA) – a type II glycoprotein expressed in 
both normal and malignant prostate cells. It has a transmembrane and a secreted form 
[Gregorakis, Holmes, and Murphy 1998]. Its function is not fully understood but the 
protein has some folate hydrolase activity [Tasch et al 2001]. PSMA expression is 
upregulated in high-grade prostate cancers, metastatic lesions and androgen-
independent disease [Wang et al 2007]. PSMA is also highly expressed in tumour 
neovasculature cells making PSMA an attractive target for selective therapies [Gong 
et al 1999]. PSMA specific targeted therapies are being developed in clinical trials 
[Olson, Heston, and Rajasekaran 2007]. 
 
Prostate stem cell antigen (PSCA) - a 123 amino acid glycoprotein which was first 
identified in 1998 [Reiter et al 1998]. It has similarities to stem cell antigen 2 (Sca 2), 
a cell surface marker in immature thymic lymphocytes, such as being attached to the 
cell membrane with a glycosylphosphatidylinositol (GPI) anchor [Antica, Wu, and 
Scollay 1997; Classon and Coverdale 1994]. 
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PSCA mRNA expression was studied in 16 different, healthy tissues but was found 
principally in prostate and placenta. Using in situ hybridization in normal prostate, the 
PSCA mRNA expression was found in the basal cell epithelium. This is the putative 
stem cell compartment of prostatic epithelium, suggesting an association between 
PSCA and prostate stem cells. PSCA mRNA expression was identified in more than 
80% of primary prostate cancers by in situ analysis, and was stronger than in adjacent 
normal glands. This observation suggests that PSCA may be up-regulated in prostate 
cancer and therefore may have some cancer specificity. The gene for PSCA is found 
on chromosome 8q24.2. This region is often affected by mutations in advanced 
prostate cancers [Cher et al 1994]. By using a series of monoclonal antibodies 
directed against PSCA, the cell surface localization of PSCA has been confirmed. 
Immunohistochemical analysis of a large series of primary tumours demonstrates that 
PSCA expression increases in more advanced stages and grades of prostate cancer. In 
addition, PSCA is expressed strongly in all cases of prostate cancer bone metastases 
examined [Gu et al 2000]. These studies support PSCA as a potential diagnostic tool 
in prostate cancer. 
 
Prostate acid phosphatase (PAP) – a prostate-specific isoenzyme of acid phosphatase 
secreted by cells in the prostate was first described in 1936. It is a 100 kDa 
glycoprotein containing two subunits
 
of approximately 50 kDa each [Gutman et al 
1936]. It is a major
 
phosphatase and a differentiation marker of epithelial cells in 
normal, 
 
prostate tissue [Yam 1974]. Its use as a marker for prostate cancer and its 
response to treatment was first described in 1941 [Huggins et al 1941] and it was used 
as such until the establishment of PSA as the new gold standard [Papsidero et al 
1980]  
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In prostate
 
epithelial tissue, there are two forms of PAP. There is an intracellular (the 
cellular)
 
form (cPAP), and the other is a secretory form
 
(sPAP), found in greater 
concentrations in the seminal fluid. There are some subtle physicochemical 
differences between the two forms, but the reasons for this are yet to
 
be established. 
Both forms can hydrolyze a wide variety of
 
organic phosphomonoesters [Vihko 1979; 
Lin et al 1983].  
Kallikrein-related peptidase 4 (KLK4) – is the fourth KLK to be described 
[Stephenson et al 1999] and has been shown to only be expressed in prostate cancers 
that express both progesterone and androgen receptors [Lai et al 2009]. KLKs have 
been shown to play a role in prostate cancer progression. They degrade the extra 
cellular matrix, activate protease-activated receptors (PAR-1,2,3 and 4) and activate 
TGF-beta1[Clements et al 2004; Takayama et al 2001; Ramsay et al 2008; Mize, 
Wang, and Takayama 2008]. 
In prostate cancer tissue, there is evidence that KLK performs a paracrine function. 
The cancer epithelium produces KLK4 which activates PAR-1 in the surrounding 
stroma, driving the releases of stimulatory cytokines such as IL-6 causing cancer cells 
to proliferate and increase production of further KLKs [Wang et al 2009].  
 
1.4 Immunotherapy  
 
Immunotherapy is the treatment of disease by inducing, enhancing, or suppressing an 
immune response. Those therapies that induce or enhance immune responses are 
called activation immunotherapies. Those therapies that suppress an immune response 
are called suppression immunotherapies. In cancer therapy, immunotherapy has 
become a standard treatment in a number of solid tumours, examples being the use of 
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interleukin 2 [IL2] in metastatic renal cell carcinoma, monoclonal antibody therapies 
in breast cancer, and Bacillus Calmette-Guérin [BCG] instillation into the bladders of 
patients with high grade superficial bladder cancer.  
Immunotherapies can also be classified as passive or active immunotherapies.  
Passive immunotherapies utilize components of the immune system that are created or 
modified outside of the individual and then reintroduced, such as monoclonal 
antibodies.  
Active immunotherapies interact with the individuals own immune system, ‘actively’ 
stimulating it to deliver a therapeutic result. These include cellular therapies, cancer 
vaccines and adjuvant therapies. 
 
1.4.1 Passive immunotherapies 
 
1.4.1.1 Monoclonal antibody therapy (mAB)  
This is the most widely used cancer immunotherapy. This is a targeted therapy, with 
the antibody directed at a specific target relating to a cancer cell. This may be a cell 
surface antigen or receptor. Since 1997, 15 different mABs have been given approval 
by the Food and Drug Administration (FDA) for direct anticancer therapy. Of these 
there are 12 ‘naked’ mABs, which work by directly stimulating the host’s immune 
system, and 3 ‘conjugated’ mABs, which are bound to chemotherapy agents, 
radioactive particles or toxins and this is how they deliver their therapeutic effect.  
The outcomes from mAB therapies have been variable with notable successes such as 
Herceptin in breast cancer and the flu-like side effects are relatively mild when 
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compared to chemotherapies. In prostate cancer the results have not been as 
successful as expected. This could be due to prostate tumour heterogeneity, with not 
all the cells expressing the target antigen.  
An agent showing promise and currently in phase 3 trials in prostate cancer is 
Ipilimumab. This is an anti CTL-associated antigen 4 (CTLA-4) mAB. CTLA-4 is a 
‘check point’ molecule expressed on activated T cells that delivers an inhibitory 
signal to these T cells. Blockading this molecule augments antitumour activity and 
has demonstrated efficacy in melanoma for which it now has a license. 
There is a possible role for radioisotope labelled mABs in the radiological staging of 
prostate cancer. The FDA has given approval to (111)In-capromab pendetide 
(ProstaScint) to be used in identifying small metastatic deposits, although there has 
been limited success [Elgamal, Troychak, and Murphy 1998; Cutino 1991]. It is best 
used in assessing those patients in whom there is evidence of biochemical failure with 
a view to identify their suitability for a salvage therapy.  
Where mABs are used therapeutically, they are often used as second or third line 
therapies. This may reduce their effectiveness, as this is when tumour burden and 
heterogeneity will be greater, and the patient’s immune system may already be 
significantly weakened.  
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1.4.2 Active immunotherapies 
1.4.2.1 Cellular therapies  
 
These involve taking cells from the patient, modifying them to recognize and kill the 
patient’s tumour and reintroducing them into the patient. Examples of this are 
lymphocyte activated killer cells and tumour infiltrating lymphocytes with IL-2. Such 
bespoke therapy is very costly and difficult to deliver commercially. The chosen cell 
type can be difficult to grow and modify in vitro and, if successfully generated, there 
are hypersensitivity risks associated with the transfusion of large numbers of cells. 
1.4.2.2 Cancer Vaccines 
 
Vaccines are a standard tool in prevention of infectious disease. In this setting, it is 
used in individuals who are free of that particular disease. In the cancer setting 
vaccines are being used in the same way for treating those strains of human papilloma 
viruses (HPV) (16 and 18) that are known to be responsible for the development of 
cervical cancer. In many countries there is now a programme of vaccination for pre-
teenage girls to be vaccinated with either Gardasil or Cervarix, two anti-HPV 
vaccines.  
For patients with established cancers, there are therapeutic cancer vaccines. These are 
designed to stimulate a response in the patient’s immune system against the cancer. 
They will do this through a generalized upregulation of the immune system as well as 
focusing an immune response against specific tumour antigens. Like the preventative 
vaccines, a cancer vaccine might consist of part or whole cancer cells alongside 
adjuvant   immune   stimulants  (e.g., IL-2).  These  are   known  as  cell-based  cancer  
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vaccines. Other cell based cancer vaccines involve using cellular constituents of the 
patient’s own immune system and modifying them to express tumour antigens and 
suitable co-stimulatory factors [Heiser et al 2002]. Another way of priming the 
immune system against a specific cancer protein is to use a vector-based vaccine 
[Eder et al 2000]. This approach uses a vector, such as a genetically engineered virus, 
to introduce specific identifiable components of the tumour to the immune system. 
Liposomal delivery of  cancer associated antigens is another method that has been 
tried in phase I/II trials [Meidenbauer et al 2000]. Immunization has been undertaken 
using specific tumour associated peptides (TAP) injected intradermally. This 
technique requires HLA typing of the patient to aid peptide selection. The patient can 
‘self select’ the appropriate peptides by looking for immune responses by patient 
CTLs in vitro against a panel of TAPs. The ones that are recognized by the patients 
CTLs are then used in the vaccination [Noguchi et al 2003]. Naked DNA vaccines 
using plasmid DNA expressing TAAs have also been used in phase I/II trials with 
some evidence of efficacy [Mincheff et al 2000].  
Like mAB therapies, the heterogeneity of tumour cells means that not all tumour cells 
will express the target antigen. These treatments are also used in the later stages of the 
disease where disease burden and heterogeneity will be greater and the patient in a 
poorer physical condition, adversely affecting the efficacy of immune-based 
treatments. The cells used can be autologous (from the patients themselves) and these 
will need culturing in vitro which will take time, is costly and difficult to deliver 
commercially. Established cancer cell lines can be used but these can have local 
hypersensitivity problems. The benefit of this approach is that the cell line can be 
genetically engineered to express co-stimulation factors or other immune stimulants. 
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Another problem with this approach is that the tumour cells are often poorly 
immunogenic. 
For prostate cancer there are a number of cancer vaccines in clinical trials with four 
principal modalities progressing to phase III clinical trials. The first vaccine is the 
Sipuleucel-T (APC8015, Provenge®; Dendreon Corporation, Seattle, WA) system. 
This consists of autologous dendritic cells that have been isolated from the patient’s 
peripheral blood mononuclear cells. The DCs are activated and loaded with a 
recombinant fusion protein of the prostate tumour antigen, PAP, linked to 
granulocyte-macrophage colony stimulating factor. The patient will get three 
intravenous infusions of these cells over a total of 6 weeks. In the phase I/II trials, this 
regime was well tolerated with some rigors and grade 1 fevers reported. T cell 
responses specifically against the target antigen was seen [Small et al 2000]. Two 
identically designed, randomized, double-blind, placebo-controlled trials (D9901 and 
D9902A) were conducted in 225 men with hormone refractory prostate cancer 
(HRPC). The 147 patients randomized to sipuleucel-T demonstrated a 33% reduction 
in the risk of death (hazard ratio, 1.50; 95% confidence interval, 1.10-2.05; P = .011; 
log-rank), compared to the 78 patients in the placebo arm. The treatment was well 
tolerated with around a third of patients experiencing chills, pyrexia, headache, 
asthenia, dyspnea, vomiting, and tremor. Two studies were undertaken as the first 
study had disease progression as a primary endpoint, and not overall survival. The 
second trial addressed the endpoint issues and the data from the two trials were 
combined [Higano et al 2009]. The American Food and Drug Agency have since 
given Sipuleucel-T a licence for the treatment of advanced, hormone resistant prostate 
cancer. 
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The second vaccine based therapy in phase III clinical trials uses the DCVax®-
Prostate (Northwest Biotherapeutics, Bothell, WA) system. Once again, autologous 
dendritic cells are used and they are loaded with recombinant PSMA. This treatment 
is delivered via an intradermal injection, rather than subcutaneously, allowing the 
dendritic cells better access to the patients lymph nodes where they can present the 
PSMA antigen to naïve T cells [Bonnotte et al 2003]. The phase I/II data from 32 
patients with hormone escaped prostate cancer (12 without evidence of metastatic 
disease and 20 with evidence of metastases) was promising, but never fully published. 
A phase III randomized, multi-centre, double blinded clinical trial involving 612 
patients was embarked upon. The trial is yet to be completed [Fishman 2009]. 
The third vaccine based therapy to go to phase III clinical trials used the Prostate 
GVAX® (Cell Genesys, Inc., San Fransisco, CA) system. This system used two 
cultured, allogenic, prostate cancer cell lines, PC-3 and LNCaP, which were 
genetically modified to express GMCSF. The cells were then irradiated, to inactivate 
them. In phase I/II trials, these cells were injected via an intradermal route using 
escalating cell numbers and lengthening treatment cycles (from 14 to 28 days). The 
treatment was well tolerated with no autoimmune reactions or serious adverse events. 
Efficacy was demonstrated by a downward deflection in the PSA kinetics in 84% of 
patients, and a significant increase in the median PSA doubling time from 28.7 weeks 
pre-treatment to 57.1 weeks post-treatment (p=0.0095) (Urba et al. 2008). Despite this 
early promise, the phase III trials were terminated based on futility analysis showing 
<30% chance of the primary trial of GVAX versus docetaxel and prednisolone 
(VITAL1) meeting its endpoint. The second trial of combination GVAX and 
docetaxel versus docetaxel and prednisolone (VITAL2) was stopped by the 
Independent Data Monitoring Committee. No data were published from these trials. 
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The fourth vaccine based therapy to get approval for a phase III trial is the ProstVac-
VF platform [DiPaola et al 2004].   This is a viral vaccine approach produced by 
combining fowlpox and vaccinia PSA vaccines with a combination of 3 costimulatory 
molecules (TRICOM), B7-1 (CD80), ICAM-1 (intercellular adhesion molecule 
1(CD54)), and LFA-3 (leukocyte function-associated antigen 3 (CD58)). In this phase 
III study, patients with hormone refractory PSA progression after local therapy will 
be treated with a prime and boost protocol using the vaccinia and fowlpox-PSA-
TRICOM vaccine combined with GM-CSF compared to a placebo control. Since 
patients will be enrolled without any evidence of metastasis, the primary endpoint of 
progression to clinically detectable metastasis will represent a firm endpoint 
independent from PSA. These data will determine the efficacy of this vaccine 
approach on prostate cancer progression. As yet, there has been no published data 
from this trial. 
1.4.3 Adjuvant immunotherapies 
 
These are any materials that, when delivered alongside another treatment, will 
enhance the immune response of an individual in relation to that treatment. Adjuvant 
immunotherapies, such as GMCSF [Fong et al 2009], often have their own toxicities 
and are often limited in the frequency and route through which they can be 
administered. 
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1.4.4 Granulocyte Macrophage – Colony Stimulating Factor (GMCSF) 
This is the name applied to the cytokine that stimulates the proliferation of 
granulocyte and macrophage progenitors in semi-solid culture to form maturing 
colonies of granulocytes and/or macrophages. GMCSF can be detected in all tissues, 
produced by local macrophages, mast cells, T cells, fibroblasts and epithelial cells. 
Other cells may also have the capacity to produce GMCSF [Burgess and Metcalf 
1980]. 
GMCSF is a pro-inflammatory cytokine. Expression of GM-CSF is elevated in a 
number of infections, malignancies, autoimmune and other inflammatory diseases, 
suggesting a role in the immune processes associated with these diseases [Fleetwood, 
Cook, and Hamilton 2005; Hamilton 2008; Raivich and Banati 2004]. One of the 
actions of GMCSF is to drive the differentiation of precursor cells such as monocytes  
into immature dendritic cells [Steinman et al 1988; Witmer-Pack et al 1987].  
The functional subset of DC created in this way is dependent on the cytokines present 
in the immediate environment. The presence of IFN- or IL-4 will facilitate the 
development of DCs which will activate T cells [Chen et al 2000]. The presence of 
IL-6 or TNF alpha will facilitate the development of macrophage-like DCs [Chomarat 
et al 2000; Chomarat et al 2003]. The presence of IL-10 will facilitate the 
development of tolerogenic DCs which can anergize T cells [Steinbrink et al 1999]. 
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1.4.4.1 Clinical trials using GMCSF 
There have been a number of clinical trials using GMCSF in isolation, or as an 
adjuvant to other therapies. Initially, trials were undertaken with GM-CSF alone. In a 
two cohort trial, a primary cohort of 22 men were initially treated with 28 day cycles 
of 250 µg/m
2
 of GMCSF daily for 14 days, followed by 14 days off [Small et al 
1999]. Of these 22 patients, 10 experienced a decline in their PSA at the end of each 
14 day treatment cycle only for this to then return to baseline on discontinuation of 
the GMCSF. In this group the median time to progression was 3.5 months. In the 
second cohort were 13 men who were also treated initially with 250 µg/m
2
 of GMCSF 
daily for 14 days, only this was followed by thrice weekly maintenance injections of 
250 µg/m
2
 of GMCSF until disease progression. In this cohort, 12 patients 
experienced a decline in their PSA but only one of these was sustained and in excess 
of 50% (PSA of 77ng/ml to 0.1ng/ml). Subsequent work has seen GMCSF used in 
combination with other therapeutic strategies. These are summarized in table 1.4. 
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A - Immunotherapy with recombinant GMCSF 
Strategy Indication Patients Toxicity Reference 
S.C. 
Recombinant 
GM-CSF 
PSA relapse 
post surgery 
30 Patients 
Decreased PSA 
doubling time 8.5 to 
15 mo 
3 Patients >50% 
PSA decrease 
Injection site 
reaction.  
Fatigue 
Flu like 
syndrome 
Rini BI JCO 
21;99-105 2003 
S.C. 
Recombinant 
GM-CSF 
PSA relapse 
M0 – M1 
26 Patients 
Dose dependent PSA 
decline (>25% in 8 
patents) 
Injection site 
reaction  
 
Malaise 
Schwaab T The 
Prostate 66:667-
74 2006 
S.C. 
Recombinant 
GM-CSF 
PSA relapse 
M0-M1 
16 patients  
6 patients 10-15% 
PSA decrease 
Injection site 
Dreicer R 
Investigational 
new drugs  
19:261-65 2001 
S.C. 
Recombinant 
GM-CSF 
PSA relapse 
HRPC 
M1 
Continuous 
vs short 
treatment  
36 patients 
PSA decline more 
common with 
continuous (12 out of 
13 pts)  
Malaise  
Flu like 
Injection site 
Small EJ 
Clin Ca Res  
5:1738-44 1999 
Recombinant 
GM-CSF + 
Thalidomide 
22 patients  
HRPC M1 
22% PR (PSA) 
All patients PSA 
response 
Injection site 
reactions 
Low blood 
counts 
Fatigue 
Dreicer R Urol 
Oncol. 2005 
23:82-6 
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B - Immunotherapy with prostate cancer cells (allogenic or autologous)  expressing 
GMGSF 
Strategy Indication Patients Toxicity Reference 
Allogenic 
cellular 
immunotherapy 
LNCaP 
PSA 
relapse 
after RRP 
Hormone 
naive 
21 patients 
76% decreased PSA 
velocity 
Injection site 
reaction  
Rash,   
Flu like 
syndrome 
Simons JW Clin 
Ca Res 12:3394-
3401 2006 
Allogenic 
cellular 
immunotherapy 
GVAX  
LNCaP and 
PC3 expressing 
GMCSF 
55 HRPC 
34 M1 
21 M0 
 
Low dose 
vs 
high dose 
55 patients 
6/55 PSA decrease 
>25%  
Reduction of PSA 
slope in both groups 
Fatigue  
Flu like 
syndrome 
Small EJ 
Clin Ca Res 
13:3383-3891 
2007 
Allogenic  
LNCaP and 
PC3 expressing 
GMCSF 
 
M1 HRPC 
 
Dose (no. 
cells) 
escalation  
80 patients 
PSA decline in 32% 
of high dose group 
Decreased osteoclast 
activity in 62% of 
tested patients 
Not reported 
Small E 
Proc ASCO 2004  
Abs. 4565 
Autologous 
vaccination with 
tumour cells 
infected with 
GMCSF 
expressing 
retrovirus 
M1 at 
prostatecto
my  
Phase I 
8 patients  
 
Immune responses to 
PCA antigens  
Injection site 
reactions 
Simons JW 
Can Res 59:5160-
68 1999 
GMCSF as an 
adjuvant to 
vaccine therapy 
Vaccine 
alone 51 
patients  
Vaccine + 
GMCSF 44 
patients 
1 CR,  8 PR with 
GMCSF 
2 CR, 17 PR w/o  
 
GMCSF 
detrimental?  
Injection site 
reactions 
Pyrexia 
Fatigue 
S.J. Simmons 
The Prostate 
1999 
39: 291 - 297 
Autologous  
cancer cells 
transduced with 
GM-CSF gene 
(MFG-GM-
CSF)  
8 prostate 
ca pt and 18 
kidney ca pt 
Immune responses to 
prostate ca antigens 
“Very few 
side effects” 
Nelson WG 
Cancer 
Chemother 
Pharmacol 
2000;46 
Suppl:S67-72.  
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C - Clinical trial using GMCSF as an adjuvant to vaccination with prostate antigens 
Strategy Indication Patients Toxicity Reference 
Plasmid  
pVAX/PSA used 
for vaccination 
with GM-CSF 
and IL2 
Phase I 
HRPC   
8 patients 
Dose 
escalation 
Immune responses to 
PSA 
in 2 of the 3 pt treated 
at high dose 
Change in PSA slope 
2 pt who showed 
immunity to PSA 
 
Concomitant 
IL2  
Miller AM 
J Immunother 
2005 4:389-95.  
PSA146-154 
(PSA-peptide) + 
GM-CSF s.c. + 
DC primed with 
peptide 
Phase 1 
M1 or locally 
advanced 
28 pt 
Immune responses to 
peptide in 50% of 
patients 
Local reaction 
– skin biopsies 
 
Perambakam S,  
Cancer Immunol 
Immunother. 
2006 55:1033-42  
 
Plasmid vector 
pVAX/PSA + 
GM-CSF + IL2 
Phase I 
HRPC  
8 pt 
Immune responses to 
PSA at high doses 2/3 
pt decline PSA slope 
2 pt who showed 
immunity to PSA 
Concomitant 
IL2 
Pavlenko M,  
Br J Cancer. 
2004 91:688-94  
Vaccinia virus 
expressing (rV-
PSA)  
Phase I 
33 pt with 
M1 or PSA 
relapse 
Dose 
escalation 
S.C. GM-
CSF in 10 pt 
 
PSA was stable in 14 
pt with or w/o GM-
CSF 
 
Injection site  
reactions Flu 
like syndrome 
 
Eder JP  
Clin Cancer Res. 
2000 6:1632-8  
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Table 1.4 A,B,C,D – Current therapeutic strategies involving the use of GMCSF 
 
Consistent with immunotherapies, there is evidence to suggest better outcomes if 
GMCSF is used in the earlier stages of prostate cancer with patients experiencing the 
better long term responses were lower tumour stage, Gleason score, and pre-treatment 
PSA level. [Dreicer 2005, Klein 2001, Rini 2003, Small 2006]. 
 
 
 
 
 
D - Clinical Trials with viral vectors expressing GMCSF 
Strategy Indication Patients Toxicity Reference 
Intralesional 
OncoVEX  
27 patients 
Single dose  
Skin mets 
from  
various 
tumours 
19 post treatment 
biopsies had 
tumour of which 14 
also had tissue 
necrosis.  
Local reaction 
(inflammation, 
erythema) 
Febrile 
response. 
Nausea fatigue. 
JCC Hu 
Clin Can 
Research 
12:6737-47 2006 
Intralesional  
Vaccinia 
expressing 
GMCSF 
7 Patients  
Skin mets 
from 
melanoma 
 
2 injections 
per week for 
6/52 
4 patients show 
response in treated 
and untreated mets. 
Distant progression.  
 
GMCSF mRNA 
 
Flu like 
syndrome 
Injection site 
reactions. 
Pustula after 
repeated 
treatments  
MJ MAstrangelo 
Cancer Gene 
Ther 6:409-22 
1998 
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1.5 Gene therapy 
1.5.1 Definition 
Gene therapy is the correction of defective genes responsible for disease development. 
There are several approaches for correcting faulty genes: 
 A normal gene may be inserted into a nonspecific location within the genome 
to replace a non-functional gene 
 An abnormal gene could be swapped for a normal gene through homologous 
recombination 
 The abnormal gene could be repaired through selective reverse mutation, 
which returns the gene to its normal function 
 The regulation of a particular gene could be altered (i.e. up regulated or down 
regulated) 
In relation to cancer gene therapies, there are two main approaches - corrective 
and cytoreductive. 
 
1.5.2 Gene therapy and prostate cancer 
 
 
Up until 2013 there have been 1701 clinical trials approved in gene therapy and 65% 
of all gene therapy clinical trials are in cancer. Since gene therapy was first used in 
prostate cancer in 1994, there have been 108 clinical trials approved of which 78 are 
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still ongoing as of June 2010 (www.wiley.com/legacy/wileychi/genmed/clinical/, 
www.gemcris.od.nih.gov/Contents/GC_CT_RPT.asp?advsrch=true). 
Prostate cancer is a disease that has a number of characteristics that make it an 
attractive target for gene therapy as identified in table 1.5. 
 
  PCA-Specific features Relevance to gene therapy 
Anatomy  Localized tumour accessible 
for procedures such as 
brachytherapy  
Accessibility for localized gene therapy and 
combined modality therapy in vivo by 
transurethral/transrectal routes  
 Accessory organ  Complete ablation of the normal organ in addition to 
the tumour is clinically undeleterious  
  Cytoreductive transgene expression required only for 
duration necessary for prostate tissue ablation 
Natural 
history  
Long pre-clinical latency  Preventive gene therapy strategies maybe feasible 
  Definition of genetic/epigenetic events underlying 
molecular progression provides rational basis for 
preventive/corrective strategies  
 Propensity for metastatic 
spread to lymphatics/bone 
Targeting of systemic gene therapy for advanced 
disease must effectively target bone and lymphatics  
Current 
treatment 
efficacy 
Failures even for localized 
disease  
Supports use of novel combined modality treatments 
to improve local control 
Ineffective for advanced 
disease  
Pressing need for alternative systemic therapies  
Biology Low mitotic rate  Effective vectors for in vivo gene delivery must 
transduce both non-dividing as well as dividing cells  
  Tumours are resistant to S-phase-dependent 
cytotoxic strategies  
 Clinical/biological transitions:  Define gene therapy targets including tumour 
suppressors, oncogenes etc., for prevention and for 
treatment of disease at various stages 
 Prostatic intraepithelial 
neoplasia (PIN) to carcinoma  
 Androgen-dependent to 
androgen-independent tumour 
growth  
Prostate-
specific genes 
and antigens  
~500 or more prostate-specific 
ESTs in addition to current 
known markers such as 
PSA/PSMA  
Facilitate prostate specific promoter/antigen 
targeting and therapeutic monitoring  
Table 1.5 – Prostate cancer-specific gene therapy strategies [Mabjeesh et al 2002]. 
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1.5.3 Therapeutic strategies in gene therapy 
1.5.3.1 Corrective  
This treatment approach involves compensating for the abnormal gene expression that 
has facilitated malignant change. As such, the gene targets are usually oncogenes or 
tumour suppressor genes.  
 
1.5.3.1.1 Oncogene suppression 
The suppression of oncogenes can be achieved by binding antisense oligonucleotides 
to the mRNA product of the oncogene, thus preventing its translation. Oncogenes, 
such as c-myc [Buttyan et al 1987], have been shown to be over-expressed in prostate 
cancer and are thus good targets for this therapeutic approach. Tumour suppression 
human prostate cancer models using a retrovirus expressing an antisense 
oligonucleotide for c-myc has been demonstrated [Steiner et al 1998]. An alternative 
method of disrupting oncogene expression is to use ribozymes to cleave specific 
sequences on the expressed oncogenic mRNA (Ast 2003). 
1.5.3.1.2 Tumour suppressor gene expression 
The classic tumour suppressor gene that is down regulated in a variety of cancers, 
including prostate cancer is p53 [Effert et al 1992]. Studies in murine models have 
demonstrated anti-tumour efficacy using a recombinant adenoviral p53 expressing 
vector [Asgari et al 1997]. In small cell cancer of the lung, p53 replacement using an 
adenoviral vector has demonstrated some efficacy  [Swisher et al 1999]. 
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1.5.3.1.3 Difficulties with corrective therapies. 
This approach, alone, is limited by the heterogeneous nature of the multiple mutations 
that will have occurred in the evolution of the cancer. Another limitation lies in the 
transduction and expression efficiencies of the current gene transfer strategies 
[Mabjeesh, Zhong, and Simons 2002]. These systems are unlikely to correct enough 
of the tumour population to be successful. This is reflected by the fact that only 9 of 
108 clinical trials relating to gene therapy in prostate cancer involve corrective 
therapies (table 1.6). To counter this, the corrective approach would need to be multi-
faceted, or used in combination with other therapeutic strategies to stand the best 
chance of success [Lu 2001].  
1.5.3.2 Cytoreductive 
1.5.3.2.1 Immunotherapies 
Immunotherapies are the most popular form of gene therapy platforms, with 74 of  
108 clinical trials relating to gene therapy in prostate cancer involving the immune 
system (table 1.6).  
1.5.3.2.2 Enzyme/prodrug therapies 
Enzyme/prodrug therapies involve the delivery of a gene expressing a particular 
enzyme to the targeted tumour cell. When expression of this enzyme is maximal, a 
prodrug is administered. Prodrugs are selected that are well tolerated by the patients. 
The enzyme converts the prodrug into a cytotoxic agent (normally poorly tolerated if 
delivered systemically) within the tumour cells [Gardner et al 2002]. An example of 
this system is the nitroreductase/CB1954 enzyme/prodrug system. This platform we 
used in our recent clinical trial and modified for the ADUP trial (see below). 
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1.5.3.2.3 Oncolytic viruses 
The use of oncolytic viruses which do not incorporate a therapeutic gene is not, by 
definition, gene therapy. This approach can be used in combination with gene therapy, 
and so the use of oncolytic viruses in isolation is worth exploring. Not all oncolytic 
viruses used in clinical trials are wild-type in nature. 
The first trial adopting this approach used CV706, a prostate-specific antigen (PSA)-
selective, replication-competent adenovirus that has been shown to selectively kill 
human prostate cancer xenografts in preclinical models [DeWeese et al 2001]. This 
was a phase 1 study so the primary endpoints were safety and efficacy with dose 
escalation from 1 × 10
11
 and 1 × 10
13
 viral particles delivered by a real-time, 
transrectal ultrasound-guided transperineal technique using a three-dimensional plan. 
The authors found that CV706 was safe and was not associated with irreversible grade 
3 or any grade 4 toxicity. 5 out of the 20 patients in the trial demonstrated a PSA 
response. All of the 5 were in the higher adenoviral dose cohorts, suggesting a dose 
related response. One of the PSA responses lasted 11 months. 
Similar responses were seen using a similar oncolytic adenovirus (CG7870) trialed in 
hormone refractory prostate cancer [Small et al. 2006]. This virus was also under 
prostate specific promoters but there were also immuno-modulating gene inserts. 5 
out of the 23 patients exhibited a 25–49% decline in PSA. Once again, this mostly 
occurred at the higher dose level. 
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1.5.3.2.4 Gene-directed radioisotope therapies 
This novel approach uses the gene expressing the human sodium iodide symporter. 
Delivered directly into the target tumour, the transfected cells will express the 
symporter. The patient is then treated with a radioisotope of iodine, I
131
. This is used 
to great effect in thyroid cancer where the cells naturally express the symporter. Those 
cells expressing the symporter will take up the radioisotope, leading to cell death 
[Spitzweg et al. 2000]. 
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Category       Number of trials 
 
Gene/promoter No. of 
trials 
Corrective   
Tumour suppressor 
gene  
 
P53 
P501 
P16 
Cytochrome P450  
RTVP-1 
3 
2 
1 
1 
1 
Oncogene c-myc 1 
Cytoreductive   
Immunotherapy PSA 
GM-CSF 
PSA/ICAM-1/LFA-3/B7.1/GM-CSF 
PSMA  
IL-2 
Il-12 
PSA/ICAM-1/LFA-3/B7.1 
Human Telomerase reverse transcriptase 
MUC-1/IL-2 
IL-2/IFN- 
HPV  
PSA/CD80 
PAP/GM-CSF 
PSMA/CD40 
Tumour RNA  
TRAIL  
IFN- β 
CMV/ 1,3 galactosyltransferase 
MUC-1/CD40-ligand 
Oncofetal antigen 5T4 /GM-CSF 
PAP/PSA 
PAP 
TNF 
REIC-Dkk-3 
16 
15 
6 
5 
4 
3 
3 
2 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
Enzyme/prodrug 
therapy 
HSV TK        
HSV TK/ cytosine deaminase  
ADV TK 
Nitroreductase/CB1954   
Ad5-yCD/mutTKSR39rep-ADP  
FP253/Fludarabine 
6 
6 
2 
1 
1 
1 
Oncolytic PSA 
Murine osteocalcin 
Oncofetal antigen 5T4 
4 
1 
1 
Gene-directed 
radioisotope therapy 
Sodium/Iodide symporter 2 
Table 1.6 details the various clinical trials and therapeutic strategies that have been 
given approval in prostate cancer. Provided by the Journal of Gene Medicine, Gene 
Therapy Clinical Trials Worldwide: Update 2012:  
[http://www.wiley.co.uk/genmed/clinical/] Table includes trials that are open, closed, 
completed, under review or in submission. Trials which are closed having never been 
initiated are excluded. 
70 
 
 
1.5.4 Delivery strategies in gene therapy 
1.5.4.1 Viral vectors 
The functional unit of gene therapy, is the therapeutic transgene linked to the 
promoter that will drive the expression of the transgene [Galanis 2001]. This unit 
needs to be delivered to the target tissue and this is most commonly done using viral 
vectors. There are a number of characteristics to consider when selecting a viral 
vector :  
The size of the transgene that can be inserted. 
The transduction efficiency 
Chromosomal insertion 
Dividing/non-dividing cells 
Titre 
Replicating/ conditionally-replicating 
Host systemic/local responses to the selected vector 
Target specificity 
Secondary effects of the wider viral genome on the target cell 
Commercial viability 
Popular vectors used in prostate cancer include herpes simplex virus and adenovirus. 
Herpes simplex virus can take a large insert of up to 30 kb and can transfect both 
replicating and non-replicating cells (useful in prostate cancer). However, the HSV 
genome can cause insertional mutagenesis and can also cause reactivation of latent 
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herpes infection. Adenovirus can be generated in far higher titres to GMP standards 
(10
11
 infectious units per ml compared to 10
7
 infectious units per ml), have a good 
safety record, can infect replicating and non-replicating cells and the viral genome 
does not cause insertional mutagenesis [Mulligan, 1993]. Unfortunately, adenovirus 
can only take inserts of up to 7.5kb and can drive a considerable inflammatory 
response. In the adenovirus, the vector is usually inserted into the genome at the 
expense of the genes that are pivotal to replication in the E1 and E3 regions and this is 
why the insert is limited to 7.5kb. By removing these genes, the vector is rendered 
replication deficient which has the advantage of limiting the vector to the target tissue. 
1.5.4.2 Non-viral vectors 
There is a variety of non-viral vectors such as for delivering gene therapy. These 
vectors are often far easier to manufacture and less immunogenic, making them 
commercially attractive. There are three main strategies involving naked DNA, 
complexed DNA and liposome envelopes. The common problem these approaches 
have is one of low transfection efficiency.  
To transfect cells with naked DNA one needs to get the DNA through the cell 
membrane. The strategies for this are largely physical ones designed at disrupting the 
membrane to allow the passage of the DNA into the cell. Techniques for this include 
electroporation, a method of using transient electric fields and cell specific media to 
temporarily disrupt the membrane and allow the movement of DNA into the cell. 
These types of technique are impractical in vivo, largely limiting their use to the 
laboratory [Boulaiz et al 2005].  
To try to get DNA through the cell membrane, attempts have been made to complex 
the DNA with other molecules or wrap them in a liposome which will bind with the 
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cell membrane and facilitate uptake of the DNA into the cell. Unfortunately, these 
approaches have low transfection efficiency in vivo [Nishikawa and Huang, 2001]. 
1.5.4.3 Tissue specificity 
A key consideration in gene therapy is how to limit the effect of the therapy to the 
target tissue, limiting side effects. The most obvious way of achieving tumour 
specificity is injecting directly into the tumour. This is easier with radiologically or 
clinically definable organs/tumours but problematic if trying to treat multiple sites in 
metastatic disease or anatomically remote sites such as the adrenal gland. There is 
also a small risk of tumour implantation when undertaking intratumoural injection in 
any organ (1.1% in hepatocellular carcinomas [Hiroshi et al 1998]). Another way of 
delivering therapy directly to the target organ is to use vectors that are delivered 
systemically but only taken up by that specific cell type [Lu et al 2001]. 
Another approach is to use a transgene that will only be expressed in the target cell 
type. This can be achieved by using a transgene which is controlled by regulatory 
elements specific to the host cell. The weakness in this approach is in poorly 
differentiated tumours or tumours that are classically heterogeneous, like prostate 
cancer. In these settings, the regulatory pathways may not be present [Bangma, 2001]. 
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1.5.5 The Birmingham prostate gene therapy clinical trials 
1.5.5.1 Background 
 
This forthcoming clinical trial using the AdGMNR virus in prostate cancer is the next 
step in a programme of research at Birmingham University exploring the utility of the 
VDEPT platform in the treatment of solid cancers. Initial clinic trials used an E1,E3-
deleted replication defective adenovirus type 5 vector expressing bacterial NTR from 
the CMV immediate early promoter, produced in  E1 complementing Per.C6 cells. 
This virus was named CTL102 and the prodrug used was CB 1954. The 
nitroreductase is an E. Coli derived enzyme that will convert the harmless prodrug, 
CB1954 into a DNA alkylating anthracycline (figure 1.7) [Bridgewater et al 1995]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 The nitroreductase and CB1954 system using an E1/E3 deleted replication 
deficient adenovirus. This figure adapted from McCormick [McCormick 2001] 
demonstrates the primary cell death from the activated prodrug and the bystander 
effect that occurs, killing neighbouring cells from the diffusion of activated prodrug 
from the dying primary cell. 
 
 
The diffusion of activated prodrug into the surrounding tissue will cause cell death in 
neighboring cells, which may not be expressing the therapeutic enzyme. This is called 
the bystander effect, and this explains the cytotoxicity rates of up to 1000 times those 
E1,E3 Ad5- 
pCMV-ntr  
 
Nitroreductase 
48hrs 
i.v. prodrug (CB1954) 
Bystander effect 
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predicted by gene transfer rates alone. This facet of the enzyme/prodrug system can 
help to compensate for low gene transfer and expression levels [Kerr et al 1997]. The 
lack of cell cycle specificity, as well as a moderate bystander effect is an advantage in 
the nitroreductase/CB1964 enzyme/prodrug system [Bridgewater et al 1997]. With 
these enzyme/prodrug systems, there is a risk that non target tissues will be affected. 
This can be minimized by tumour specific vector targeting or gene regulation. 
After encouraging results in cell culture and animal models [Weedon SJ. et al 2000 ], 
clinical trials were undertaken in cancers of the liver (CTC99020; GTAC Ref No 
032). Palmer reported direct intratumoural injection of CTL102 in patients suffering 
from primary and metastatic liver tumours was feasible and well tolerated [Palmer 
DH. et al 2003]. Good levels of expression of nitroreductase were achieved in those 
tumours injected with 1x10
11 
virus particles. This system was then used in the prostate 
cancer trial CTC01010 (GTAC Ref No 055) 
1.5.5.2 The CTC01010 trial 
The prostate trial was aimed at patients diagnosed with primary and locally recurrent 
adenocarcinoma of the prostate. The trial consisted of two arms, an initial operable 
and a subsequent inoperable arm [Patel et al 2009]. 
1.5.5.2.1  “Operable” Arm –  
A total of 20 patients who were scheduled for radical prostatectomy received CTL102 
alone via intraprostatic injection prior to surgery. Objectives of this phase of the study 
were safety, tolerability and level of NTR expression in the resected specimen. 
Immunohistochemistry demonstrated NTR staining in the glandular epithelium of the 
tumour and of the normal prostate tissue at all dose levels (5x10
10
 to 1x10
12
 vps). 
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Expression of NTR was found in 30%-50% of the tumour specimen slides and 
seemed to increase when using higher vector doses or multiple injections, however 
there was no statistically significant relationship between virus dose and extent of 
NTR expression. The distribution of NTR expression was patchy and mostly localised 
at the site of injection, hence the rationale for the altered injection technique in the 
current trial. Gene therapy was well tolerated with only one patient having a possible 
DLT (transient bilirubin increase) at a dose of 5x10
10
 virus particles. This cohort was 
expanded but there were no other treatment related serious adverse events and dose 
escalation was resumed. Other adverse events were transient grade 3 lymphopaenia (4 
patients) and grade 2 hepatic transaminases increase (3 patients).  
1.5.5.2.2 “Inoperable – Therapeutic” Arm –  
A total of 19 patients with locally relapsed prostate cancer had escalating doses of 
CTL102 (5x10
10
 to 1x10
12
 vp), followed by iv CB1954. Serious adverse events 
occurred in 2 of the 5 patients treated with 1x10
12
 vps. Based on safety and efficacy 
data from the first two arms, an expanded cohort of patients was treated with 5x10
11
 
vps. There was some indication of efficacy in terms of PSA decrease and 
stabilization. One month after treatment, 2 patients showed PSA decline > 50%, 
which was maintained for 7 and 10 months respectively. Five patients showed a 
decline of 10% - 50% and 3 patients had PSA progression with a PSA increase > 
10%. The median time to PSA progression was 8.1 months, which was greater than 
the predicted time to PSA progression, although this difference was not quite 
statistically significant (see Figure 1.8). Fourteen of the 19 patients received a second 
cycle of treatment on the basis of indications of efficacy, and 5 of them remained 
progression free until the end of the study (median time 11.4 months).  
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Figure 1.8 – Kaplan-Meier survival curve for patients from the treatment arm of the 
CTC01010 gene therapy trial with the predicted survival curves for the patients and 
the 95% confidence interval. The survival advantage demonstrated by the trial 
survival curve is not quite clinically significant. 
 
1.5.5.2.3 Results 
Five patients underwent post treatment prostate biopsies at least one month after the 
gene therapy. In 4 of these 5 patients the histopathology showed lymphocyte 
infiltration, although viable tumour cells were found in all 5 biopsies. The tolerability 
of the CTL102/CB1954 combination was good -  the most common side effects were 
fever, grade 1–2 hepatic toxicity, grade 2 nausea and grade 1-2 diarrhoea. Virus DNA 
was detectable in the blood immediately after tumour injection and was cleared within 
24 hours in most patients. CB1954 pharmacokinetics showed a profile similar to that 
seen in the trial of CB1954 alone.  
Administration of CTL102 plus CB1954 has been well tolerated with no evidence of 
significant treatment related toxicity to date. Administration of doses up to 5 x 10
11
 
viral particles to patients in the liver study (CTC99020), have shown no indication of 
toxicity.  
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Analysis of patient samples 24 hours after viral administration has shown that virus is 
not present in blood, urine or faeces, and therefore shed virus does not appear to be a 
significant safety concern. PK analysis of CB1954 has indicated that the prodrug 
behaves as expected and is rapidly cleared by 2-phase exponential decay, achieving 
expected peak concentrations of around 7uM 
All patients had evidence of pre-existing immunity to adenovirus.  Following 
administration of CTL102 most developed increased levels of Ad specific antibodies. 
These responses increased up to 3 months post-injection and were generally higher in 
individuals receiving higher doses of virus. Immune responses were not associated 
with any significant level of toxicity, although 24% of patients in the prostate trial did 
experience some pyrexia up to 24 hours post injection. 
In the prostate trial, transient lymphopaenia was the most common abnormality post 
inoculation and occurred during the first 24 hours in 80% of the patients. This was 
mild and did not result in any opportunistic infections. 41% of the patients 
experienced a grade 1 transaminitis post inoculation. 33% of the patients experienced 
grade 1 transient thrombocytopaenia day 4-5 post inoculation. 
Overdosing with CB1954 could lead to more severe gastrointestinal toxicity, 
particularly, nausea, vomiting and diarrhoea. These should be treated appropriately 
and would be expected to subside rapidly. 
In summary, data from the CTC01010 trial showed: 
• Intratumoural administration of virus at doses up to 1 x 1012 virus particles is 
not associated with significant treatment-related toxicity. In some cases there was 
evidence of mild lymphopaenia, but this was transient and only seen at doses >1 x 
10
10 
virus particles. 
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• Subsequent administration of CB1954 is well tolerated although patients do 
experience some nausea/vomiting and/or diarrhoea, as seen using CB1954 alone. 
 
• Intratumoural injection of CTL102 results in the transduction of tumour cells, 
as demonstrated by expression of the NTR transgene in liver and prostate tumours. 
 
• Administration of 5 x 1010 virus particles produced sufficient NTR protein for 
potential therapeutic effect. 
 
• Virus was not detected in the blood, urine or faeces 24 hours after virus 
administration, indicating that virus shedding is not a safety concern. 
 
• Pharmacodynamics of CB1954 administration were as predicted from the 
Phase I CB1954 alone study [Chung-Faye G. et al 2001]. 
 
• In the prostate trial, there was an indication of efficacy, as measured by 
decrease or stabilisation of serum PSA levels [Patel P. et al 2009]                                                                                          
 
• There was preliminary evidence of immunostimulation as shown by transient 
T cell responses to prostate tumour antigens PSA and PSMA in some patients. 
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1.5.6 The ADUP trial 
 
Given the evidence of immune responses of patients in the CTC01010 trial, a gene 
expressing GMCSF was added to the vector. This was designed to enhance the local 
immune response in patients undergoing this therapy. This new construct is called 
AdGMNR (figure 1.9). 
 
 
Figure 1.9 – The gene map of AdGMNR, an E1,E3 deleted adenovirus with the CMV 
promoter/nitroreductase/IRES/GMCSF insert at the E1 locus. 
 
The effects of co-expression of a powerful cytokine (mGMCSF) with NTR in a 
bicistronic adenoviral vector have been investigated in murine models. Data from 
these experiments show that the Ad-NTR-mGMCSF vector plus CB1954 has a 
greater effect than Ad-NTR + CB1954 or Ad-mGMCSF + CB1954, on tumour 
progression in TRAMP prostate cancer cell xenografts in nude mice (Young et al 
2008). 
The mechanism of cell death in the trial patients will be through apoptosis rather than 
necrosis and, as such, could be considered to have a weak immunostimulatory impact. 
Work in mice using monoclonal antibodies targeting anti-TNF-related apoptosis-
inducing ligand (TRAIL) receptors [Uno et al 2006] combined with APC stimulating 
anti-CD40 and anti-CD137 eradicated established solid tumours. This would suggest 
80 
 
that, with suitable co-stimulation, apoptotic cell death can prove to be 
immunostimmulatory. 
In those prostates removed from patients in the operable arm, patchy NTR expression 
was demonstrated, suggesting the trans-rectal route has insufficient accuracy to 
deliver virus to the entire prostate. Work done by DeWeese’s group in dogs had 
shown encouraging results using a transperineal (figure 1.10) route for administration 
using a brachytherapy template. This technique is used in humans for the accurate 
placement of brachytherapy seeds in the prostate for the treatment of prostate cancer  
[DeWeese TL. et al 2003]. 
 
 
Figure 1.10 – Using a brachytherapy-type template and transrectal ultrasound probe to 
map the prostate and accurately site needles within the prostate. 
 
A 0.1ml injection of virus solution will mechanically flow through 4mm of the 
prostate and diffuse a further 1mm (i.e. a radius of 5mm). The introduction of 0.1ml 
of virus solution will cause the prostate to increase in size and the amount it increases 
is a direct product of the number of injections. These elements need to be considered 
when calculating dose planning and placement. 
With a better delivery technique and an immunostimulatory addition to the VDEPT 
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platform a new trial was conceived using the new AdGMNR virus and CB1954. This 
is the ADUP trial. 
 
1.6 Aims of the project 
 
Building on our units experience from the CTC01010 trial and in preparation for the 
ADUP trial, the aims of the project were 
1. To validate the AdGMNR viral construct for the application to the Gene Therapy 
Approval Committee (GTAC) for approval to proceed to a phase I/II clinical trial in 
patients with locally advanced, castrate resistant non-metastatic prostate cancer 
patients who are not suitable for radiotherapy or surgery. 
2. To develop and validate an assay to monitor changes in cellular immune responses 
in patients undergoing the AdGMNR trial (the tertiary endpoint of the clinical trial) to 
GCLP standards. 
3 To use this assay in patients with prostate cancer at various stages of the disease to 
document the immune responses in these populations. These data would be helpful in 
interpreting the results from the trial patients. 
 
 
 
 
 
 
82 
 
2 Materials and Methods 
 
2.1  Introduction 
Generally the methods used in the thesis were based on “Molecular Cloning: A 
Laboratory Manual [Sambrook et al, 1989]” or “Current Protocols in Molecular 
Biology [Ausubel et al, 1998]” unless otherwise described. All materials purchased 
from supplier companies were used according to manufacturer’s instructions unless 
otherwise stated. 
All experiments with micro-organisms and blood products were performed in 
specified work places in the School for Cancer Sciences at the University of 
Birmingham. All experiments involving live bacteria were performed in an ACGM 
(advisory committee on genetic manipulation) containment level 2 room, and all 
procedures involving eukaryotic cell culture and viruses were carried out in class 2 
biological safety cabinets in the 3
rd
 floor tissue culture room at the School for Cancer 
Sciences which is also ACGM containment level 2. 
 
2.2  Tissue culture 
2.2.1 Maintenance and Passage of Human Cells in Culture 
All cells in culture were kept in Galaxy R 37C humidified incubators with 5% CO2 
(RS Biotech, Irvine, UK).  
2.2.2 Maintenance of cell lines 
Unless otherwise stated, cell lines were obtained internally, within the School for 
Cancer Studies (table 2.1). Cells were grown in 25 cm
2
, 75 cm
2
 or 150 cm
2
 tissue 
culture flasks in appropriate growth media supplemented with foetal calf serum (FCS) 
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and glutamine (Table 2-1), kept at 37°C in a humidity-controlled incubator with 5% 
CO2 and maintained with fresh media twice a week. The media was routinely 
supplemented with the antibiotics penicillin (100 iu/ml) and streptomycin (100 
mg/ml) (pen/strep). Before reaching confluence, cells were passaged into a new flask. 
This involved carefully removing all the media from the cells with a pipette and 
gently washing the cells with PBS. 3-5 ml of Trypsin-EDTA solution (0.05% (w/v) 
Trypsin and 0.02% (w/v) EDTA) was then added before incubating at 37°C and 5% 
CO2 for 1-3 minutes depending on cell type. Once the cells started to lift into 
suspension, the flask was tapped briskly with an open palm three to four times to 
detach the remaining adherent cells. 3-5 ml of suitable medium was added to the cells 
and these were then aliquoted at a 1:10 dilution into a new flask for routine passage or 
at a suitable dilution after counting if the cells were required for an experiment. 
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Cell lines Cell types Culture media 
PC3 
(ATCC #CRL-
1435) 
Prostate carcinoma 
clavicle metastsis. 
Transformed but 
not immortalized. 
P53 deleted. 
[Kaighn et al, 
1979] 
DME/HEPES with 10% 
FCS, 2 mM glutamine 
22Rv1 
(ATCC #CRL-
2505) 
Prostate carcinoma 
primari. 
Transformed but 
not immortalized. 
P53 normal. 
[Sramkoski et al, 
1999] 
DME/HEPES with 10% 
FCS, 2 mM glutamine 
DU 145 
(ATCC #HTB-
81) 
Prostate carcinoma 
brain metastasis. 
Transformed but 
not immortalized. 
P53 mutated. 
[Mickey et al 
1980] 
DME/HEPES with 10% 
FCS, 2 mM glutamine 
Table 2.1. Cell lines and Culture media. Media, FCS and glutamine were prepared 
by the kitchen in the Cancer Research UK Institute for Cancer Studies from 
ingredients supplied by Gibco Life Technologies; DME/HEPES, HEPES buffered 
Dulbecco’s modified Eagle’s medium. 
 
In every experiment using cells, cell counting was done by resuspending the cells and 
then pipetting 20 μl of them onto a chamber of a Hycor KOVA Glasstic Slide 10 
with a grid cell counter (Hycor Biomedical Inc.). The number of cells in a small grid 
were counted under a light microscope using phase contrast illumination. To estimate 
the cell concentration, the average number of cells per small grid were multiplied by 
10,000 resulting in the number of cells per ml. Cell viability was assessed by staining 
with x0.4% Trypan blue. 
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2.2.3 Cryogenic preservation of cells  
When cells were to be frozen for storage, they were trypsinised as usual. The 
trypsinisation was halted by adding 10 ml of growth medium once the cells had 
detached from the floor of the flask. The suspended cells were transferred to a 15 ml 
tube and centrifuged at 1,200 rpm (177 x g) for 5 minutes at 4°C (in a Heraeus 
Megafuge 2.0R). The supernatant was discarded and the cell pellet was resuspended 
in 1 ml of FCS containing 10% dimethyl sulphoxide (DMSO). The resulting cell 
suspension was transferred to a labeled cryovial and slowly frozen down to -80°C at a 
rate of 1°C per minute in a Nalgene
TM
Cryo 1°C freezing container. After 2hours, the 
cryovial was placed in a -176°C liquid nitrogen freezer for long-term storage. 
To use frozen cells in an experiment, the cells would first be defrosted rapidly in a 
37°C water bath. Then 10 mls of medium at 37°C would be added to the cell 
suspension, and the tube centrifuged in a Heraeus Megafuge 2.0R for 10 minutes at 
2000 rpm (492 x g). The supernatant would be discarded and the resulting cell pellet 
would then be gently resuspended in pre-warmed medium and transferred to a labeled 
tissue culture flask. The medium would be replaced with fresh medium the next day. 
 
2.3 Adenoviruses 
Unless otherwise stated all viruses were obtained from Dr. P.Searle.  
 
2.3.1 Infecting Cells with Adenoviruses 
Unless otherwise stated, cells were infected/exposed to the various different 
Adenoviruses and vectors by the two following methods. 
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2.3.1.1 Infecting Cells Growing as a Monolayer 
Cells were seeded onto tissue culture flasks and plates at least 24 hr prior to infection. 
To determine the number of cells present per well or flask, replica wells/flasks were 
harvested by trypsinisation and counted using a Glasstic Slide 10 (Hycor KOVA, 
Edinburgh, UK). Media was removed from cells growing as monolayers and virus 
added in the smallest volume of medium possible to completely cover the monolayer. 
After 90 min incubation (37C, 5% CO2) virus was removed from the cells and fresh 
medium added. 
 
2.3.1.2 Infecting Cells in Suspension 
Adherent cells that were to be infected in suspension were removed from flasks either 
by addition of EDTA and agitation or by scraping the monolayer into medium using a 
cell scraper so virus receptors were not removed from their surface. Cells were 
examined microscopically, if aggregates of cells were present then a single cell 
suspension was produced by rapidly passing the cells through a 0.2 m diameter 
needle. Cells were then counted as before. The desired number of cells, either 
suspended in this manner or from cells that grow in suspension culture, were pelleted 
by centrifugation (538 g) and supernatant discarded. Cells were re-suspended in a 
small volume of media containing virus (typically 200 μl for less than 1x106 cells). 
Cells were incubated with virus for 90 min (37C, 5% CO2) before excess volume 
(typically 10 ml) of medium was added. Cells were pelleted by centrifugation (538 g) 
and supernatant discarded before the cells were re-suspended in fresh medium. 
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2.3.2 In vitro cytotoxicity assay (MTT assay) 
The MTT assay is a colorimetric assay that measures cell viability. MTT (3-(4, 5-
dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide) is a tetrazolium dye that 
is reduced by the activity of NAD(P)H-dependent oxidoreductase cellular enzymes to 
its insoluble formazan, giving a purple color. Selected cells growing in culture flasks 
were harvested by trypsinisation, resuspended in infection medium and incubated 
with concentrations of AdGMNR, AdCMV-GMCSF (negative control) and CTL 102 
(positive control) of 30 and 300 pfu/cell for 90 minutes. After infection, cells were 
seeded at 1 x 10
5
 cells per well in 150 µl medium on a 96 well flat bottomed plate and 
allowed to adhere overnight. Medium was removed after 48 hours, and prodrug was 
added in 180 µl medium to each well in quadruplicates of varying concentration. 
Prodrug was removed after 16 hour incubation at 37°C and replaced with 180 µl fresh 
medium. On day five, medium was removed and replaced with 150 µl fresh culture 
medium containing 0.5 mg/ml MTT, diluted fresh from a 5mg/ml stock solution. 
Plates were incubated for three hours at 37°C before the MTT solution was aspirated 
from the wells. Plates were dried for 30 minutes at room temperature before the 
addition of 150 µl DMSO to each well. Absorbance at 490 nm was read using a 
Victor plate reader (PerkinElmer, Monza, Italy (Formerly Wallac, Finland)). 
 
2.4 Detection of protein expression in mammalian cells 
2.4.1 Preparation of protein samples from cells in tissue culture 
Cells were prepared at a density of 1 x 10
5
 per ml and 1 ml of cell solution was added 
to wells on a 24-well plate. These cells were then infected with the desired viruses and 
harvested at selected time points. Medium was removed and the cells washed with 
PBS. Cells were then incubated with 125 l of urea sample buffer (USB) (6M urea, 
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10% glycerol, 2% SDS, 100 mM DTT and 80 mM Tris pH 6.8). After 3 minutes of 
incubation the suspension was removed from the well and pipetted into an eppendorf 
tube. The eppendorf tubes were then placed in a heating block at 100°C for 10 
minutes. The protein concentration could now be assayed using the Bradford/Bio-Rad 
assay (see later). The samples were then stored at -20°C.  
2.4.2 Detection of protein expression by Western blotting 
2.4.2.1 Seperating the protein bands 
Expression of particular proteins in the cellular protein samples generated from the 
6M urea lysis of our cells could be detected using Western blotting. Western blotting 
consisted of three consecutive steps:  
 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE). 
 Transfer of proteins to a nitrocellulose membrane.  
 Visualisation of the proteins with immunoglobulin antibodies against 
the specific proteins using an enhanced chemiluminescence system. 
  
Our SDS-PAGE step involved generating a fresh 12% resolving gel and a 5% 
stacking gel. These gels were made in the gel apparatus rack (Biometra, Florida, 
USA) using the ingredients listed in table 2.2. The APS was never more than a month 
old, and the TEMED always added last.  
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Solution 
components 
12% resolving gel 
(10 ml) 
5% stacking gel 
(4 ml) 
H20 3.3 ml 2.7 ml 
30% acrylamide mix 4 ml 670 l 
1.5 M Tris (pH 8.8) 2.5 ml - 
1.0 M Tris (pH 6.8) - 500 l 
10% SDS 100 l 40 l 
10% APS 100 l 40 l 
TEMED 10 l 6 l 
Table 2.2. Ingredients of an SDS-PAGE 10% APS = ammonium persulphate (0.1 g in 
1ml). Lasts for one month at 4°C once made up. 30% acrylamide mix (37.5:1 
acrylamide/bisacrylamide ratio) from BioRad. 
 
 
The resolving gel solution was placed between the glass plates of the gel apparatus 
rack up to the level of the green bar holding the plates. The rack was then topped up 
with dH2O whilst the gel sets. After 15-30 minutes the polymerisation of the resolving 
gel was complete. The dH2O was then removed and the stacking gel was overlaid on 
the resolving gel to the top of the plates and a comb inserted to create the wells. Once 
set, the comb was removed, a Tris-glycerine electrophoresis running buffer (25 mM 
Tris pH 8.3, 250 mM glycerine and 0.1% SDS) was poured into the electrophorator 
and the wells were loaded with equal amounts of the protein samples, appropriate 
positive and negative controls and a kaleidoscope standard protein marker (Bio-Rad). 
130 volts was applied across the gel for 90 minutes. Once electrophoresis was 
complete, the proteins that had spread across the acrylamide gel were transferred to a 
nitrocellulose membrane (Biotrace NT, Gelman Sciences, Pall Corporation). To do 
this, the gel and membrane were sandwiched between two sheets of 3MM Whatman 
filter paper and assembled into a blotting rig. The rig was completely submerged in 
transfer buffer (39 mM glycine, 48 mM Tris pH 8.3, 0.037% SDS and 20% 
methanol). 100 volts was applied across the transfer buffer for 1-2 hours until the 
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kaleidoscope markers were seen to have transferred to the nitrocellulose membrane 
from the gel. 
 
2.4.2.2 Detection and visualisation of the protein bands 
Once the protein transfer was complete, the membranes were blocked with a blocking 
solution (5% non-fat milk made from dried milk powder in PBS/0.1% Tween) for 
more than 60 minutes at room temperature or agitated overnight at 4°C. This step was 
repeated with the required primary antibody diluted in blocking solution. The 
dilutions and antibodies are listed in table 2.3. After adding the primary antibody, the 
membranes were washed three times with a washing buffer (PBS/0.1% Tween) for 10 
minutes on a 3D rocking platform at room temperature. Then the membranes were 
incubated for further hour at room temperature with the appropriate secondary 
antibody, and then washed three times with the washing buffer. Once, completed, one 
final 10 minute wash was undertaken using PBS without 0.1% Tween. 
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Antibody Size of target Information Dilution used 
Actin 45 kDa Mouse monoclonal 1:20,000 
-tubulin 55 kDa Mouse monoclonal 1:2000 
Anti-mouse n/a Peroxidase conjugate 1:1000 
Anti-sheep n/a Peroxidase conjugate 1:5000 
Anti-rabbit n/a Peroxidase conjugate 1:2000 
Table 2.3. Antibody information and dilutions for Westerns (All antibodies bought 
from Sigma) 
 
The ECL (enhanced chemiluminescence) detection step was carried out using the 
manufacturers (Amersham Pharmacia Biotech) protocol. This involved mixing 3 ml 
of each ECL reagent together and then soaking the blot membranes in it for 60 
seconds. Kodak X-OMAT AR 8x10 inch film was exposed for anytime up to 30 
minutes, depending on the strength of the signal. The exposed radiographs were then 
developed in a Kodak X-O-graph developer in a dark room. 
 
2.4.3 Determination of Protein Concentration by the Bradford Assay 
The Bradford reagent (BioRad, Basingstoke, UK) was diluted 1 in 5 in dH2O. This 
solution was then filtered with an Acrodisc with a 0.45 m pore size (Pall, 
Portsmouth, UK). 180 μl of the filtrate was added to wells in a 96 well flat bottom 
plate. 20 μl of two fold serial dilutions of 1 mg/ml bovine serum albumin (BSA) in 
the same buffer as the protein being measured was added to the wells. 20 μl of two 
fold serial dilutions of the target protein was also added. The plate was incubated for 
10 min at room temperature and the plate was measured at an absorbance at  = 595 
nm using a plate reader (Bio-Tek Kontron Instruments, Watford, UK). Protein 
concentration was calculated using linear regression from a standard curve generated 
from the values of absorbance at  = 595 nm of known concentrations of BSA 
dilutions.  
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2.4.4 Detection of green fluorescence protein (GFP) and red fluorescence 
protein (RFP) by flow cytometry 
To quantify GFP and/or RFP expression in cells mediated by viral vectors bearing the 
GFP and or RFP gene, fluorescence activated flow cytometry was used. 
Approximately 3 x 10
5
 cells were plated in 24-well plates, infected with the desired 
moi of viral vectors and harvested at different time points. To harvest, the medium 
was aspirated and the cells washed with PBS. The PBS was aspirated and 200 l 
trypsin/EDTA added. The cells were incubated at 37°C for 10 minutes then 1 ml of 
PBS + 2% FCS was added. They were transferred to a 2 ml eppendorf tube and spun 
for 5 minutes at 2000 rpm (492 x g). The supernatant was poured off and another 1 ml 
of PBS + 2% FCS added to resuspend the cells. The same centrifugation was carried 
out but with the pellet resuspended in 500 l 3.7% formaldehyde (diluted in PBS) and 
transferred to a FACS tube, wrapped in silver foil and kept at 4°C until flow 
cytometry was performed. They could be kept for one week before analysis using an 
Epics
®
 XL-MCL Flow Cytometry machine (Beckman Coulter). 20,000 cells were 
counted per sample and gated for side scatter and forward scatter. 
2.5 Flow Cytometry 
This section will describe methods for measurement of cell surface antigen and the 
expression of fluorescent proteins. 
2.5.1 Sample Preparation  
Adherent cells were selected to be stained with antibody. To avoid the removal of cell 
surface antigens the cells were removed from flasks by either the addition of EDTA 
and agitation or by scraping the monolayer into the culture medium using a cell 
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scraper. The cells were then examined microscopically, and if cell aggregates were 
present, then a single cell suspension could be produced by passing the cell 
suspension through a 0.2 m diameter needle. The cells were then counted as before. 
A suspension of the desired number of cells was generated and the cells pelleted by 
centrifugation (538 x g) for 5 minutes. The supernatant was discarded. The cells in the 
pellet were re-suspended in 4 ml cold FACS buffer (PBS, 2% FCS), pelleted by 
centrifugation (538 x g, 4C) and then re-suspended in 50 μl of FACS buffer 
containing the primary antibody at 4C. The cells were incubated in this way for 1hr 
at 4C before being washed with 3 ml cold FACS buffer and pelleted by 
centrifugation (538 x g, 4C) for 5 minutes. If the primary antibody was directly 
conjugated to a fluorophore then the pellet was re-suspended in 0.3-0.5 ml FACS fix 
(PBS, 2% FCS), 4% paraformaldehyde (v/v). If the primary antibody was not 
conjugated to a fluorophore the pellet was re-suspended in 50 μl of FACS buffer with 
a suitable secondary antibody labelled with a fluorophore. The cells were then 
incubated for a further hour at 4C before being washed with 3 ml cold FACS buffer 
and pelleted by centrifugation (538 g, 4C) for 5 minutes. This pellet was re-
suspended in 0.3-0.5 ml FACS fix. Once these steps were complete, the fixed samples 
could be stored in the dark for a maximum of 72 hours at 4C. During this time the 
analysis by flow cytometry could be undertaken.  
For every set of cells stained with a primary antibody (developed in a specific 
mammalian species) (+fluorophore), a replicate set of cells was stained with an 
appropriate isotype control antibody (developed in the same mammalian species) , as 
a negative control. For analysis of GFP expression only, adherent cells could be 
removed from flasks by trypsinisation. The cell suspensions were washed with 4 ml of 
cold FACS buffer and pelleted by centrifugation (538 x g) before being re-suspended 
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in FACS fix (0.3-0.5 ml) and stored in the dark at 4C until analysis by flow 
cytometry (within 72 hours).  
 
2.5.2 Antibodies for Flow Cytometry 
The following antibodies were used to phenotype T cells and B cell blasts. All 
antibodies were raised in mice 
Antigen Fluorophore Isotyp
e 
Clone Source 
CD80 RPE-Cy5 IgG1 2D10 Serotec # MCA2813C  
CD88 FITC IgG2a P12/1 Serotec # MCA2059F 
CD14 RPE-Cy5 IgG2a TÜK4 Serotec # MCA1568C  
Table 2.4 Antibodies for Flow Cytometry. 
Antigen Fluorophore Isotype Clone Source 
Rat surface 
marker 
RPE IgG1 W3/25 
Serotec # 
MCA928PE 
Rat surface 
marker 
FITC IgG1 W3/25 
Serotec # 
MCA928F 
Rat surface 
marker 
RPE-Cy5 IgG2a 
MRC 
OX-34 
Serotec # 
MCA929C 
Rat surface 
marker 
unconjugated IgG1 W3/25 
Serotec # 
MCA928  
Table 2.5 Isotype Control Antibodies for Flow Cytometry. 
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2.5.3 Analysis of Cells by Flow Cytometry 
Cells were analysed using a four colour Beckman Coulter XL flow cytometer using 
Coulter System II software for data acquisition and WinMDI software for data 
presentation.  
The first samples analysed were the cells stained with isotype control antibodies (table 
2.5). Using forward and side scatter properties the desired cell population, stained 
with the appropriate anti-antigen antibody (table 2.4), could be selected by ‘gating’ 
the population with the software. This allows the exclusion of debris and the majority 
of dead cells. Voltages were typically set so the negative control in each channel 
generated a peak fluorescence from between 10 and 1. When using multicolour 
staining, the appropriate colour controls were analysed and compensated for with 
reference to the other colours being analysed. Once this step was completed, the 
voltages, gates and compensation were kept constant for all cells subsequently 
analysed. More than 2x10
4
 events needed to be analysed per sample for the result to 
be accepted.  
 
Both the percentage positive and mean fluorescence (Mn. Fl.) data were analysed. 
Percentage positive is the percentage of the gated cells that fluoresce above the level 
of the negative isotype control (or unstained cells if only GFP expression was being 
measured). This was measured using a marker set to include only 2% of the negative 
control cells. Mean fluorescence refers to the mean fluorescence in each channel for 
all the cells gated on and not just positively fluorescing cells.  
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2.6  Microscopy 
A Zeiss Axiovert 25 inverted microscope was used for all phase-contrast and 
fluorescence microscopy using 5x, 10, 20, 40x objectives with 21x, 42x, 84x and 
168x overall magnification. Pictures were taken using a Spot camera and processed 
using Spot Advanced software (Diagnostic Instruments, Michigan, USA). The 
fluorescence pictures shown have the same exposure and gain settings for green 
colour only with an exposure time of 2 secs and the gain set at 4.  
 
 
2.7 Experiments on samples from patients and donors. 
 
2.7.1 Samples 
Blood and tissue samples throughout the project were obtained following an informed 
written consent from healthy consenting members of the Institute or patients suffering 
from prostate cancer in all cases. Local ethical approval was obtained prior to study to 
carry out this research project (LREC 2002/292; LREC 5689; RRK 1986; and 
Protocol CTL 102/CB1954/CTC01010: Version VII (last update 09-01-06)). Patients 
were recruited from outpatient clinics at the University Hospital Birmingham NHS 
Trust. Blood and tissue collection protocols are outlined in Appendix 1. Control 
subjects were obtained from healthy volunteers without a history of malignant 
disease.  
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2.7.1.1 Separation of Peripheral Blood Mononuclear Cells and Plasma from 
Whole Blood or Buffy Coats 
120mls of whole blood was obtained from consenting donors. 100mls of this was 
placed into syringes containing sodium heparin (10 U/ml) and processed as soon as 
possible. The other 20mls was placed into clot activating red top vacutainers for the 
extraction of the serum. Buffy coats were obtained from West Midlands Blood 
Transfusion Service (WMBTS). Both were diluted by the addition of an equal volume 
of RPMI 1640 and layered on top of 15 ml of Lymphoprep (Nycomed, Torshov, 
Norway) before centrifugation (800 x g) for 30 min. Peripheral blood mononuclear 
cells (PBMCs) were removed from the sample/medium interface with a Pasteur 
pipette. PBMCs were washed twice by the addition of RPMI1640 and pelleting cells 
by centrifugation (538 x g followed by 250 x g) for 5 minutes. Cells were re-
suspended in RPMI 1640  medium and counted as above.  
For the serum extraction, the vacutainers are stood on the bench for 6 hours at room 
temperature. The tubes are then centrifuged at 2000 rpm (492 x g) for 10 minutes. 
Using a pastette, the clear serum extracted. 7 mls of blood produces approximately 4 
mls of plasma. The plasma is transferred to a labelled 15ml Falcon tube and placed in 
a water bath at 56
o
 centigrade for 30 minutes to heat inactivate it (the serum can then 
be  stored in a –20o centigrade freezer) 
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2.7.1.2 The manufacture of B Cell blasts 
Once the PBMCs were extracted using the Lymphoprep density gradient extraction 
technique The PBMCs were then incubated in media for two hours to allow the 
monocytes to adhere to the plate. The non-adherent population were then removed 
and washed. Two thirds of the cells were then put in cryostorage to be used as the 
‘responder cells’, and the other third were used for the manufacture of the B cell 
blasts. 
These cells were incubated on an irradiated (10000 Rads) feeder layer of murine L 
cells expressing human CD40 ligand for 48 hours in B cell media containing 10 mls 
of mixed human sera, 100l of 5g/ml IL-4 and 66l of 1mg/ml cyclosporin A in 
RPMI (to inhibit T cells) in 90ml IMDM with 5ml 200mM glutamine and 5ml 
penicillin/streptomycin solution. After 48 hours, the B cells are removed from the 
feeder layer using a pastette and plated out on a fresh feeder layer of irradiated murine 
CD40 ligand expressing L cells for 48 hours in B cell media contained mixed human 
sera, IL-4 and cyclosporin A. This passage was repeated a further 4 times until a 
characteristic clumping was evident in the B cell population. These B cells are 
designated B cell blasts. 
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2.7.1.3 B cell preparation using Mega CD40L and autologous sera.  
120mls of blood was taken from suitably consenting subjects. 20mls was used to 
extract serum. The PBMCs were extracted from the remaining 100 mls of blood using 
the Lymphoprep density gradient extraction technique, as before. The PBMCs are 
then incubated in media for two hours to allow the monocytes to adhere to the plate. 
The non-adherent population are then removed and cleaned. Two thirds of the cells 
are then put in cryostorage, and the other third are used for the manufacture of the B 
cell blasts.  
 
These cells are incubated for 48 hours in B cell media from a stock consisting of 
90mls IMDM, 10mls autologous sera, 100l 5g/ml IL-4, 5ml 200mM glutamine, 
5ml penicillin/streptomycin solution and 66l 1mg/ml cyclosporin A (to inhibit T 
cells) as well as 150ng of soluble human CD40L (MEGA CD40L). After 48 hours, 
the B cell suspension is centrifuged at 538 x g for 5 minutes. The pellet is washed and 
then plated out at 48 hours in B cell media.. This passage was repeated every 48 hours 
for a further 4 times until a characteristic clumping was evident in the B cell 
population. These B cells are designated B cell blasts. 
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2.7.1.4 Nucleofection of B cell blasts 
The evening before the nucleofection is planned (halfway through the last passage of 
the B cell blasts) the autologous ‘responder cells’ were taken out of cryostore, thawed 
and rested in media overnight. 
The B cell blasts were counted, washed and centrifuged. The pellet was reconstituted 
in a volume of media creating a cell suspension of 1x10
6
/ml cells. 1mls were then 
placed in a separate 15ml sterile test tube and centrifuged at 1500RPM for 5 minutes. 
The residual media was aspirated carefully with 200µl Gilson pipette. The pellet is 
then suspended in premixed nucleofector reagent (Amaxa) specific for human B cells. 
The suspension was transferred to a nucleofector cuvette. 10g of the plasmid DNA 
for the chosen antigen (e.g. BMLF-1) was then added and the cuvette placed in an 
Amaxa nucleofector set on programme U15 (the programme specific for human B 
cells). Once the programme was complete, the suspension was carefully transferred 
into a Bijou containing 1 ml cell culture media.  

2.7.1.5 Transfection of the B cell blasts 
The PBMCs are counted, washed and centrifuged. The pellet is reconstituted in a 
volume of media that will create a cell suspension of 1x10
6
/ml cells. 1ml is then 
placed in a 35mm culture dish. A further 1ml of media is added. A transfection 
complex is prepared using 97 l of serum free media, pipetted into a 1.5ml tube. Into 
the centre of the media (avoiding the sides of the tube), 3 l of the FuGENE6 
Transfection Reagent is pipetted. Flick the tube to mix and leave to stand at room 
temperature for 5 minutes. 2 g of the plasmid DNA is added and the tube is flicked 
to mix. The tube is left to stand for 15-45 minutes at room temperature. The 
transfection complex is added drop wise to the 35mm plate whilst gently swirling the 
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media. Expression is maximal at 48 hours and at this point, the cells suspension is 
centrifuged at 1500RPM for 5 minutes. The pellet is resuspended in 1 ml of cell 
culture media. 
 
2.7.1.6 IFN-  ELISpot Assay 
The IFN-  ELISpot was performed using a commercial kit containing both capture 
and biotinylated detection antibodies and a streptavidin bound alkaline phosphatase 
(AP) (Mabtech, Nacka Strand, Sweden). MAIP N45 96 well plates (Millipore, (U.K.) 
LTD, Watford, UK) were coated with 50 μl of anti human IFN-  monoclonal Ab (1-
D1K) diluted to 15 g/ml in PBS for 3 hrs at room temperature (or overnight at 4C). 
The antibody was flicked off and each well was then washed six times with 200 μl of 
RPMI 1640 and then incubated with 200 μl RPMI 1640, 10%FCS for 1hr at 37C in 
an incubator. The medium was flicked off the plate and the subject cells and antigen 
were added in a total volume of 100 μl of RPMI 1640, 10% autologous serum, 2 mM 
glutamine, 100 U/ml penicillin and 0.1mg/ml streptomycin. The cells were at a 
density between 5x10
4
-5x10
5
 cells/well. The plates were incubated for 16 hr in an 
incubator at 37C (5% CO2) before the cells were removed and wells washed six 
times with PBS, 0.05% Tween 20. 50 μl of biotinylated anti- IFN-  Ab (7-B6-1) 
diluted to 1 g/ml in PBS was added to each well and incubated for 3-4 hrs at room 
temperature. The antibody was flicked off and the wells washed six times with PBS, 
0.05% Tween 20. Then 50 μl of streptavidin-AP (diluted 1 in 1000 in PBS) was added 
to each well. The plates were incubated for 1 hr at room temperature. The 
streptavidin-AP was flicked off and the wells were washed six times with PBS, 0.05% 
Tween 20. 50 μl of development reagent (1000 fold dilution of AP colour reagent A 
and B (BioRad) in 1X AP colour development buffer (BioRad) was added to each 
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well. The plates were incubated for 10-20mins at room temperature or until colour 
had developed. At this point, the reaction was stopped by washing thoroughly with 
tap water. Plates were left to air dry overnight before the number of spots formed in 
individual wells was counted. The spots were counted using an AID automated elispot 
reader using AID 3.1 software (AID, Strassberg, Germany). The results are 
represented as the mean (of three replicate wells) number of spot forming cells 
(SFCs). 
 
 
2.7.1.7 Protocol for Intracellular Staining With the FIX & PERM® Cell 
Fixation & Permeabilization Kit 
For each sample to be analyzed the appropriate volume of the conjugated anti-HA 
antibody and the appropriate isotype control is added to an appropriate, labelled 5 ml 
tube. 1 x 10
6
 cells of the nucleofected B cell blasts in 100 μl RPMI 1640 were 
pipetted into each tube. The tubes were gently mixed using a Vortex, and the tubes are 
incubated for 15 minutes in the dark at room temperature. We then added 100 μl of 
Reagent A (Fixation Medium) and incubated for a further 15 minutes in the dark at 
room temperature. 
We then added 3 ml wash medium (PBS + 0.1% NaN3 + 5% FBS) and centrifuged 
for 5 minutes at 300–350 x g. We then aspirated the supernatant and vortexed to fully 
resuspend the cell pellet. 100 μl of Reagent B (Permeabilization Medium) and the 
recommended volume of anti-HA antibodies or the corresponding isotype control 
were added to the pellets. The samples were then mixed with the Vortex for 1–2 
seconds and incubated for 20 minutes in the dark at room temperature. The sample 
was then washed with 3 ml wash medium and centrifuged for 5 minutes at 300–
350xg. The supernatant was then aspirated. The cells were either resuspended in 
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sheath fluid for immediate analysis, or fixed in 0.5 ml of 0.1% paraformaldehyde and 
stored at 2–8°C in the dark. Fixed cells should be analyzed within 18 hours.  
The cells were analysed using a four colour Beckman Coulter XL flow cytometer 
using Coulter System II software gated on SSC and FL-3 for data acquisition and 
WinMDI software for data presentation.  
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3 Validation of the AdGMNR construct 
3.1 Introduction  
 
The CTC 01010 (GTAC Ref No 055) trial demonstrated that a replication deficient 
adenoviral vector (CTL102) coding for NTR could be injected into human prostate 
where the transgene is successfully expressed. With the systemic injection of the 
prodrug, CB1954, there was biochemical evidence of tumour response in some 
patients as well as evidence of possible immune responses. With a modified virus, 
AdGMNR, and a modified method of delivery, using a brachytherapy type template 
transperineal delivery, the new virus required in vitro validation before entering it into 
clinical trial.  In this chapter, I am presenting data validating the in vitro efficacy of 
AdGMNR on human prostate cancer cell lines. In these experiments we also explore 
other variants of NTR obtained by selection and screening in E. coli of libraries of 
NTR mutants with amino acid substitutions at active site residues identified by X-ray 
crystallography.  With these data, I aim to demonstrate:  
 
 That the human prostate cancer cell lines PC3, DU145 and 22Rv1 can be 
infected with constructs using an E1, E3-deleted, replication defective 
Adenovirus type 5 vector. 
 
 That the NTR and GMCSF proteins are expressed in human prostate cancer 
cell lines infected with AdGMNR. 
 
 That human prostate cancer cell lines infected with AdGMNR are sensitised to 
CB 1954. 
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 That AdGMNR is equivalent to CTL102 in its expression of NTR and ability 
to sensitise cells to CB1954 
 
 That the GMCSF produced by human prostate cancer cell lines infected with 
AdGMNR is biologically active.  
The data presented are the best representative data from each experiment which was 
repeated at least three times. If there was excessive variation further repeats of the 
experiment was undertaken. 
3.2 Susceptibility of PC3, DU145 and 22Rv1 prostate cancer cell 
lines to infection by adenovirus 
 
The extent of binding and uptake of adenovirus vectors has been found to vary 
between cell types. In order to investigate the relative infection efficiencies of the cell 
lines DU145, PC3 and 22Rv1 the following experiments were set up. Susceptibility to 
infection was assessed by measuring GFP expression following infection with 
AdGFP, an E1, E3 replication defective adenovirus construct expressing GFP from 
the CMV IE promoter. The cells were infected with a range of multiplicities of 
infection (moi), and GFP expression was monitored by flow cytometry 2 days 
following infection.  
Figure 3.1 demonstrates the increasing expression of GFP by DU145 cells infected 
with increasing moi (pfu/cell) of AdGFP demonstrating moi dependant infectivity. 
These results demonstrate susceptibility of these prostate cancer cells to infection with 
adenovirus vectors 
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moi (pfu/cell) % expressing GFP Mean fluorescence 
Control 0 67.36 
500 94 686.28 
5000 95 5316.04 
 
Figure 3.1. Histogram of flow cytometry on DU145 cells infected with AdGFP 
 
When comparing the mean fluorescence in these cell lines after infection, we 
observed that the primary prostate cancer cell line, 22Rv1 was significantly (P=0.046 
in unpaired t-test) more susceptible to infection than another, metastatic prostate 
cancer cell line, DU145 when comparing moi of 300 pfu/cell as shown in figures 3.2 
and 3.3. 
 
 
500 pfu/cell Control 
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Figure 3.2. Infectability of prostate cancer cell lines with E1 deleted AdGFP at 
various MOI (pfu/cell)  
 
 
Figure 3.3. Fluorescent microscopic appearance of prostate cancer cell lines infected 
with various MOI (pfu/cell) of AdGFP. 
 
Control 30 pfu/cell 300 pfu/cell 
Multiplicity Of Infection (pfu/cell) 
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3.3 NTR and GMCSF proteins are expressed in human prostate 
cancer cell lines infected with AdGMNR  
3.3.1 NTR Expression by PC3 And DU145 cell lines after infection by 
AdGMNR, AdCMV-GMCSF and CTL102 
 
DU145 and PC3 cells were infected with varying quantities of AdGMNR, AdGMCSF 
(negative control) and CTL 102 (positive control). The cells were then lysed in urea 
and NTR expression measured with Western Blotting. 
 
 
 
Figure 3.4. Western Blot of NTR expressed by PC3 cells 96 hours after infection by 
AdGMNR, AdGMCSF and CTL 102  
 
The Western blot demonstrates similar expression levels of NTR by AdGMNR and 
the positive control (CTL102), in these prostate cancer cell lines when infected by the 
same concentration of virus particles (fig 3.4). This confirms that the insertion of the 
IRES and hGMCSF coding sequences into the expression cassette has not resulted in 
any detectable change in the level of NTR expression from the CMV promoter. As 
expected, there is no expression of NTR in the control (AdGMCSF) demonstrating 
that the expression of NTR is due to the presence of the NTR gene in the vector. 
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3.3.2 GMCSF expression by PC3 and DU145 cell lines after infection by 
AdGMNR, AdCMV-GMCSF and CTL102 
 
DU145 and PC3 cells were infected with varying quantities of AdGMNR, 
AdGMCSF) and CTL 102. The expression of GMCSF was assayed using a 
commercial ELISA kit. 
 
 
Figure 3.5. GMCSF expression by PC3 and DU145 cells infected by AdGMNR and 
AdGMCSF, with CTL 102 as the control virus at 48 hours post infection. The controls 
are cells in media alone. All values represent the mean plus or minus the standard 
deviation. 
 
The results from the ELISA demonstrate similar levels of GMCSF expression by 
AdGMNR infected prostate cancer cells and the positive control (AdGMCSF infected 
prostate cancer cells) when these prostate cancer cell lines are infected by the same 
number of plaque forming units. There is no expression of GMCSF in the control 
DU145 cells and the negative controls (CTL102 infected prostate cancer cells) 
demonstrating that the expression of GMCSF is due to the presence of the GMCSF 
gene in the vector (Figure 3.5). Uninfected PC3 cells produce a low level of GMCSF 
(<10ng/ml). This was a consistent feature when the experiment was repeated. This has 
been noted in the literature (Rokhlin OW. et al 1996). Infection with just 3 pfu/cell of 
AdGMNR 
AdGMCSF 
CTL102 
AdGMNR 
AdGMCSF 
CTL102 
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either Ad-NRGM or Ad-GM-CSF resulted in 25 to 27.1 ng/ml/10
6
/48hrs of GMCSF 
in comparison to 6 to 10 ng/ml/10
6
/48hrs of GMCSF in CTL102 and uninfected cells. 
With higher MOI the levels of GMCSF were higher.  
The time-dependence of GM-CSF production was also examined. The experiment 
was repeated with the media being changed every 24 hours and the media being 
removed was aliquoted and stored at -20C. Figure 3.6 demonstrates that for those 
cells infected by AdGMNR, the greatest expression of GMCSF was seen between 48 
and 72 hours. In both of these experiments, the levels of GMCSF expression are lower 
in the AdGMNR infected prostate cancer cells when compared to AdGMCSF infected 
prostate cancer cells. This observation was consistent, and also evident in the 22RV1 
cell line. This may be due to the position of the gene in relation to the internal 
ribosome entry site. 
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Figure 3.6. GMCSF expression by DU145 cells over time after infection with 
CTL102 (A), AdGMCSF (B) and AdGMNR (C). Medium was changed every 
24 hours and the concentration of GMCSF in the old medium was measured by 
ELISA 
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3.4 Human prostate cancer cell lines infected with AdGMNR are 
sensitised to CB 1954 
 
Expression of E.coli NTR in a range of tumour cell lines, as well as in some normal 
tissues, has been shown to enable these cells to convert the prodrug CB 1954 into its 
active cytotoxic form resulting in cell killing at concentrations of CB 1954 which 
have no effect on non-expressing cells (Bridgewater JA. et al 1995, Green NK. et al 
1997).  This section summarises studies which demonstrate that NTR expression 
sensitises cell lines derived from human prostate tumours to CB 1954 when cultured 
in vitro. These studies show that NTR expression can result in efficient killing of 
these cells by prodrug applied to the cells in culture.  
 
PC3 and DU145 cells were harvested by trypsinisation, resuspended in infection 
medium and incubated with varying concentrations of AdGMNR, AdGMCSF 
(negative control) and CTL 102 (positive control) from 0 to 300 pfu/cell for 90 
minutes. The cells were then seeded into micro-wells (1 x 10
5
 cells/well) and 
incubated for 48 hours to allow full expression of the transgenes. After this expression 
period, the cells were exposed to a range of concentrations of CB 1954. Cell viability 
was then determined using an MTT assay. The results for DU145 cells and PC3 cells 
are shown in figure 3.7. The uninfected cells were susceptible to high concentrations 
of CB1954. Those cells infected with AdGMCSF had no change in sensitivity to 
CB1954 from uninfected cells, at either MOI. Those cells infected with CTL102 and 
AdGMNR had a virus dose-dependent increase in sensitivity to CB1954. 
These figures show that the greater the multiplicity of infection with NTR expressing 
vectors, the more sensitive the prostate cancer cell lines are to the prodrug CB1954. 
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From the IC50 measures, in both cell lines, the CTL 102 was marginally more 
cytotoxic than AdGMNR in combination with CB1954 but this was not statistically 
significant. 
Prostate cancer cells infected with non-NTR expressing adenoviral vectors are 
insensitive to CB1954. The figures also show that this sensitivity is dose dependent 
and that in high doses CB1954 is toxic to all the prostate cancer cells regardless of 
infection. 
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Figure 3.7: Relative survival of prostate cancer cell lines following 
infection with AdGMCSF, CTL102 or AdGMNR at 0, 30 or 300 pfu/cell 
and treatment with different concentrations of CB1954. 
 
 
cells: DU145 PC3 
virus moi 
(pfu/cell) 
0 30 300 0 30 300 
AdGMCSF 362.8  281.6  256.6  238.8 235.5 241.0  
CTL102 232.9 12.0 3.9  291.6 6.0 2.4  
AdGMNR 323.9 12.3  4.3  305.7  9.8  4.3  
 
Table 3.2: IC50 (CB1954 concentration resulting in 50% reduction in 
viable cells) following infection with the 3 viruses. IC50 determined from 
the curves in Figure 3.7. 
 
Infection of the human prostate cancer cell lines with AdGMNR resulted in 
sensitisation to killing by CB 1954. The results from the negative control 
(AdGMCSF) demonstrated adenovirus infection per se did not contribute to this cell 
killing. The results from the positive control (CTL102) demonstrate that the addition 
of the GMCSF gene has slightly diminished the amount of cell kill in cells infected 
with AdGMNR and exposed to CB1954.  
AdGMCSF CTL102 AdGMNR 
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3.5 Biological activity of GMCSF produced by PC3 and DU145 cell 
lines after infection by AdGMNR  
 
GMCSF causes mononucleocytes to differentiate into immature dendritic cells. In 
differentiating, various cell surface proteins change. In this assay, we look for changes 
in expression of CD14. This is expressed in mononucleocytes but not in immature 
dendritic cells. If the supernatant taken from infected cells contains biologically active 
GMCSF then this supernatant will drive mononucleocytes to differentiate in to 
immature dendritic cells. This can be confirmed by seeing changes in the levels of 
expression of CD14. 
 
DU145 and PC3 cells suspended in growth medium were mixed with suspensions of 
varying concentrations of AdGMNR,  ps1307 (a virus identical to AdGMNR except 
that the NTR gene has two amino acid changes in the active site) and CTL 102 
(negative control) for 90 minutes and seeded into tissue culture plates with fresh 
media. The cells were then incubated at 37C for approximately 96 hours, and the 
growth medium was removed and replaced with fresh medium every 24 hours. The 
removed medium was aliquoted and frozen at -20C. 
 
Freshly isolated PBMCs were plated out at 1x10
7
 cells/ml in medium and incubated 
for 2 hr (37C, 5% CO2). Non-adherent cells were removed by two washes with 5 ml 
of PBMC medium before addition of 2mls PBMC medium and 3mls of the infected 
cell supernatants. As a positive control, 100ng/ml commercial grade GMCSF at 
varying concentrations was added to some of the wells. Cells were fed by half 
medium change at day three. After 5 days, the cells were phenotyped by measuring 
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cell surface antigen using monoclonal Antibody for CD14 and flow cytometry. Figure 
3.8 demonstrates changes in CD14 expression in mononucleocytes after exposure to 
the supernatants of prostate cancer cell lines infected with AdGMNR, ps1307 and 
CTL102, as well as cells exposed to GMCSF solutions. 
 
Figure 3.8. CD14 expression in non-adherent PBMCs after exposure to supernatants 
from DU145 cells infected with GMCSF expressing viruses (AdGMNR and ps1307a) 
at varying multiplicities of infection or recombinant GMCSF at varying 
concentrations. All values represent the mean plus or minus the standard deviation. 
 
As mononucleocytes differentiate into immature dendritic cells they stop expressing 
CD14. This experiment demonstrates that the supernatants of prostate cancer cells 
infected with AdGMNR and positive controls (varying doses of GMCSF), as well as 
GMCSF solution cause mononucleocytes to lose expression of CD14, suggesting 
differentiation into immature dendritic cells and indicating the presence of active 
GMCSF. Mononucleocytes exposed to the negative control (supernatant from prostate 
cancer cells infected with CTL102) are just as likely to express CD14 as those which 
are mock infected indicating that it is unlikely that GMCSF is present. These data 
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suggest that the GMCSF released by prostate cancer cells infected with AdGMNR 
and the mutant strain ps1307a is biologically active. 
3.6 Comparing the efficacy of AdGMNR with similar viruses 
ps1307 and ps1308 expressing improved mutants of NTR and 
AdGMNR in PC3 cell lines  
 
During the validation work for AdGMNR, other constructs using modified NTR 
instead of wildtype were used to see if the efficacy of the system could be improved 
upon. The data presented in figure 3.9 show that the modified constructs could 
considerably improve the efficacy of the VDEPT platform with regards to cell kill, 
without compromising the production of GMCSF. 
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Figure 3.9. PC3 cells are infected with two different E1/E3 deleted adenoviruses 
(ps1307 and 1308a) expressing GMCSF with various mutations of NTR. CTL102 and 
AdGMNR are used as positive controls for wildtype NTR and GMCSF. The figures 
demonstrate that ps1307a and 1308a increasingly sensitize PC3 to CB1954 [A] 
without impacting on GMCSF secretion [B]. All values represent the mean plus or 
minus the standard deviation. 
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GMCSF secretion by PC3 cells infected at varying MOI (PFU) of 
E1/E3 deleted adenoviruses engineered to express NTR +/- GMCSF 
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3.7 Summary 
 
In this chapter, we have presented data that demonstrate that the E1/E3 depleted 
adenoviral vector will successfully infect prostate cancer cell lines. We have also 
demonstrated that, once infected, these cell lines will express both the nitroreductase 
and the GMCSF gene inserts. The expressed NTR is active and will cause cell death 
in the infected prostate cancer cell population when those cells are exposed to the 
inactive prodrug, CB1954, in a dose dependent fashion and equivalent to CTL102. 
The expressed GMCSF is biologically active, showing a similar effect on PBMCs as 
commercially available reconstituted GMCSF. Exposure of PBMCs to the supernatant 
from infected cells causes phenotypic changes with a down-regulation of the 
expression of CD14, a step in the development of immature dendritic cells. Although 
we are using wildtype NTR in the trial construct, future trials could benefit from more 
active mutants of NTR. 
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4 Development and validation of a reproducible assay of 
cellular immune responses to common prostate cancer 
associated antigens 
4.1 Introduction 
 
Cancer sciences at Birmingham University will be undertaking their second gene 
therapy clinical trial, using a virus delivered enzyme-prodrug therapy in prostate 
cancer. An E1/E3 deleted replication deficient adenovirus will be used expressing 
wild-type NTR and GMCSF with a CMV promoter. The virus will be delivered using 
a brachytherapy style technique in patients with locally advanced hormone escaped 
prostate cancer under general anaesthetic. 48 hours after the injection of the virus, the 
patient will receive a systemic dose of the harmless prodrug CB1954. This is 
converted to a DNA cross-linking cytotoxic drug in those cells expressing NTR, 
causing cell death. The previous trial (CTC01010) used a similar construct but 
expressing only wild-type NTR which was delivered via an ultrasound guided trans-
rectal route under local anaesthetic. Despite patchy expression within the prostate, 
there was evidence of efficacy as seen with PSA responses in some of the patients. 
Also noted was some evidence of immune responses in these patients with heavy 
lymphocyte infiltration noted in those patients who had been biopsied after treatment. 
These immune responses led to the inclusion of gene expressing the powerful 
immune-stimulant GMCSF for the second clinical trial. The trial is a phase I/II study 
so the primary objectives are safety and tolerability. The secondary objectives are 
tumour responses as measured by PSA and the tertiary objective is a change in 
immune response.  
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The aim of the work reported in this chapter is to develop and validate a reproducible 
assay to identify immune responses in patients with prostate cancer that can be used to 
measure this tertiary objective. 
To observe the impact of treatment in the immune system, we intend to measure T 
cell responses. This can be done by looking at T cell responses to peptides or whole 
antigens. The attraction of using peptides is that the assays are easier to perform. The 
disadvantage is that the peptide epitopes are HLA specific and thus knowledge of the 
epitopes and HLA types of the subjects are required. Using whole antigen is attractive 
as the antigen is processed within the autologous APC and this avoids the need for 
HLA typing and the patient’s own cells select their own epitope. The challenge with 
this approach is getting the whole antigen into the APCs. Initially, we adapted a B cell 
blast assay developed in the School for Cancer Sciences at Birmingham University by 
the melanoma group. These B cell blasts are developed from the blood of a subject 
and used as antigen presenting cells (APCs). These APCs are nucleofected by 
electroporation with plasmid expressing whole tumour antigen (MART-1 in the 
melanoma patients). After overnight incubation the cells are mixed with autologous 
non-adherent PBMCs and any IFN- released is assayed for by using an ELISA 
technique. The melanoma group had tried to use an ELIspot technique but found too 
much background IFN- release in their controls. 
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Figure 4.1. Schematic for autologous B cell blasts nucleofected with tumour 
antigens and IFN- ELIspot and ELISA assay 
 
4.2 Initial trial of previously established protocol using autologous B 
blasts to present nucleofected antigen in an ELIspot assay 
 
The suitably consented subject was venesected and 120mls of heparinized blood was 
drawn. 
The PBMCs were then extracted using a Lymphoprep density gradient extraction 
technique. Once the monocytes are removed, the remaining cells were washed with 
two thirds of the cells being frozen and stored in liquid nitrogen. The other third were 
then used to create B cell blasts. This process involved using four to six 48 hour 
passages on an irradiated feeder layer of murine L cells expressing human CD40 
ligand with mixed human sera, IL-4 and cyclosporin A (to inhibit T cells). Once the 
cells started to bunch, they were designated B cell blasts. 
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The autologous ‘responder cells’ were taken out of cryostore, thawed and rested in 
media overnight. The nucleofected B cell blasts were at a concentration of 1 x 10
6
/ml 
and therefore at the correct concentration to be added to the wells on the plate 
(100µl/well). 
The responder cells were added to the wells at a cell concentration of 5 x 10
6
 cells/ml 
in ELISpot medium. Using PHA as a positive control, PBMCs and nucleofected B 
blasts on their own as negative controls IFN- ELISpot assays were undertaken and 
wells using a 10 fold dilution of the responder cells were also tested. The results of 
the ELISpot are shown in fig 4.1. In these experiments, an ELISA for IFN- was also 
undertaken (fig 4.2) using the medium removed from the wells after the overnight 
incubation. 
The data shown in figures 4.1 and 4.2 demonstrate that when nucleofected B cell 
blasts from an individual with known EBV exposure are nucleofected with the EBV 
antigen BMLF-1 and then incubated with autologous PBMCs a measurable release of 
IFN- occurs. The ELISA demonstrates that this response increases with the number 
of PBMCs in the wells.  
Unfortunately, there is considerable background release of IFN- in the control wells, 
and this high background could make it impossible to detect small, specific T cell 
responses. This corroborates the experience of the colleagues who attempted to use 
this assay to monitor melanoma antigen-specific T cell responses in clinical trial 
patients. It was therefore decided that the assay was unsuitable in its current form, and 
we therefore considered possible causes of the high background. We considered that 
the following features of the protocol were probably contributing causes of the high 
background:   
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 The use of a murine feeder cell layer. 
There could potentially be a variety of foreign antigens from the mouse 
cells, some of which may trigger responses in the assay. 
 The use of mixed human sera and foetal calf serum in B cell media. The 
mixed human sera and the foetal calf serum components in the media may 
have antigens that could trigger immune responses in the assay. 
 The destructive nature of nucleofection. 
The act of nucleofection causes some cell death and the consequent 
release of antigens may trigger immune responses in the assay. 
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Figure 4.2. Wells in triplicate from an Elispot for IFN- release by PBMCs 
from an A1 B8 B62 C10 C7 HLA typed donor, mixed with autologous B cell 
blasts nucleofected with the EBV antigen BMLF -1 and controls. 

 
 
Figure  4.3. IFN-  release by PBMCs from an A1 B8 B62 C10 C7 HLA typed 
donor, mixed with B cell blasts nucleofected with the EBV antigen BMLF -1 
and controls as assayed by ELISA. 
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4.3 Assay improvement by avoidance of murine feeder cells and use 
of autologous serum utilizing both nucleofection and 
transfection  
 
A suitably consented subject was venesected, and 100mls of heparinized blood drawn. 
At this time, 20mls of blood was also taken to generate autologous sera. The sera was 
used instead of mixed human sera. A commercially available soluble human CD40 
ligand was used in the B cell manufacture process rather than CD40 ligand expressing 
murine L cells.  The CD40 ligand used was MegaCD40L™, a highly active construct 
in which two trimeric CD40 ligands which were artificially linked via the collagen 
domain of ACRP30/adiponectin. This construct very effectively simulates the natural 
membrane-assisted aggregation of CD40L in vivo. 
In parallel, the experiment is undertaken using a commercially available transfection 
kit (FuGENE) to attempt transfection rather than nucleofection for delivering the 
plasmid DNA to the B cell blasts to see if this is a better alternative. 
We wanted to establish at what point in the B cell blast development, the B cell blasts 
are best suited to present antigen to stimulate an IFN-  response measurable by 
ELIspot. Those cells being passaged to become B cell blasts were sampled at passage 
(P) 1, 3 and 5. These cells were frozen and put in cryostore. The evening before the 
nucleofections and transfections were planned (halfway through the last passage of 
the B cell blasts) the PBMCs and P1 and P3 B cell blasts were taken out of cryostore, 
thawed and rested in media overnight. The B cell blasts were then nucleofected or 
transfected and incubated with the PBMCs overnight. When the experiment was 
complete, they were assayed with ELISpot immediately in the nucleofected cell 
population. The ELISpot was undertaken at 48 hours in the transfection cell 
population to allow adequate expression. 
127 
 
 
 
 
Figure 4.4 - Wells in triplicate from an Elispot for IFN- release by PBMCs from an 
A1 B8 B62 C10 C7 HLA typed donor. The PBMCs were mixed with B cell blasts 
from various points in passage with megaCD40L and autologous sera and 
nucleofected with the EBV antigen BMLF -1 and controls. The cytokine activity 
results are shown as there were too many spots for the reader in some of the wells 
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Figure 4.5- Wells in triplicate from an Elispot for IFN- release by PBMCs from an 
A1 B8 B62 C10 C7 HLA typed donor. The PBMCs were mixed with B cell blasts 
from various points in passage with megaCD40L and autologous sera and transfected 
with the EBV antigen BMLF -1 and controls. The cytokine activity results are shown 
with spot counts in brackets.  
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Differences in mean cytokine activity with background responses 
subtracted between nucleofected and transfected cells from an ELISpot for IFN- 
release by PBMCs from an A1 B8 B62 C10 C7 HLA typed donor. The PBMCs were 
mixed with B cell blasts after first, third and fifth passage with megaCD40L and 
autologous sera and nucleofected/transfected with the EBV antigen BMLF -1 and 
controls. All values represent the mean plus or minus the standard deviation. 
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Figures 4.3 and 4.4 showed that in samples from the same donor nucleofection 
resulted in a far greater response in the ELISpot than transfection. This is keeping 
with observations in the literature [Maurise, R. et al 2010] although the differences 
vary with cell type. 
There was considerable improvement in the background response as evidenced in the 
controls for using megaCD40L and autologous sera. The background in both the 
nucleofected and transfected cells was similar. Using MegaCD40L allowed the B cell 
blasts to generate spots from the first passage. 
Given these observations we were keen to establish whether B cell blasts generated 
using a murine L cell feeder layer and mixed human sera are also able to generate 
spots on an ELISpot after the first passage? We were also keen to establish if the 
difference in background is due to the differences in B cell blast generation. 
4.4 Optimizing B cell generation for a nucleofection based IFN- 
ELISpot assay. 
 
A suitably consented subject was venesected and 100mls of heparinized blood drawn. 
At this time, 20 mls of blood is also taken to generate autologous sera. On this 
occasion, some B cells were generated on irradiated murine L cells in monolayer with 
mixed human sera and some B cells were generated using megaCD40L and 
autologous sera. B cells were sampled at each passage and frozen. After 4 passages, 
all the constituent cells are thawed out and nucleofected with BMLF-1. The cell 
numbers per well were adjusted to 1.5x10
5 
B cell blasts and 7.5x10
5
 PBMCs per well 
to try to get a countable number of spots per well. At each passage a small sample of 
the B cells were taken and phenotyped for expression of the co-stimulatory molecules 
CD80 and CD86. 
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Figure 4.7 - Comparing the IFN- ELISpot assay for B cell  blasts at passage 1-4 
generated by using a murine L cell layer with mixed human sera vs those generated 
by MegaCD40L and autologous human sera (A). The cells are nucleofected with 
BMLF-1 plasmid in an A1 B8 B62 C10 C7 HLA typed donor at 7.5x10
5 
PBMCs to 
1.5x10
5
 B cell blasts per well. The difference in the background spot counts is 
demonstrated in (B). The data from the spot counts are represented in the line 
chart(C). All values represent the mean plus or minus the standard deviation. 
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Figure 4.9 – Phenotypic changes of B cell blasts generated with murine L cell layer 
and mixed human sera with CD86 expression recorded on the y axis and CD80 
expression recorded on the x axis 
 
Figure 4.8 – Phenotypic changes of B cell blasts generated with MegaCD40L™ 
and autologous sera with CD86 expression recorded on the y axis and CD80 
expression recorded on the x axis 
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Figure 4.10. Comparing the phenotypic changes of B cell blasts generated with 
murine L cell layer and mixed human sera vs. Mega CD40L and autologous human 
sera 
 
 
The data in figures 4.6 demonstrate that B cell blasts generated with MegaCD40L™ 
and autologous human sera produced spots in the ELIspot from the first passage. 
Figure 4.7 showed that over 80% of B cell blasts generated with MegaCD40L™ and 
autologous human sera expressed co-stimulatory factors CD80 and CD86 from the 
first passage. Figure 4.6 demonstrated that B cell blasts generated with the murine L 
cell feeder layer and mixed human sera took three passages before good numbers of 
antigen-specific spots were found in the ELIspot. Figure 4.9 also showed that CD80 
and CD86 expression increased with sequential passage with the murine L cell feeder 
layer and mixed human sera with 80% of B cell blasts expressing costimulatory 
factors CD80 and CD86 after three passages. There were fewer background spots in 
the ELIspot using B cell blasts generated with MegaCD40L™ and autologous human 
sera (Figure 4.6). 
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4.5 Handling the PBMCs whilst awaiting the generation of the B cell 
blasts. 
 
The findings in 4.4 suggest the nucleofection and ELIspot assay using B cell blasts 
generated with MegaCD40L™ and autologous human sera, can be undertaken after 
one passage. We wanted to establish the optimum time for the passage and also 
identify how best to handle the PBMCs during this time. 
Once again, blood was taken from an EBV exposed donor, and the PBMCs extracted. 
Some PBMCs were frozen and some of the PBMCs were placed in cell culture media 
in a 37
o 
C incubator. Those PBMCs set aside for B cell blast preparation only 
undertake one passage with MegaCD40L™ and autologous sera. During this passage, 
small samples of the developing B cell blasts and the incubated PBMCs were taken at 
12, 24 and 36 hours and phenotyped for the expression of the co-stimulatory 
molecules CD80 and CD86 using flow cytometry. The B cell blasts are nucleofected 
with BMLF-1 after 36 hours incubation and the IFN- ELISpot assay was done with 
1.5x10
5 
B cell blasts per well and 7.5x10
5
 PBMCs per well. The results are shown in 
figures 4.10. This experiment demonstrates the need for careful handling of the 
PBMC population as they can undergo phenotypic change, which can impact on the 
background seen in the assay. The experiment was undertaken on two other donors 
and similar results were seen. 
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Figure 4.11 - ELIspot assay of interferon gamma release by frozen and incubated 
PBMCs in response to autologous B cell blasts generated by a single passage 
MegaCD40L™ and autologous human sera which are expressing BMLF-1 after 
Amaxa nucleofection 
135 
 
4.6 Selecting the best plasmid construct for the assay  
 
We were keen to explore the best plasmid backbone for the nucleofection step. Using 
PBMCs extracted from Buffy coat samples, CD40 L activated B cells were produced 
using a murine L cell feeder layer. These cells were nucleofected using 4 different 
plasmid constructs  
 SL 1 (pCMV-TnT-EGFP) 
 pPS1098A8  
 4B6 (pPG004B6)  
 4A8 (pPG004A8) containing green fluorescent protein (GFP).  
All four constructs use the CMV immediate early promoter to express EGFP, 
however they differ in the following ways: 
pCMVpTNT-EGFP includes a hybrid CMV/beta-globin intron upstream of the EGFP 
gene, and uses 3' end sequences (for addition of polyA and mRNA termination) from 
SV40 virus. The plasmid also contains some sequences from bacteriophage f1, and 
SP6 and T7 polymerase promoters that can be used to transcribe the EGFP in vitro  
pPS1098A2 is in a retrovirus vector plasmid (based on pLNCX [Miller, A.D. 1989]), 
hence contains upstream and downstream LTRs, and the neomycin-resistance gene.  
4B6 and 4A8 plasmids contain the Ii invariant chain leader sequence (which may 
possibly reduce apparent expression of EGFP due to endosomal degradation) and HA-
tag. pPG004A8 incorporates the beta-globin 2nd intron, and 3' end signals from the 
human complement C2 gene (the same combination as in CTL102 and AdNRGM). 
pPG004B6 has no intron, and uses the 3' end signals from the bovine growth hormone 
gene (sourced from pCDNA3).  
136 
 
Using flow cytometry and microscopy the most effective construct was selected. By 
repeating the flow cytometry at 48 and 72 hours post nucleofection, it was 
demonstrated that GFP expression was greatest at 24 hours post nucleofection (Fig 
4.11) and the SL1 construct appeared to perform best in nucleofection. Using this 
construct, five plasmids were then made replacing the GFP with one of five prostate 
TSAs (PSA, PSMA, PSCA, PAP and KLK4).  
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Figure 4.12 Percentage of cells expressing GFP in CD40L activated B cells 
nucleofected with different GFP expressing plasmid constructs over time 
 
4.7 Multiple antigen nucleofection 
 
When looking at a number of antigens, parallel assays can be run using individual 
antigens. However, if cell numbers  are limited, it could be more efficient to analyze 
multiple antigens in the same reactions.  
We wanted to see if it were possible to use multiple antigens within one assay and 
assess what implications this may have on the results. CD40L activated B cells were 
nucleofected with 12 g of plasmid expressing GFP and 2 g of plasmid expressing 
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GFP diluted with plasmids expressing 5 different PSTAs in equal 2 g quantities (12 
g in total). The expression of GFP was measured using flow cytometry. There was a 
small decrease in the percentage of GFP expressing cells (figure 4.12) and the mean 
fluorescent intensity was reduced by 7% 
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Figure 4.13 Dilutional effects of multiple antigen nucleofection on their expression. 
CD40L activated B cells were nucleofected with 2 g of SL-1 plasmid expressing 
GFP and 2 g each of SL-1 plasmid expressing the 5 prostate tumour antigens and 2 
g each of SL-1 plasmid expressing GFP and the 5 prostate tumour antigens. The 
expression of the GFP was measured with flow cytometry. 
 
These data were unable to tell us if the GFP +ve cells were co-expressing any of the 
PSTAs. To look at co-expression in multi-antigen nucleofection, CD40L activated B 
cells were nucleofected with a plasmid expressing GFP and a plasmid expressing red 
fluorescent protein (RFP). The percentage of nucleofected cells expressing these 
proteins was measured using flow cytometry. 32% of cells expressed both RFP and 
GFP. 16% were positive for GFP alone and 10% were positive for RFP alone (figure 
4.13).    
 
138 
 
 
 
Figure 4.14 Dilutional effects of multiple antigen nucleofection on their expression. 
CD40L activated B cells were nucleofected with 2 g GFP and 2 g of RFP. The 
expression of the GFP and RFP was measured with flow cytometry. 32% of the cells 
expressed both GFP and RFP with 41% expressing neither. 17% expressed GFP alone 
and 10% expressed RFP alone. 
 
The experiments described above indicated that, although co-nucleofection of 
multiple plasmids could lead to co-expression of multiple antigens in some cells (GFP 
and RFP co-expression), not all the nucleofected cells would necessarily express all 
the antigens, and there could be some reduction in the level of expression of any one 
antigen.  To investigate the possible impact of this in the ELIspot assay, CD40L 
activated B cells from a healthy EBV exposed donor were nucleofected with BMLF-1 
plasmid alone and the BMLF-1 plasmid mixed with 5 PSTAs plasmids. In this 
experiment, we are assuming that the donor will not mount a significant response to 
the PSTAs.  As shown in Figure 4.14, there was no significant difference in the 
ELISpot counts.  
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Figure 4.15 Dilutional effects of multiple antigen nucleofection on the IFN-  ELISpot 
assay. CD40L activated B cells from a donor with known EBV exposure were 
nucleofected with 2 g BMLF-1 plasmid and 2 g each of the 5 prostate tumour 
antigens. Further CD40L activated B cells from the same donor were nucleofected 
with 2 g of BMLF-1. The nucleofected cells were then mixed with PBMCs from the 
same donor and an ELISpot performed. All values represent the mean plus or minus 
the standard deviation. 
 
These data suggest that multiple antigen nucleofection will lead to a variety of single 
and multiple antigen expression in the target cells and that this will not significantly 
dilute the response to any one of these antigens. 
4.8 Adding the invariant chain to utilize the MHC class II pathway 
 
Using nucleofection to create antigen expressing cells, the endogenously expressed 
antigens will be presented via the MHC class I pathway. We wanted to see if we 
could use the MHC class II pathway as well to enhance the assay further. The 
additional presentation of antigen via this route would allow the detection of CD4 T 
cell mediated responses as well. To do this, PSTAs with invariant chain (IC) were 
developed. CD40L activated B cells from a prostate cancer patient were nucleofected 
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with either PSTAs or PSTAs with IC. The ELISpot assay and an IFN- ELISA were 
undertaken. There was a greater spot count and IFN- release seen in the assays using 
the invariant chain (figure 4.15). This was the consistent finding in patients with 
stronger responses. In patients with weaker responses, there were no significant 
differences between PSTAs with IC and PSTAs without IC. 
 
Figure 4.16 Effects on the IFN-  ELISpot of the addition of the invariant chain to the 
PSTAs. CD40L activated B cells from a patient with Gleason 3+4=7 prostate cancer 
on active surveillance were nucleofected with 5 PSTAs with IC, 5 PSTAs without IC 
and an empty vector as control. The nucleofected cells were then mixed with PBMCs 
from the same donor and an ELISpot performed. All values represent the mean plus 
or minus the standard deviation. 
 
4.9 Nucleofection and the impact on cells 
 
The process of nucleofection can be harmful to cells and we wanted to know what 
impact it had on cell survival. To measure this we used a propidium iodide assay. We 
found that the number of cells that died during nucleofection with 5 PSTAs varied 
from 9 to 25% across eight samples (mean 17.9 SD 5.67) compared with 6% of cells 
nucleofected with no antigen. 
141 
 
4.10 Measuring nucleofection efficiency 
 
All the PSTAs used had a haemagglutin (HA) tag attached to them. The purpose of 
this was to allow us to measure the efficiency of nucleofection. This would be 
measured as the percentage of the cells that were expressing HA after nucleofection. 
Assaying for this proved difficult at first as the HA was intracytoplasmic. A 
reproducible assay was possible using the FIX & PERM® kit from Caltag Med-
systems. This cell fixation and cell permeabilization kit achieves mild fixation and 
permeabilization of cells that leaves their morphological flow cytometric scatter 
characteristics intact. This enables the accurate identification of intracellular markers, 
such as HA. We used a FITC labelled anti-HA antibody and figure 4.16 shows a 
typical result. A commercially generated E. coli positive control whole cell lysate 
(ab5395) and mock nucleofected CD40L activated B cells were used as the negative 
control. 
 
 
Figure 4.17. Nucleofector efficiency as measured in CD40L activated B cells 
nucleofected with 5 PSTAs with HA tag using the Fix and Perm kit with FITC 
labelled anti HA antibodies. We found that nucleofection efficiency in our assay was 
consistently between 25 and 45%. 
 
invariant 
invariant 
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4.11 Optimizing the number of antigen expressing cells 
 
In optimizing the  number of antigen expressing  cells  in  the assay  we  needed to see 
what impact the number of antigen expressing cells has on the spot count. To measure 
this, sequential dilutions of antigen expressing cells were used in the IFN-  ELISpot 
assays. The results demonstrated that any number above 10,000 cells per well 
appeared adequate (figure 4.17, an example with nucleofector efficiency of 42.7% 
therefore around 4,270 antigen expressing cells per well). Increasing the cell numbers 
beyond 10,000 has no significant impact on the assay. 
The HA tag was useful in ensuring adequate nucleofection and is a tool to allow 
correction for variability in the nucleofection efficiency. Provided 10,000 
nucleofected cells are used, variations in nucleofection efficiency from 20% or more 
have no significant impact on the spot counts in our assays. 
 
 
 
 
Figure 4.18. Effects of sequential dilution of CD40L activated B cells nucleofected to 
express BMLF-1 (nucleofection efficiency 42.7%) from an EBV exposed donor on 
the ELISpot assay. All values represent the mean plus or minus the standard 
deviation. 
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4.12 Summary 
 
The results in this chapter have illustrated the development of a reproducible assay for 
quantifying cellular immune responses to prostate tumour antigens by measuring the 
number of IFN- releasing cells in blood samples from patients. A variety of 
approaches were used to generate autologous cells suitable for presenting a panel of 
prostate cancer tumour antigens. The initial assay had unacceptably high background, 
but this was reduced by modifying the process for generation of the antigen 
presenting cells (B-blasts) from PBMC. Optimal cell handling was identified to 
ensure a protocol that could be reproduced in a clinical trial setting. 
We explored the implications of multiple antigen nucleofection and found this was 
practical, improving the sensitivity and the cost efficiency of the assay. Our data has 
demonstrated that using an invariant chain with the plasmid insert further improves 
the sensitivity of the assay. Attaching an HA tag to the plasmid being inserted through 
electroporation nucleofection allows one to measure the efficiency of the 
nucleofection.  This allows one to monitor the efficiency of the nucleofection step in 
the assay. 
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5 Results from the Immune Responses in Adenocarcinoma 
Prostate (IRAP). Study REC reference number 
09/H1202/1 and CRCTU protocol number RG_08-098 
 
5.1 Introduction 
 
The primary endpoints of the forthcoming ADUP study are safety and adverse events 
with a secondary endpoint of anti-tumour activity as measured by serum prostate 
specific antigen (PSA). The trial has a tertiary endpoint of evidence of immune 
responses. To measure this outcome we will be using the CD40 ligand activated B 
cell / IFN-  ELISpot immune assay described and validated in chapter 4. Before 
using this assay on trial patient samples, the Immune Responses in Adenocarcinoma 
of the Prostate (IRAP) study was conceived.  
The main purpose of this study is to validate assays for measuring cell-mediated 
immune responses in patients with prostate cancer and the objectives are summarised 
in table 5.1. We wanted to explore the immune responses in patients with prostate 
cancer to a pool of 5 prostate specific tumour antigens (PSTAs):  
 Prostate Specific Antigen (PSA) 
 Prostate Specific Membrane Antigen (PSMA) 
 Prostate Stem Cell Antigen (PSCA) 
 Prostate Acid Phosphatase (PAP) 
 Kallikrein-related peptidase 4 (KLK4) 
For the purposes of this study we did not seek to undertake the assays in healthy 
donors as we were unable to counsel them suitably as to how to interpret the results 
and whether there may be implications for the donor with regards to his prostate 
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5.2 Study design 
Table 5.1 - IRAP study objectives 
 
We aimed to recruit up to 50 patients [table 5.2], who were to be undergoing surgical, 
radiotherapeutic, medical (hormonal) or conservative treatment for their prostate 
cancer to the study. We aimed to recruit the majority of patients when they were 
newly diagnosed with prostate cancer, and include longitudinal observations upon 
diagnosis and subsequent therapy. We aimed to recruit about 10 patients from each 
treatment group.  
 
We aimed to further develop and validate laboratory-based assays that have been 
described in chapter 4. As shown in table 5.1, the study aims to generate a body of 
baseline data on the immune responses to the PSTAs in newly diagnosed patients, any 
changes following primary treatment, as well as in patients at later stages of the 
disease and in healthy donors. The information gained will be valuable background 
Primary objective:  To optimize and validate assays for 
measuring immune responses to prostate 
cancer 
 To determine if immune responses to 
prostate and prostate cancer antigens can 
be detected and quantified in prostate 
cancer patients. 
         Secondary objectives:   
 
 To generate baseline data to help 
interpret immune response data from a 
forthcoming gene therapy clinical trial. 
         Tertiary (Exploratory) Objectives: 
 
 To observe any changes in the      immune 
response with treatment 
 To identify any patient, treatment, tumour 
characteristics that may influence the 
immune response.  
 To assess if there is any relationship 
between the level of immune response 
and the patients response to treatment, as 
assessed by the prostate cancer tumour 
marker PSA in the blood.  
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for our planned gene and immunotherapy, and for the planning of other 
immunotherapies or more detailed cohort studies. 
Eligible patients were identified amongst those diagnosed with prostate cancer at the 
Queen Elizabeth Hospital, Birmingham. Staff at the Queen Elizabeth Hospital and at 
the Institute for Cancer Studies at the University of Birmingham were eligible for 
recruitment as healthy donors (see table 5.2). 
 
           Inclusion criteria 
 
          Exclusion criteria 
 
Patients  Histologically proven 
adenocarcinoma of the 
prostate  
 Informed consent  
 Age greater than 18 
 Normal haemoglobin 
 
 Evidence of active pathologies or  
undergoing treatments that potentially  
affect the outcome measurements 
 Inability to give informed consent 
 Advanced disease state with a life  
expectancy of less than three months 
Donors  Informed consent            
 Age greater than 18 
 Normal haemoglobin 
 
 No  personal history or family history of  
adenocarcinoma of the prostate 
 No urinary tract infection (including  
prostatitis) within the last year 
 Not taking any prostate related medication  
(such as 5 alpha-reductase inhibitors) 
 Evidence of active pathologies potentially 
affecting the outcome measurements 
 Actively involved in this study 
 
Table 5.2 - IRAP recruitment criteria 
 
Ethical approval for the IRAP study was obtained from the South Birmingham Ethics 
Committee (reference 09/H1202/1). Recruitment started in February 2009 and over 
the following 14 months, 38 patients were recruited. 
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5.3 Study patients and methods 
 
Study 
 ref no. 
History/histology Treatment  Risk 
stratification 
(D’Amico) 
PSA (ng/ml) 
at diagnosis 
P001 Organ confined prostate 
cancer Gl 3+4=7 
HIFU Low 6.5 
Q001 Organ confined prostate 
cancer Gl 4+5=9 
Naive High 58 
Q002 Organ confined prostate 
cancer Gl 3+4=7 
Naive High 8.9 
Q003 Locally advanced prostate 
cancer Gl 4+3=7 
Naive Medium 12.5 
Q004 Locally advanced prostate 
cancer Gl 4+4=8 
Post TURP but 
naive 
Medium 204 
Q005 Organ confined prostate 
cancer Gl 3+3=6 
Naive Low 6.2 
Q006 Organ confined prostate 
cancer Gl 3+3=6 
Naive Low 9.9 
Q007 Locally advanced prostate 
cancer Gl 4+4=8 
Hormone 
refractory 
Medium 745 
Q008 Locally advanced prostate 
cancer Gl 5+4=9 
Naive High 116 
Q009 Organ confined prostate 
cancer Gl 4+4=8 
Observation Medium 12.6 
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Q010 Locally advanced prostate 
cancer Gl 4+5=9 
Naive High 21.4 
Q011 Organ confined prostate 
cancer Gl 4+4=8 
Naive Medium 8.7 
Q012 Organ confined prostate 
cancer Gl 3+3=6 
Observation Low 3.4 
Q013 Locally advanced prostate 
cancer Gl 5+5=10 
Naive High 166 
Q014 Locally advanced prostate 
cancer Gl 4+5=9 
Naive High 59.2 
Q015 Locally advanced prostate 
cancer Gl 4+3=7 
Naive Medium 503.5 
Q016 BPH on biopsy Naive N/A 2.9 
Q017 BPH  TURP/naive N/A 39.8 
Q018 Locally advanced prostate 
cancer Gl 4+5=9 
Naive High 11.4 
Q019 Organ confined prostate 
cancer Gl 3+3=6 
Naive Low 6.7 
Q020 Biopsies and TURP for ? 
locally advanced prostate 
cancer but BPH 
Naive / recent 
retention and 
infection 
N/A 860 
Q021 Organ confined prostate 
cancer  Gl 3+4=7 
Observation Low 3 
Q022 Prostatitis 
 
Naive N/A 84 
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Q023 Locally advanced prostate 
cancer Gl 4+3=7 
Hormone 
refractory 
Medium 23 
Q024 Locally advanced prostate 
cancer Gl 4+5=9 
Naive High 14.9 
Q025 Locally advanced prostate 
cancer Gl 4+5=9 
Post TURP 
Treatment 
naive 
High 95 
Q026 Organ confined prostate 
cancer Gl 3+3=6 
Observation Medium 12.3 
Q027 Organ confined prostate 
cancer Gl 3+4=7 
Observation Medium 12 
Q028 Locally advanced prostate 
cancer Gl 4+5=9 
Hormone 
refractory 
High 72 
Q029 Locally advanced prostate 
cancer Gl 4+5=9 
Hormone 
refractory 
High 254 
Q030 Locally advanced prostate 
cancer Gl 4+5=9 
Hormone 
refractory 
High 12 
Q031 BPH on TURP 
 
Observation N/A 24 
Q032 Locally advanced prostate 
cancer Gl 4+4=8 
Hormone 
refractory 
Medium 21 
Q033 Organ confined prostate 
cancer Gl 3+4=7 
Naive Low 15 
Q034 Organ confined prostate 
cancer Gl 3+3=6 
Observation Low 23 
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Q035 Locally advanced prostate 
cancer Gl 4+5=9 
Hormone 
refractory 
High 21 
Q036 Organ confined prostate 
cancer Gl 3+3=6 
Naive Low 15 
Q037 Locally advanced prostate 
cancer Gl 5+5=10 
Hormone 
refractory 
High 35 
Table 5.3 IRAP patients disease state (observation includes watchful waiting and 
active surveillance) 
 
Of the 38 patients recruited to the study so far, we have data on all 38 patients but we 
only have follow up data on 10 patients. All the blood samples taken were 
immediately transferred to the laboratory where the PBMCs were removed, aliquoted 
and labelled and put into cryostorage. The immune response assays were done in 
batches, adhering to the SOP developed in chapter 4 (see appendix 1). No issues with 
the SOP became apparent during the course of the IRAP study. 
5.4 Study results 
 
IFN- ELISpot responses to the five tumour antigens were seen in all the patients 
tested. Reassuringly, the assay seemed robust and repeatable with a relatively 
consistent background spot count (mean 11.3, SD 8.2). The IFN- ELISpot responses 
to PSTAs varied with disease stage and treatment (see figure 5.1 for typical PSA 
profiles and IFN- ELISpot data for each patient group; IFN- ELISpot data for all 
patients are summarised in Figure 5.2).  
In our subjects, the viability of the nucleofected B cell blasts was measured using PI 
staining and flow cytometry. The mean survival was 34.9% of nucleofected cells (SD 
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5.42). The nucleofection efficiency was also measured and the mean efficiency was 
32.4% (SD 10.0). Reassuringly, all the nucleofections were greater than 20%.  
Figure 5.2A demonstrates that there are minimal cellular immune responses to the 5 
common prostate tumour antigens in patients with benign complaints of the prostate. 
These 3 patients entered the study as they were presumed to have prostate cancer. On 
further investigation, after recruitment into the study, they were found to have benign 
complaints of the prostate. These data demonstrated a trend toward stronger immune 
responses in patients with treatment naïve prostate cancer when compared to patients 
with treatment naïve benign prostatic diseases (p=0.138). The treatment naive patients 
represent prostate cancer patients with disease at a variety of grades and stages in 
progression. This is consistent with the wide spread of results we see in figure 5.2A.  
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Figure 5.1. The PSA kinetics and IFN- ELIspot of selected patients from the IRAP 
study. (A) The PSA kinetics and IFN- ELIspot demonstrating the immune response 
to 5 PSTAs in a patient with prostatitis. (B) The PSA kinetics and IFN- ELIspot 
demonstrating the immune response to 5 PSTAs in a treatment naïve patient with high 
risk prostate cancer. (C) The PSA kinetics and IFN- ELIspot demonstrating the 
immune response to 5 PSTAs in a treatment failing patient with high risk prostate 
cancer. (D) The PSA kinetics and IFN-  ELIspot demonstrating the immune response 
to 5 PSTAs in a patient with low risk prostate cancer who has not been undergoing 
any treatment (active surveillance). The arrows on the PSA kinetic graphs show the 
point at which the IFN- ELIspot was undertaken. The IFN- ELISpot results are the 
number of IFN- spots per 5 x 105 PBMCs. PSA is measured in ng/ml. All values 
represent the mean plus or minus the standard deviation. 
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The active surveillance group have strong immune responses to PSTAs when 
compared with the wider treatment naive group. These patients will have undergone 
at least one biopsy over the previous 18 months and will have been carrying an 
indolent malignancy in their prostate for probably much more than 18 months. When 
applying the unpaired student t test to the data, the hormone escaped group in figure 
5.2A have significantly weaker immune responses when compared to the wider 
treatment naive group (p=0.014) and those on active surveillance (p<0.0001). Their 
responses are comparable to patients with benign disease.  
When the treatment naïve patients are divided into high, intermediate and low risk 
groups (figure 5.2B) using D’Amico’s classification, the high risk group had 
significantly weaker immune responses than those patients with intermediate 
(p=0.016) and low risk prostate cancer (p=0.031).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. This figure shows the level of T cell response to PSTAs, monitored via 
IFN-  ELISpot, for patients with benign and malignant prostate disease. (A) The spot 
counts have been grouped by the point at which they have reached in their treatment. 
All values represent the mean plus or minus the standard deviation. (B) The results for 
the treatment naïve patients has been grouped by their D’Amico risk classification. 
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During the period of the study, we were able to capture a second sample from 10 
patients at a subsequent routine hospital appointment. The follow-up data for the 10 
patients in the study is shown in figure 5.3B. In this group, one patient had undergone 
HIFU and demonstrated a significant increase in immune response. Six other patients 
were being managed with hormone deprivation therapies of which two were 
diagnosed hormone refractory at their second visit, two were stable on Active 
surveillance and one had undergone a transurethral resection of his prostate gland. 
These patients demonstrated a variety of changes in their immune responses. Figure 
5.4 identifies those patients who have undergone an intervention for their prostate and 
in all these patients there had been an increase in immune responses over time. Figure 
5.5 identifies those patients in whom there had been no new intervention between 
samples. In 5 of the 6 patients, there was a decline in immune responses over time.  
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Figure 5.3. The PSA kinetics and IFN-  ELISpot demonstrating the immune response 
to 5 PSTAs in 10 patients for whom repeat samples were available.  (A) The PSA 
kinetics of 4 of the patients is demonstrated and the points at which the IFN-  
ELISpots were undertaken are shown by arrows. Q008a, Q017and Q024 have high 
grade disease and are being managed with hormones. P001 has low grade disease and 
has been managed with HIFU. (B) The changes in immune responses with time in 10 
patients on whom we have data are demonstrated. All values represent the mean plus 
or minus the standard deviation. 
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Fig 5.4. Changes in immune responses with time after intervention. Patient Q003 was 
treatment naive at the time of the first sample and then underwent prostatectomy. 
Q011 was treatment naïve when the first sample was taken and was then commenced 
on LHRH analogue hormone manipulation. Q017 was on LHRH analogue hormone 
manipulation at the time of the first sample with the second sample being taken after 
the patient had undergone TURP. P001 had been treated with HIFU prior to his first 
sample. The second sample was taken after the patient had received a second HIFU 
treatment. All values represent the mean plus or minus the standard deviation. 
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Fig 5.5 Changes in immune responses with time without intervention. The immune 
responses decreased over time in five of the six patients undergoing therapy or active 
surveillance, in whom there had been no change in their treatment. All values 
represent the mean plus or minus the standard deviation. 
 
 
 
 
157 
 
5.5 Summary 
 
The use of a CD40L activated B cell based IFN- assay of peripheral blood in patients 
undergoing treatment for prostate cancer can be done. Despite the modifications to the 
assay that are discussed in chapter 4, the assay still detects a persistent and consistent 
low level of background which was never more than 20% of the overall signal seen 
when the PSTAs were used. This assay can be used to measure changes in the cellular 
immune response that might occur through the course of treatment and will make a 
suitable experimental tool for the forthcoming gene and immunotherapy trial. We 
have yet to define the ideal timing of the post treatment assay, but expect to have this 
identified before the trial begins. The small repeat sample size of 10 makes it difficult 
to interpret whether the variation in repeat samples is due to variability of the assay, 
or actual changes in the immune response being measured. Further work is required to 
validate these observations. 
These observations have been made on a small sample size (38 patients) with smaller 
subsets making robust statistical evaluation difficult. These data do suggest some 
trends which can support some hypotheses in regards to cellular immune responses in 
prostate cancer. 
The change in immune response noted in the single patients treated with HIFU (a 
thermo-therapeutic strategy) is particularly interesting (figure 5.3). Measurable 
changes in inflammatory cytokines have been described in the published literature [Li 
LY. et al 2009] and one might expect this treatment to be quite immunostimulatory. 
Low levels of immune response are noted in the hormone escaped patients. This is 
also noted in those treatment naïve patients with high grade disease (Fig 3B). These 
observations can generate the two hypotheses; that failing immune surveillance 
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facilitates disease grade progression in prostate cancer, or that disease grade 
progression inhibits immune surveillance in prostate cancer. 
 
Changes in the tumour [Blades RA. et al 1995], tumour infiltrating lymphocytes (TIL) 
[Sfanos KS. et al 2008] and the tumour microenvironment [Shafer-Weaver KA. et al 
2009, Joel B. et al 1997] have been associated with local failure of immune responses 
(immunoediting). With ethics in place to look at TILs, there is an opportunity to look 
at any possible relationship between TIL phenotype and the level of peripheral 
immune responses to PSTAs. By capturing data on a larger population of prostate 
cancer patients we can start to understand more about the natural history of immune 
surveillance in prostate cancer. This may help us identify which treatments and at 
which points in the disease pathway that immunotherapies might be used. 
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6 Discussion 
 
6.1 AdGMNR validation 
 
The CTC01010 gene therapy trial in prostate cancer demonstrated that the VDEPT 
platform using an E1/E3 deleted adenovirus via a trans-rectal delivery route and the 
CB1954 prodrug was safe with virus doses of up to 1x10
12
. The PSA kinetics of the 
patients in the trial demonstrated efficacy with a mean decline in PSA of 23.2% after 
treatment with the mean time to the PSA nadir being 2.4 months and 9 of the 19 
patients still having a negative PSA velocity at 6 months after their primary treatment. 
The trial highlighted the limitations of using a transrectal route for virus delivery with 
immunostaining demonstrating less than 50% of prostates treated with the largest 
viral dose expressing NTR. The trial also demonstrated evidence of cellular immune 
responses with lymphocytic infiltration in post treatment biopsies in some of the 
patients. 
Given these findings, the ADUP trial was proposed to address virus delivery and to 
try and enhance the observed immune responses. For delivery, the virus is to be 
delivered via a transperineal route using a brachytherapy template. To harness any 
immune responses, the cytokine GMCSF has been added to the virus construct, called 
AdGMNR.  
In the first results chapter, we present the results from the validation of AdGMNR. 
The construct could infect a variety of prostate cancer cell lines effectively. We 
selected the metastatic prostate cancer cell lines, PC3 (from an androgen resistant, non 
PSA secreting clavicular bone metastasis), DU145 (from an androgen resistant, non 
PSA secreting brain metastasis) and 22RV1 (a cell line developed from an androgen 
160 
 
sensitive, PSA secreting xenograft, CWR22). It is interesting to note that the better 
differentiated 22RV1 cell line displayed much greater infectability with regards to our 
Ad5 construct. In the ADUP trial, our patients with have androgen insensitive disease 
which we have shown is infected by the construct but poses the question of whether 
this platform would have greater efficacy in androgen sensitive disease. 
Whether the construct is coding for GFP, NTR or GMCSF, infected cells will express 
the gene insert. This expression occurs in a dose dependant way but there are 
variations in expression between the cell lines. When the construct is encoding for 
both NTR and GMCSF with an IRES, the upstream gene expression is no different 
because of the addition of the downstream gene and IRES. The expression of 
GMCSF, which is the downstream gene, is reduced slightly when compared to its 
expression without the NTR and IRES upstream. Expression of both genes varied 
over time with the greatest expression occurring between 48 and 72 hours. This is to 
be expected and validates the timing of the prodrug in the ADUP trial at 48 hours. 
The cell culture work demonstrated that prostate cancer cell lines infected by 
AdGMNR are sensitised to the prodrug CB1954 and the cells will die in a dose 
dependent way when the prodrug is applied 48 hours after infection. The sensitivity of 
the infected cell line is also dose dependent with the amount of prodrug required to 
kill 50% of the cells decreasing if more AdGMNR is used at the time of infection. 
Testing the supernatant from prostate cancer cell lines infected with AdGMNR we 
were able to explore whether GMCSF was present and then explore whether the 
supernatant containing the expressed GMCSF was biologically active. We know that 
PBMCs express CD14 on their surface. If these cells are exposed to GMCSF, some 
will differentiate into immature dendritic cells and in doing so, stop expressing CD14. 
We demonstrated that the supernatants from prostate cancer cells infected with 
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AdGMNR and the same construct expressing only GMCSF reduced the number of 
cells expressing CD14 by over 50%. This was the same as the changes seen in 
PBMCs exposed to various dilutions of commercially available recombinant human 
GMCSF. Even at very high dilutions, these changes were observed reflecting the 
potency of GMCSF as a cytokine. Assuming that 1cm
3
 of prostate tissue contains 1.2 
x 10
9 
prostate cells (based on HELA cell models), the local dose of GMCSF could be 
as high as 100 mg/cm
3
 of prostate per day in the prostates of patients in the ADUP 
trial. In clinical trials there are systemic doses ranging from 125-500 mg/m2 delivered 
in a variety of schedules ranging from daily to 3 times a week. 
The data demonstrate that the levels of GMCSF vary between cell lines, and this was 
a consistent feature. The greater expression in PC3 cells compared to DU145 cells 
cannot be explained by differences in infectability. The AdGFP work had 
demonstrated that DU145 cells were slighter more susceptible to infection with our 
E1, E3 deleted Ad5 platform. Some prostate cancer cell lines, such as PC3, 
autonomously secrete GMCSF when stressed and this may help account for the 
differences in the levels of GMCSF secretion in the cell lines. With the heterogeneity 
of prostate cancers we would expect to see similar variability in the responses of 
patients in the ADUP trial. 
We have shown that the expression of GMCSF reaches a peak at 48 hours. It is at this 
time that a patient treated with the AdGMNR virus would be receiving their dose of 
CB1954. As such, cell death would be occurring within the subsequent 24 hours. This 
means that the patient will have received a short but continuous neoadjuvant local 
dosing with GMCSF from the infected prostate cells. There are a few similar clinical 
trials in the literature, such as the recombinant vaccinia virus encoding human 
prostate-specific antigen (rV-PSA). In this trial, 10 of the 33 patients received a 
162 
 
subcutaneous injection of 250mcg of GMCSF on treatment days -1, 0, 1, 2 at the site 
of the subcutaneous injection of the rV-PSA [Eder J, P. et al 2000]. The rationale for 
this dosing regimen came from a rat model [Disis et al 1996]. A more recent study in 
a murine model not only confirmed that this dose schedule was optimal, but also 
demonstrated that it enhanced the CEA-specific T-cell responses when a recombinant 
vaccinia virus was used as an immunogen [Kass et al 2000]. Those patients receiving 
the GMCSF had a slightly greater incidence of low grade toxicity, but there was a 
non-significant trend to greater efficacy as measured by PSA response.  
Aside from improving the delivery strategy and introducing immunostimulation to the 
platform, much work had been done in the laboratory on improving the efficacy of the 
NTR. A number of mutant strains of NTR had been developed and when comparing 
them with wild-type their performance was dramatically enhanced as measured by 
cell death with the administration of CB1954. These mutants demonstrated 
comparable levels of GMCSF generated. The benefits of these mutant strains could 
include the need for less virus which would have cost benefits and the need for less 
prodrug. The mutant strains might also generate a greater bystander effect which 
could benefit the efficacy of the treatment. 
With the introduction of a transperineal injection method and the addition of the 
immunostimulant GMCSF it was felt further modifications to the trial design would 
make it harder to identify which modification was responsible for any changes 
observed in outcome. Pending the outcome of the ADUP trial, the mutant NTR strains 
as well as enhanced prodrugs may form the basis of future clinical trials.  
The target patient population lends itself well to this trial. The patients will have 
biochemical and histological evidence of local recurrence. The patient will have 
evidence of evolving castrate resistant disease with a climbing PSA despite 
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biochemical evidence of castrate levels of testosterone. In current guidelines, these 
patients are not eligible for modifications to their treatment until they become 
symptomatic. This can take many months and the lack of an active therapy for these 
patients is an unmet need. As the disease burden is still relatively low, it makes it an 
attractive target for an immunotherapy. Many immunotherapy trials occur in patients 
with advanced, highly heterogeneous, burdensome disease in which poor outcomes 
are likely. Best results with immunotherapies are seen in early, low volume disease. 
The ideal population for this platform would be patients with newly diagnosed, organ 
confined disease with smaller prostate and low risk disease, the group usually opting 
for traditional brachytherapy. 
One of the differences between the ADUP trial and CTC01010 trial is that we are 
unable to deliver a boost dose. This is due to the differences in virus delivery between 
the two studies. The transrectal approach under local anaesthetic that was used in 
CTC01010 is much easier to repeat than using the transperineal approach under a 
general anaesthetic. The value of the boost doses was unclear from the CTC01010 
trial given the small numbers. The question over whether boost doses will improve the 
efficacy of the platform would need to be addressed in a separate trial. 
It will be interesting to see the impact the GMCSF has on the success of this platform. 
There are a number of further immunomodifying treatments that might also be used to 
enhance the immune elements of the platform such as checkpoint inhibitors like 
ipilimumab or cyclophosphamide to inhibit the action of T reg cells. 
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6.2 Development of the immune assay 
 
For the forthcoming ADUP trial, a reliable, validated immune assay was required to 
identify immune responses in patients with prostate cancer. This assay could then be 
used to measure the immune responses in ADUP trial patients, the tertiary objective 
of the study. Within the University, there had been a recent immunotherapy trial in 
melanoma for which an IFN- based ELISpot assay had been developed. This assay 
involved the use of a whole protein (MART-1) being inserted into an antigen 
presenting cell (a B cell blast in this instance) using nucleofection. Subsequently the B 
cell blast is allowed to present the appropriate antigen to autologous T cells. The 
attraction of using whole peptide in this approach is that it avoided the need for HLA 
typing patients and finding suitable HLA specific antigens. Avoiding patient selection 
on the grounds of HLA type would make recruitment to the trial much easier. 
Our initial experiments using the melanoma group’s assay demonstrated that the assay 
worked when using the BMLF -1 protein (an early lytic EBV protein) on samples 
from EBV exposed donors. The assay demonstrated strong responses from EBV 
exposed patients, when compared with empty vector controls. The problems with the 
assay were the lengthy and variable manner in which the B cell blasts were developed 
and the level of background spots seen in the control wells of the ELISpot. The 
Melanoma group had experienced this problem themselves and had settled for using 
ELISA data instead. Our early experiments had demonstrated that ELISA was very 
straightforward but gave quite variable results when repeated in the same donor so we 
elected to attempt to refine the B cell blast assay.  
We felt the possible steps in the assay that could be implicated in the high background 
readings are: 
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 Use of the irradiated murine L-cell monolayer 
as a source of CD40L 
 Use of commercially sourced human serum in 
the B cell media 
 Use of nucleofection in protein insertion 
 Storage and handling of the evolving B cell 
blasts 
 Storage and handling of the PBMCs 
 
6.2.1 Reducing the background readings 
 
In the early experimental work with the assay, we changed from using the 
commercially available mixed human sera to simply taking an extra 20 mls of non-
heparinized blood from the subject. This sample was used to generate enough 
autologous serum for the generation of the incubation media for the evolving B cell 
blasts. We also stopped using the irradiated murine L-cell feeder monolayer and 
incubated out evolving B cell blasts in media containing a commercially available 
CD40L called MegaCD40L™. This is a highly active construct in which two trimeric 
CD40 ligands are artificially linked via the collagen domain of ACRP30/adiponectin. 
This construct very effectively simulates the natural membrane-assisted aggregation 
of CD40L in vivo. 
The results from this approach were very encouraging, with a great improvement in 
the level of background activity that was seen in the control wells. We were keen to 
see if the nucleofection step might be contributing to the background readings that we 
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were seeing in the assay. It was evident using a PI cell viability assay that there was 
considerable cell death occurring after nucleofection. We explored the possibility of 
using commercially available transfection systems instead of using nucleofection. The 
attraction of this approach was that it would be cheaper and there would be much less 
cell death in the B cell blast population. This would have the benefit of leaving us a 
greater number of B cell blasts for use in the experiments, increasing the number of 
replications in each experiment as well as possibly reducing the level of background 
activity in the controls. We were also keen to identify the technique that would give 
the most consistent expression levels. We initially identified the most effective 
available transfection kit by comparing the JETPEI and FUGENE systems. 
Transfecting PC3 cells with GFP and measuring expression with flow cytometry 
demonstrated that the FUGENE system was superior. To establish if transfection with 
the FUGENE system could be used as an alternative to nucleofection, the autologous 
serum and MegaCD40L immune responses assay was run in parallel with cells from 
the same EBV exposed donor. The experiment repeatedly demonstrated no 
meaningful difference in the background responses seen in the ELISpot between the 
two protein insertion methods. There was a significant difference between the 
ELISpot results with the nucleofected cells generating many more spots per well. 
These data would suggest that the cell death caused by nucleofection does not cause a 
strong response as measured by the assay and that it is more effective at delivering 
antigen to the B cell blast. Nucleofection was the favoured method of plasmid 
insertion. 
Within this experiment we also aimed to identify the point at which the evolving 
CD40L stimulated B cells would deliver the best results in the assay. Developing 
CD40L stimulated B cells were sampled at the 1
st
, 3
rd
 and 5
th
 passage. In the 
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nucleofected cells, there were strong responses after the first passage and these 
responses remained consistent through the third and fifth passage. 
To investigate this further we took blood from an EBV exposed donor and developed 
CD40L stimulated B cells using both the murine L cell feeder layer and the 
MegaCD40L techniques. Cells were sampled at the 1
st
, 2
nd
, 3
rd
 and 4
th
 passage, 
nucleofected with BMLF-1 and the IFN-  ELISpot assay undertaken. Those cells 
prepared with the MegaCD40L were demonstrating strong responses after the first 
passage but those cells prepared using the murine L cell feeder layer didn’t start to 
generate meaningful responses until the fourth passage. The empty vector controls in 
the murine L cell feeder layer consistently had a much greater background spot count 
than those from the MegaCD40L controls. 
 
6.2.2 Optimizing the standard operating procedure 
 
During the B cell blast manufacture, we looked for phenotypic changes in the cells 
that could enable us to better understand and measure their development. We 
measured expression of the co-stimulatory molecules, CD80 and CD86 in the cell 
population during the sequential passages and found that B cell blasts grown with 
MegaCD40L expressed CD80 and CD86 much earlier than those B cell blasts grown 
using the murine monolayer. The changes in the expression of these co-stimulatory 
molecules mirrored the spot counts seen in the ELISpot assays. These data suggest a 
possible utility for the expression of CD80 and CD86 as markers for B cell blast 
development.  
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The accelerated development of B cell blasts with MegaCD40L caused us to look at 
how best to handle the PBMCs during the B cell blast manufacture process. The 
original assay involved the freezing of PBMCs and their subsequent thawing. To 
optimize the assay, we needed to characterize any phenotypic changes that were 
occurring in the PBMC population that might be affecting the ELISpot. Using blood 
from an EBV exposed donor and the BMLF-1 plasmid we compared the outcomes of 
PBMCs that had been frozen with PBMCs that we maintained in culture media. We 
found that PBMCs maintained in culture media had a higher background in the 
ELISpot than the frozen PBMCs. When we characterised the phenotype of the 
PBMCs, we found that there was an increase in expression of CD80 and CD86. 
Initially, the expression of these co-stimulatory markers was the same in frozen and 
the non-frozen PBMCs but after 24 hours, the increase became apparent. We therefore 
still recommend the freezing of the PBMCs. 
Having established that the B cell blasts could be generated with a single passage in 
MegaCD40L containing media with autologous serum to help minimize the 
background readings, we wanted to identify the best insertion plasmid to use in the 
experiment. Four different plasmid constructs (SL1, ps1089A8, 4B6, 4A8) were 
generated, containing green fluorescent protein (GFP). This allowed us to identify 
which construct gave the greatest expression of GFP after nucleofection and at what 
time point after nucleofection was the expression greatest. The SL1 plasmid 
consistently generated the greatest expression of GFP and in all the plasmids the 
expression of GFP was greatest at 24 hours after nucleofection. These data confirmed 
that the ELISpot was best undertaken within 24 hours after nucleofection. 
THE SL1 plasmid was then used to construct five new plasmids, replacing the GFP 
with one of five PSTAs (PSA, PSMA, PSCA, PAP and KLK4). These PSTAs are 
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commonly associated with prostate tumours and we wanted to explore immune 
responses to all 5 of the antigens as we are not going to know which, if any of these 
antigens were being expressed by the tumours of the trial subjects. Ways of 
approaching this experimentally included undertaking five separate nucleofections per 
subject on one set of B cell blasts, divide the subjects B cell blasts into 5 and 
nucleofect each cohort with a different plasmid or undertake a single nucleofection 
using all five plasmids in one set of B cell blasts per subject.  
To test the impact on expression with multiple plasmid nucleofection in one go, we 
nucleofected B cell blasts from a single donor with the GFP expressing plasmid and 
compared GFP expression with B cell blasts nucleofected with the GFP expressing 
plasmid diluted down with even concentrations of plasmids expressing the 5 PSTAs. 
We found that there was a reduction in the percentage of GFP expressing cells from 
49% to 41%. Repeating the experiment with plasmid expressing GFP and RFP rather 
than the plasmids expressing PSTAs allowed us to demonstrate that variably 29-36% 
of surviving B cell blasts nucleofected with both plasmids expressed both fluorescent 
proteins with 14-17% expressing GFP alone and 10-11% expressing RFP alone. 
Around 40% of the nucleofected cells did not express either of the fluorescent 
proteins. These data gave us confidence that our 5 PSTA nucleofected B cell blast 
population would have cells expressing one or more of the PSTAs. 
We then undertook ELISpots on EBV exposed patients using B cell blasts 
nucleofected with BMLF-1 alone or BMLF-1 diluted with equal concentrations of 
plasmids expressing the 5 PSTAs so the overall quantity of plasmid used was the 
same. We found that the dilution of the BMLF-1 consistently yielded no significant 
difference in the spot counts on the ELISpot. In our experiments we found that 
multiple antigen nucleofection led to a variable expression of single and multiple 
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antigens in the target cells but this did not appear to impact on the ELISpot responses 
to any individual antigen. This could be explained by the fact that there are probably 
only a small number of T cells specific for the antigen being presented by the 
nucleofected B cell blast and so the sensitivity of the assay only deteriorates when the 
density of B cell blasts expressing that antigen is very low. 
Using nucleofection in this way we would expect the expression of the nucleofected 
antigen to occur through the MHC 1 pathway. By adding the invariant chain to the 
antigen, we wanted to see if we could utilize the MHC II pathway.  
The ELISpot assay was undertaken using blood samples from prostate cancer patients, 
nucleofecting with plasmids expressing the five PSTAs or the five PSTAs with 
invariant chain. Significant increases in the number of spots were consistently seen in 
those patients in which a strong response was seen. In those patients with weak 
responses, the difference was much less and was mostly not significant. As a 
consequence, the preferred assay would use the plasmids expressing PSTAs with the 
invariant chain. 
Using a propidium iodide assay, we found that nucleofection with the 5 PSTAs was 
harmful to the B cell blasts with 9 to 25% of cells dying. We also identified that the 
effectiveness of nucleofection varied within the same cell population nucleofected 
with the same plasmids with expression varying from 25% - 48%. The impact of this 
variability on the validity of the assay needed exploring. By using a HA tag in the 
plasmids the nucleofected cells could be probed for the intracytoplasmic expression of 
HA using the commercial ‘fix and perm’ assay. This allowed the results to be 
normalized for nucleofection efficiency, as calculated from the percentage of the cells 
expressing of intracytoplasmic HA. By looking at the ELISpot results from 
sequentially diluted nucleofected B cell blasts, it was evident that the percentage of B 
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cell blasts expressing antigen had little impact on the number of spots seen in the 
assay. This would suggest that the prostate antigen specific T-cells are highly 
sensitive and able to identify prostate antigen expressing B cells even when in low 
concentrations. Provided the nucleofection efficiency is greater than 20% the assay is 
a reliable measure of prostate antigen specific T-cells.  
 
6.3 Measuring immune responses in prostate cancer patients 
 
Having demonstrated that multiple antigen nucleofection and subsequent ELISpot 
could be done with a protocol that minimized background responses, we wanted to 
apply the assay to prostate cancer patients.  To explore this, we undertook a study 
titled, ‘immune responses in adenocarcinoma of the prostate (IRAP). The aim of this 
study was to apply the assay in a clinical setting, allowing us to further refine the 
assay in preparation for the ADUP clinical trial. It would also give us an opportunity 
to catalogue immune responses in prostate cancer patients to help us interpret the 
results from the ADUP trial. By sampling patients with various disease grades and 
stages, the data would also help hypothesis formation for future studies. After suitable 
ethical and research and development approval, prostate patients were recruited from 
prostate clinic and from the ward. 
It was reassuring to find that patient recruitment to the study was straightforward. 
Only 5 patients (12%) declined to participate demonstrating the acceptability of the 
tests to this patient population. There were no difficulties encountered with the 
retrieval of blood samples from theatres and outpatients and their transfer to the 
laboratories in the School for Cancer Sciences. The cellular yields from the samples 
were satisfactory for the completion of the assays with cells to spare. It was noted that 
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the yields from the theatre patients were slightly higher, and that could reflect their 
relative dehydration (as the patient has been starved for a general anaesthetic) or that 
they were a younger cohort of patients. In the forthcoming ADUP trial, the patients 
will have their primary sample taken in theatre and I expect the cellular yields to also 
be high. 
The assay performed well in this patient population with consistently low background 
readings and consistent spot counts. We found evidence of immune responses to 
prostate tumour antigens in both patients with prostate cancer, and patients without 
prostate cancer. The levels of response were much less in the non-cancer patients but 
within the cancer patient cohort we found a wide variety of responses. In patients with 
low volume early stage disease the responses were brisk, as were the responses in 
patients on active surveillance. These findings are consistent with immuno-editing 
theory but, in the active surveillance patients, these findings could be attributed to the 
fact the patients are undergoing regular prostate biopsies. In those patients with 
advanced disease, the immune responses were far less evident. This could be due to 
exhaustion of the T cell populations targeting our panel of prostate specific tumour 
antigens and this may be contributing to the progression of the disease. It may be 
because of progressive loss of MHC expression in these tumours, their increasing 
heterogeneity or mechanisms within the progressive tumour microenvironment that 
there is suppression of this T cell population. It is possible that these patients have 
always had poor responses, and that has contributed to their disease progression. 
It was interesting to observe a trend towards an increase in immune responses from 
low risk to intermediate risk patients before the drop in immune responses seen in 
high risk patients. Initially, this increase could be due to increase in disease volume 
without a major shift in cellular morphology driving greater immune responses. As 
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the disease progresses and the cellular morphology becomes more poorly 
differentiated the immune responses coincidently drop away. There will usually be 
greater disease bulk in these patients making it difficult to identify why the immune 
responses decrease. It could be morphology, tumour volume or both that is driving the 
exhaustion of the T cell response. It could also be that failure in the immune response 
facilitates the progression of prostate cancer in these patients. 
This raises interesting considerations for the timing of immune–related therapies in 
prostate cancer. Clinical trials using the autologous dendritic cell based vaccine 
therapy, Sipuleucel T were undertaken on patients with advanced disease. If our 
observations are a genuine reflection of the patterns of immune responses in prostate 
cancer patients then these patients might be expected to benefit least from this type of 
treatment. If it were practical, it would be interesting to see how efficacious this 
treatment would be in patients with earlier staged disease. The ADUP trial will be 
recruiting patients at an earlier stage in their disease pathway than those in the 
Sipuleucel T trials and the disease bulk will be much less. The immune stimulating 
element of the treatment should benefit from this and it will be interesting to monitor 
the immune responses in these patients as their treatment progresses.  
In the study, we were fortunate enough to get sequential samples on 10 patients. In 
those patients in whom there were no treatment modifications, the immune responses 
appear to be gradually declining. Those patients in whom a direct insult to the prostate 
is offered, there appears to be an upward trend in the immune responses. The most 
remarkable change in immune responses is seen in the patient who underwent HIFU. 
This observation is consistent with observations made in the literature relating to this 
treatment in the prostate and other organs. Given the coagulative necrosis caused by 
the HIFU, and the rim of thermally stressed but surviving tissues, there would be an 
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expectation to see immune responses mounted to antigens released within the 
treatment environment. It would be worth further study to see if this is a consistent 
feature for this treatment and if similar responses are seen in other thermotherapeutic 
modalities such as cryotherapy. If this is a consistent observation, it would be worth 
investigating whether neoadjuvant use of immune stimulants alongside 
thermotherapies can be used to enhance their efficacy, or even see them used in 
advanced disease to try and offer local disease control whilst delivering a systemic 
immune benefit.  
If the assay were used serially in a patient it would be interesting to see if it could 
have a role in predicting outcome, particularly in those patients who would ordinarily 
select active surveillance. We have seen the gradual decline over time in patients on 
stable treatment, and this kind of assay could serve as an indicator for contemplating a 
treatment change or escalation. The limitations with the assay, would be in the cost 
and logisitics involved in delivering it in mainstream healthcare and, consequently, it 
is likely to remain a research tool. 
 
 
 
 
 
 
6.4 Summary 
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In this thesis I have demonstrated the modified virus AdGMNR will infect prostate 
cancer cells and the NTR and GMCSF genes are expressed. Those cancer cells 
expressing NTR and subsequently exposed to CB1954 will die with neighbouring 
cells also dying, due to the bystander effect. The GMCSF produced by infected 
prostate cancer cells will induce morphological changes in PBMCs consistent 
differentiation into immature dendritic cells. 
I have adapted an ELISpot assay that gave high background readings. Modifying the 
assay has minimized those background readings. The platform allows us to test for 
responses to a panel of 5 prostate specific cancer antigens. I expect this to increase the 
sensitivity of the assay. 
I have used the assay on a number of prostate cancer patients at various disease stages 
and have been able to measure immune responses in a satisfactory way. The observed 
immune responses show consistencies with immune editing theory, and generates 
some good background data against which we can compare the results from the 
forthcoming ADUP trial as well as helping to formulate possible hypotheses to be 
tested in future studies. 
 
 
 
 
 
6.5 Future work 
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We have started to recruit to the ADUP trial, and will start to generate data on the 
immune responses in these patients as they undergo treatment. I am keen to explore 
the immune responses in a larger cohort of prostate cancer patients undergoing 
treatment with a particular emphasis on thermotherapies. I would like to identify 
which treatments appear most immuno-stimulatory and would therefore lend 
themselves best to augmentation with immuno-modulating agents. These data would 
help us select treatments to take forward into clinical trials with neo-adjuvant 
immunotherapies. 
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